
International Nonproprietary Names for Pharmaceutical Substances (INN)

RECOMMENDED International Nonproprietary Names: List 77

Notice is hereby given that, in accordance with paragraph 7 of the Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances [*Off. Rec. Wld Health Org.*, 1955, **60**, 3 (Resolution EB15.R7); 1969, **173**, 10 (Resolution EB43.R9); Resolution EB115.R4 (EB115/2005/REC/1)], the following names are selected as Recommended International Nonproprietary Names. The inclusion of a name in the lists of Recommended International Nonproprietary Names does not imply any recommendation of the use of the substance in medicine or pharmacy.

Lists of Proposed (1–113) and Recommended (1–74) International Nonproprietary Names can be found in *Cumulative List No. 16, 2015* (available in CD-ROM only).

Dénominations communes internationales des Substances pharmaceutiques (DCI)

Dénominations communes internationales RECOMMANDÉES: Liste 77

Il est notifié que, conformément aux dispositions du paragraphe 7 de la Procédure à suivre en vue du choix de Dénominations communes internationales recommandées pour les Substances pharmaceutiques [*Actes off. Org. mond. Santé*, 1955, **60**, 3 (résolution EB15.R7); 1969, **173**, 10 (résolution EB43.R9); résolution EB115.R4 (EB115/2005/REC/1)] les dénominations ci-dessous sont choisies par l'Organisation mondiale de la Santé en tant que dénominations communes internationales recommandées. L'inclusion d'une dénomination dans les listes de DCI recommandées n'implique aucune recommandation en vue de l'utilisation de la substance correspondante en médecine ou en pharmacie.

On trouvera d'autres listes de Dénominations communes internationales proposées (1–113) et recommandées (1–74) dans la *Liste récapitulative No. 16, 2015* (disponible sur CD-ROM seulement).

Denominaciones Comunes Internacionales para las Sustancias Farmacéuticas (DCI)

Denominaciones Comunes Internacionales RECOMENDADAS: Lista 77

De conformidad con lo que dispone el párrafo 7 del Procedimiento de Selección de Denominaciones Comunes Internacionales Recomendadas para las Sustancias Farmacéuticas [*Act. Of. Mund. Salud*, 1955, **60**, 3 (Resolución EB15.R7); 1969, **173**, 10 (Resolución EB43.R9); Resolución EB115.R4 (EB115/2005/REC/1) EB115.R4 (EB115/2005/REC/1)], se comunica por el presente anuncio que las denominaciones que a continuación se expresan han sido seleccionadas como Denominaciones Comunes Internacionales Recomendadas. La inclusión de una denominación en las listas de las Denominaciones Comunes Recomendadas no supone recomendación alguna en favor del empleo de la sustancia respectiva en medicina o en farmacia.

Las listas de Denominaciones Comunes Internacionales Propuestas (1–113) y Recomendadas (1–74) se encuentran reunidas en *Cumulative List No. 16, 2015* (disponible sólo en CD-ROM).


| | |
|---|--|
| Latin , English, French, Spanish: Recommended INN | <i>Chemical name or description; Molecular formula; Graphic formula</i> |
| DCI Recommandée | <i>Nom chimique ou description; Formule brute; Formule développée</i> |
| DCI Recomendada | <i>Nombre químico o descripción; Fórmula molecular; Fórmula desarrollada</i> |

adegramotidum

| | |
|--------------|--|
| adegramotide | human Wilms tumor protein (WT33)-(34-51)-peptide |
| adégramotide | protéine tumorale de Wilms humaine (WT33)-(34-51)-peptide |
| adegramotida | proteína tumoral de Wilms humana (WT33)-(34-51)-péptido |
| | $C_{87}H_{123}N_{19}O_{24}$ |
| | H-Trp-Ala-Pro-Val-Leu-Asp-Phe-Ala-Pro- -Pro-Gly-Ala-Ser-Ala-Tyr-Gly-Ser-Leu-OH 10 18 |

adomeglivantum


| | |
|--------------|--|
| adomeglivant | 3-(4-((1S)-1-[(4'- <i>tert</i> -butyl-2,6-dimethyl[1,1'-biphenyl]-4-yl)oxy]-4,4,4-trifluorobutyl)benzamido)propanoic acid |
| adoméglivant | acide 3-(4-((1S)-1-[(4'- <i>tert</i> -butyl-2,6-diméthyl[1,1'-biphényl]-4-yl)oxy]-4,4,4-trifluorobutyl)benzamido)propanoïque |
| adomeglivant | ácido 3-(4-((1S)-1-[(4'- <i>terc</i> -butil-2,6-dimetil[1,1'-bifenil]-4-il)oxi]-4,4,4-trifluorobutil)benzamido)propanoico |
| | $C_{32}H_{36}F_3NO_4$ |



afabycinum

| | |
|-----------|---|
| afabycin | {6-[(1E)-3-{methyl[(3-methyl-1-benzofuran-2-yl)methyl]amino}-3-oxoprop-1-en-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)methyl dihydrogen phosphate |
| afabicine | dihydrogénophosphate de {6-[(1E)-3-{méthyl[(3-méthyl-1-benzofuran-2-yl)méthyl]amino}-3-oxoprop-1-én-1-yl]-2-oxo-3,4-dihydro-1,8-naphthyridin-1(2H)-yl)méthyle |

afabicina

dihidrogenofosfato de {6-[(1*E*)-3-{metil[(3-metil-1-benzofuran-2-il)metil]amino}-3-oxoprop-1-en-1-il]-2-oxo-3,4-dihidro-1,8-naftiridin-1(2*H*)-il]metilo $C_{23}H_{24}N_3O_7P$ **alicapistatum**


alicapistat

(2*R*)-1-benzyl-*N*-[(2*RS*)-4-(cyclopropylamino)-3,4-dioxo-1-phenylbutan-2-yl]-5-oxopyrrolidine-2-carboxamide

alicapistat

(2*R*)-1-benzyl-*N*-[(2*RS*)-4-(cyclopropylamino)-3,4-dioxo-1-phénylbutan-2-yl]-5-oxopyrrolidine-2-carboxamide

alicapistat

(2*R*)-1-bencil-*N*-[(2*RS*)-4-(ciclopropilamino)-1-fenil-3,4-dioxobutan-2-il]-5-oxopirrolidina-2-carboxamida $C_{25}H_{27}N_3O_4$ **alidornasum alfa #**

alidornase alfa

$N^{2,1}$ -glycyl-deoxyribonuclease I (DNase I), human, produced in *Nicotiana tabacum* cell culture, glycoform alfa, chemically amidated by condensation of an average of about 10-12 molecules of ethane-1,2-diamine per enzyme molecule with free carboxy groups to give *N*-(2-aminoethyl) carboxamide groups (about 7 per molecule on average) and intramolecularly *N,N'*-(ethane-1,2-diyl)-bridged pairs of carboxamide groups

alidornase alfa

$N^{2,1}$ -glycyl-déoxyribonucléase I (DNase I), humaine, produite par cultures de cellules de *Nicotiana tabacum*, glycoforme alfa, formant des fonctions amides par condensation chimique d'en moyenne environ 10-12 molécules d'éthane-1,2-diamine par molécule d'enzyme avec des groupes carboxy libres pour donner des groupes *N*-(2-aminoéthyl) carboxamide (environ 7 par molécule en moyenne) et des ponts intramoléculeaires de groupes *N,N'*-(éthane-1,2-diyl) entre des paires de groupes carboxamides

alidornasa alfa

$N^{2,1}$ -glicil-desoxiribonucleasa I (DNasa I), humana, producida en cultivos de células de *Nicotiana tabacum*, glicofoma alfa, glicofoma alfa, formadora de funciones amidas por condensación química por término medio de 10-12 moléculas de etano-1,2-diamina por molécula de enzima con grupos carboxi libres para proporcionar grupos *N*-(2-aminoetil) carboxamida (aproximadamente 7 por molécula por término medio) y los puentes intramoleculares de grupos *N,N'*-(etano-1,2-diil) entre pares de grupos carboxamidas

```
GLKIAAFNIQ TFGETKMSNA TLVSYIVQIL SRYDIALVQE VRDShLTAVG 50
KLLDNLNQDA PDTYHYVVSE PLGRNSYKER YLFVYRPDQV SAVDSYYDD 100
GCEPCGNDF NREPAIVRFF SRFTVEVREFA IVPLHAAPGD AVAEIDALYD 150
VYLDVQEKWG LEDVMLMGDF NAGCSYVRPS QWSSIRLWTS PTFQWLIPDS 200
ADTTATPTHC AYDRIVVAGM LLRGAVVPS ALPFNFQAA YGLSDQLAQAI 250
SDHYPEVML K 261
```

Disulfide bridges location / position des ponts disulfure / posiciones de los puentes disulfuro
102-105, 174-210

N-glycosylation sites / sites de N-glycosylation / sitios de N-glicosilación
Asn 19, Asn 107

Ethane-1,2-diamine modification sites: Asp and Glu residues and C-terminal

andecaliximab #
andecaliximab

immunoglobulin G4-kappa, anti-[*Homo sapiens* MMP9 (matrix metallopeptidase 9, gelatinase B)], chimeric monoclonal antibody;
gamma4 heavy chain (1-442) [chimeric VH (*Mus musculus* IGHV2-9*02 -(IGHD) -*Homo sapiens* IGHJ4*01) [8.7.9] (1-115), *Homo sapiens* IGHG4*01 (CH1 (116-213), hinge S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-214')-disulfide with kappa light chain (1'-214') [chimeric V-KAPPA (*Mus musculus* IGKV6-17 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dimer (221-221":224-224")-bisdisulfide

andécaliximab

immunoglobuline G4-kappa, anti-[*Homo sapiens* MMP9 (matrice métallopeptidase 9, gélatinase B)], anticorps monoclonal chimérique;
chaîne lourde gamma4 (1-440) [VH chimérique (*Mus musculus* IGHV2-9*02 -(IGHD) -*Homo sapiens* IGHJ4*01) [8.7.9] (1-115), *Homo sapiens* IGHG4*01 (CH1 (116-213), charnière S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA chimérique (*Mus musculus* IGKV6-17 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dimère (221-221":224-224")-bisdisulfure

andecaliximab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* MMP9 (matriz metalopeptidasa 9, gelatinasa B)], anticuerpo monoclonal quimérico;
cadena pesada gamma4 (1-440) [VH quimérico (*Mus musculus* IGHV2-9*02 -(IGHD) -*Homo sapiens* IGHJ4*01) [8.7.9] (1-115), *Homo sapiens* IGHG4*01 (CH1 (116-213), bisagra S10>P (223) (214-225), CH2 (226-335), CH3 (336-440), CHS (441-442)) (116-442)], (129-214')-disulfuro con

la cadena ligera kappa (1'-214') [V-KAPPA quimérico (*Mus musculus* IGKV6-17 -*Homo sapiens* IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dímero (221-221":224-224")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLQESGPG LVKPSSETLSL TCTVSGFSLI SYGVHWVRQP PGRGLEWLVG 50
 IWTGGTTNYN SALMSRFTIS KDDSKNTVYL KMNSLKTEDT AIYYCARYYY 100
 GMDYWGQGTI VTVSSASTKG PSVFP LAPCS RSTSESTAAL GCLVKDYFPE 150
 PVTVSWNSGA LTVSGVHTFPA VLQSSGLYSL SSVVTVPSSS LGKTTYTCNV 200
 DHKPSNTKVD KRVESKYGPP CPFCPAPEFL GGPSVFLFPP KPKDTLMISR 250
 TPEVTCVVVD VSQEDPEVQF NNYVDGVEVH NAKTKPREEQ FNSTYRVVVS 300
 LTVLHQDWLN GKELYKCKVSN KGLPSSIEKT ISKAKQPRE PQVYTLPPSQ 350
 EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTFP PVLDSGDSFF 400
 LYSRLTVDKS RWQEGNVFSC SVMHEALHNH YTKSLSLSL GK 442

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVT ITCKASQDVR NTVAWYQQKPK GKAPKLLIYS 50
 SSYRNTGVPD RFSGSGSGTD FTLTISLQA EDVAVYCCQ HYITPPTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFF PREAKVQWKV 150
 DNALQSGNSQ ESVEEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGECC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 142-198 256-316 362-420
 22"-95" 142"-198" 256"-316" 362"-420"
 Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"
 Inter-H-L (CH1 10-CL 126) 129-214' 129"-214"
 Inter-H-H (h 8, h 11) 221-221" 224-224"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2N84.4:
 292, 292"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaríos complejos fucosilados

apararenonum

apararenone


N-[4-(4-fluorophenyl)-2,2-dimethyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl]methanesulfonamide

apararénone

N-[4-(4-fluorophényl)-2,2-diméthyl-3-oxo-3,4-dihydro-2*H*-1,4-benzoxazin-7-yl]méthanesulfonamide

apararenona

N-[4-(4-fluorofenil)-2,2-dimetil-3-oxo-3,4-dihidro-2*H*-1,4-benzoxazin-7-il]metanosulfonamida

 $C_{17}H_{17}FN_2O_4S$


apimostinelum

apimostinel



L-threonyl-L-prolyl-2-benzyl-L-prolyl-L-threoninamide

apimostinel

L-thréonyl-L-prolyl-2-benzyl-L-prolyl-L-thréoninamide

apimostinel

L-treonil-L-prolil-2-bencil-L-prolil-L-treoninamida



aprutumabum #
aprutumab

immunoglobulin G1-lambda1, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, CD332)], *Homo sapiens* monoclonal antibody; gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD)-IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfide with lambda1 light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimer (231-231":234-234")-bisdisulfide

aprutumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* FGFR2 (récepteur 2 du facteur de croissance des fibroblastes, récepteur du facteur de croissance des kératinocytes, KGFR, CD332)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD)-IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), charnière (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfure avec la chaîne légère lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimère (231-231":234-234")-bisdisulfure

aprutumab

immunoglobulina G1-lambda1, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de los fibroblastos, receptor del factor de crecimiento de los queratinocitos, KGFR, CD332)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD)-IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), bisagra (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfuro con la cadena ligera lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

| | | | | | |
|------------|------------|------------|------------|------------|-----|
| EVQLLESGGG | LVQPGGSLRL | SCAASGFTFS | SYAMSWVRQA | PGKLEWYSA | 50 |
| ISGSGTSTYY | ADSVKGRFTI | SRDNSKNTLY | LQMNLSRAED | TAVYYCARVR | 100 |
| YNWNGHDWFD | PWGQGLTVT | SSASTKGPSV | FPLAPSKST | SGGTAALGCL | 150 |
| VKDYFPEPVT | VSWNSGALTS | GVHTFPAVLQ | SSGLYSLSSV | VTVPSSSLGT | 200 |
| QTYICNWNHK | PSNTKVDKVK | EPKSCDKTHT | CPPCPAPELL | GGPSVFLFPP | 250 |
| KPKDTLMISR | TPEVTCVVVD | VSHEDPEVKE | NWYVDGVEVH | NARTKPREEQ | 300 |
| YNSTYRVVSV | LTVLHQDQLN | GKEYKCKVSN | KALPAPIEKT | ISKAKGQPRE | 350 |
| PQVYTLPPSR | DELTKNQVSL | TCLVKGFPYS | DIAVEWESNG | QPENNYKTPP | 400 |
| PVLDSGSGFF | LYSKLTVDKS | RWQQGNVFS | SVMHEALHNH | YTKKSLSLSP | 450 |
| G | | | | | 451 |

Light chain / Chaîne légère / Cadena ligera

| | | | | | |
|------------|------------|------------|------------|------------|-----|
| QSVLTQPPSA | SGTPGQRVTI | SCSGSSSNIG | NNYVSWYQQL | PGTAPKLLIY | 50 |
| ENYNRPAGVP | DRFSGSKSGT | SASLAISGLR | SEDEADYCS | SWDDSLNYWV | 100 |
| FGGKTLTVL | GQPKAAPSVT | LFPSSSEELQ | ANKATLVCLI | SDFYPGAVTV | 150 |
| AWKADSSPVK | AGVETTTPSK | QSNNKYAASS | YLSLTPEQWK | SHRSYSCQVT | 200 |
| HEGSTVEKTV | APTECS | | | | 216 |

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|--------------------|---------|-----------|-----------|-----------|
| Intra-H (C23-C104) | 22-96 | 149-205 | 266-326 | 372-430 |
| | 22"-96" | 149"-205" | 266"-326" | 372"-430" |

| | | |
|--------------------|---------|-----------|
| Intra-L (C23-C104) | 22'-89' | 138'-197' |
| | 22"-89" | 138"-197" |

| | | |
|------------------------|----------|-----------|
| Inter-H-L (h 5-CL 126) | 225-215' | 225"-215" |
| Inter-H-H (h 11, h 14) | 231-231' | 234-234" |

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2N84.4:
302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanes de tipo CHO biantenaríos complejos fucosilados

aprutumabum ixadotinum #
aprutumab ixadotin

immunoglobulin G1-lambda1, anti-[*Homo sapiens* FGFR2 (fibroblast growth factor receptor 2, keratinocyte growth factor receptor, KGFR, CD332)], *Homo sapiens* monoclonal antibody conjugated to an auristatin W derivative;
gamma1 heavy chain (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfide with lambda1 light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimer (231-231":234-234")-bisdisulfide; conjugated, on an average of 4 lysyl, to *N*-(5-carboxypentyl)-*N*-demethyl-auristatin W (AW) C^{1.5}-(1,2-oxazinan-2-yl) derivative

aprutumab ixadotine

immunoglobuline G1-lambda1, anti-[*Homo sapiens* FGFR2 (récepteur 2 du facteur de croissance des fibroblastes, récepteur du facteur de croissance des kératinocytes, KGFR, CD332)], *Homo sapiens* anticorps monoclonal conjugué à un dérivé de l'auristatine W;
chaîne lourde gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17,1 (CH1 (123-220), charnière (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfure avec la chaîne légère lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dimère (231-231":234-234")-bisdisulfure; conjugué, sur 4 lysyl en moyenne, au dérivé C^{1.5}-(1,2-oxazinan-2-yle) de *N*-(5-carboxypentyl)-*N*-desméthyl-auristatine W (AW)

aprutumab ixadotina

immunoglobulina G1-lambda1, anti-[*Homo sapiens* FGFR2 (receptor 2 del factor de crecimiento de los fibroblastos, receptor del factor de crecimiento de los queratinocitos, KGFR, CD332)], *Homo sapiens* anticuerpo monoclonal conjugado a un derivado de la auristatina W; cadena pesada gamma1 (1-451) [*Homo sapiens* VH (IGHV3-23*01 (98.00%) -(IGHD) -IGHJ5*02) [8.8.15](1-122) -IGHG1*01, Gm17.1 (CH1 (123-220), bisagra (236-345), CH2 (236-345), CH3 (346-450), CHS K>del (451)) (123-451)], (225-215')-disulfuro con la cadena ligero lambda1 (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (90.70%) -IGLJ3*02) [8.3.11] (1'-110') -IGLC2*01 (111'-216')]; dímero (231-231'':234-234'')-bisdisulfuro; conjugado, en 4 grupos lisil por término medio, con el derivado C^{1,5}-(1,2-oxazinan-2-ilo) de *N*-(5-carboxipentil)-*N*-desmetil-auristatina W (AW)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50
ISGSGTSTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYCARVR 100
YNNWNGDWFDPWQQTGLTVT SSASTKGPVS FPLAPSKST SGGTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPVSSSLGT 200
QTYICNVNHK PSNTKVKDKV EPKSCDKTHT CFPKPAPELL GGPVFLPPP 250
KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NNYVDGVEVH NAKTKPREEQ 300
YNSTYRWSV LTVLHQDWLNL GKEYKCKVSN KALPAPIEKI ISKAKGQPRE 350
PQVYTLPPSR DELTQNQVSL TCLVKGFPYS DIAVEWESNG QPENNYKTTT 400
PVLDSGSEFF LYSKLTVDKRS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP 450
G 451
```

Light chain / Chaîne légère / Cadena ligera

```
QSVLTQPPSA SGTGQQRVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY 50
ENYNRPAGVP DRFSGSKSGT SASLAISGLR SEDEADYCS SWDDSLNYWV 100
FGGGTKLTVL GQPKAAPSVT LFPSSSEELQ ANKATLVCLI SDFYPGAVTV 150
ANKADSSPVK AGVETTTPSK QSNNKYAASS YLSLTPQWQK SHRSYSCQVT 200
HEGSTVEKTV APTECS 216
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22°-96' 149°-205' 266°-326' 372°-430'
 22°-96" 149°-205" 266°-326" 372°-430"
 Intra-L (C23-C104) 22°-89' 138°-197'
 22°-89" 138°-197"
 Inter-H-L (h 5-CL 126) 225°-215' 225°-215"
 Inter-H-H (h 11, h 14) 231°-231' 234°-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

302, 302"


Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales

An average of 4 lysyl are substituted

4 lysils sont substitués en moyenne.

4 lisils estan substituidos pro término medio.



asciminibum

asciminib


N-[4-(chlorodifluoromethoxy)phenyl]-6-[(3*R*)-3-hydroxypyrrolidin-1-yl]-5-(1*H*-pyrazol-3-yl)pyridine-3-carboxamide

asciminib

N-[4-(chlorodifluorométhoxy)phényl]-6-[(3*R*)-3-hydroxypyrrolidin-1-yl]-5-(1*H*-pyrazol-3-yl)pyridine-3-carboxamide

asciminib

N-[4-(clorodifluorometoxi)fenil]-6-[(3*R*)-3-hidroxipirrolidin-1-il]-5-(1*H*-pirazol-3-il)piridina-3-carboxamida

$$C_{20}H_{18}ClF_2N_5O_3$$
**atuveciclibum**

atuveciclib


(+)-[3-[[4-(4-fluoro-2-methoxyphenyl)-1,3,5-triazin-2-yl]amino]phenyl)methyl](imino)(methyl)-λ⁶-sulfanone

atuvéciclib

(+)-[3-[[4-(4-fluoro-2-méthoxyphényl)-1,3,5-triazin-2-yl]amino]phényl)méthyl](imino)(méthyl)-λ⁶-sulfanone

atuveciclib

(+)-[3-[[4-(4-fluoro-2-metoxifenil)-1,3,5-triazin-2-il]amino]fenil]metil](imino)(metil)-λ⁶-sulfanona

$$C_{18}H_{18}FN_5O_2S$$
**audencelum**

audencel

autologous interleukin (IL)-12-secreting dendritic cells (DCs), loaded with autologous tumour lysate, comprising >70% of total immune cells. The cells are differentiated from autologous monocytes by culturing in the presence of interleukin (IL)-4 and GM-CSF (granulocyte-macrophage colony-stimulating factor), following which they are exposed to the patient's tumor protein/tumor-associated antigen (TAA), and subsequently to lipopolysaccharide (LPS) in the presence of interferon gamma (IFN-γ) to enable IL-12 secretion.

audencel
 cellules dendritiques autologues sécrétant de l'interleukine-12 (IL-12), chargées avec un lysat de tumeur autologue, comprenant plus de 70% du total des cellules immunitaires. Les cellules sont différenciées à partir de monocytes autologues par une culture en présence d'interleukine-4 (IL-4) et de facteur de stimulation des colonies de granulocytes et de macrophages (GM-CSF), ensuite elles sont exposées à la protéine tumorale/antigène associé à la tumeur du patient, puis au lipopolysaccharide (LPS) en présence d'interféron gamma (IFN- γ) afin de permettre la sécrétion d'IL-12.

audencel
 células dendríticas autólogas que secretan la interleukina-12 (IL-12), cargadas con un lisado de tumor autólogo, que comprende más del 70% del total de células inmunitarias. Las células se diferencian a partir de monocitos autólogos a través de un cultivo en presencia de interleukina-4 (IL-4) y del factor de estimulación de las colonias de granulocitos y de macrófagos (GM-CSF), a continuación ellas se exponen a la proteína tumoral/antigénica asociada al tumor del paciente (TAA), y después al lipopolisacárido (LPS) en presencia del interferón gamma (IFN- γ) para permitir la secreción de la IL-12.

birabresibum

birabresib


2-[(6*S*)-4-(4-chlorophenyl)-2,3,9-trimethyl-6*H*-thieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-yl]-*N*-(4-hydroxyphenyl)acetamide

birabrésib

2-[(6*S*)-4-(4-chlorophényl)-2,3,9-triméthyl-6*H*-thiéno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazépin-6-yl]-*N*-(4-hydroxyphényl)acétamide

birabresib

2-[(6*S*)-4-(4-clorofenil)-2,3,9-trimetil-6*H*-tieno[3,2-*f*][1,2,4]triazolo[4,3-*a*][1,4]diazepin-6-il]-*N*-(4-hidroxifenil)acetamida

C₂₅H₂₂ClN₅O₂S**branaplamum**


branaplam

5-(1*H*-pyrazol-4-yl)-2-{6-[(2,2,6,6-tetramethylpiperidin-4-yl)oxy]pyridazin-3-yl}phenol

branaplam

5-(1*H*-pyrazol-4-yl)-2-{6-[(2,2,6,6-tétraméthylpipéridin-4-yl)oxy]pyridazin-3-yl}phénol

branaplam

5-(1*H*-pirazol-4-il)-2-{6-[(2,2,6,6-tetrametilpiperidin-4-il)oxil]piridazin-3-il}fenolC₂₂H₂₇N₅O₂brazikumabum #
brazikumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* IL23A (interleukin 23 subunit alpha, IL-23A, IL-23 subunit p19, IL23p19)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-450) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.17] (1-124) -IGHG2*01, G2m.. (CH1 (125-222), hinge (223-234), CH2 (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-216')-disulfide with lambda light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ3*02) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (226-226":227-227":230-230":233-233")-tetrakisdisulfide

brazikumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* IL23A (interleukine 23 sous-unité alpha, IL-23A, IL-23 sous-unité p19, IL23p19)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-450) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.17] (1-124) -IGHG2*01, G2m.. (CH1 (125-222), charnière (223-234), CH2 (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-216')-disulfure avec la chaîne légère lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ3*02) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226":227-227":230-230":233-233")-tétrakisdisulfure

brazikumab

inmunoglobulina G2-lambda, anti-[*Homo sapiens* IL23A (interleukina 23 subunidad alfa, IL-23A, IL-23 subunidad p19, IL23p19)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-450) [*Homo sapiens* VH (IGHV3-33*01 (99.00%) -(IGHD)-IGHJ3*02) [8.8.17] (1-124) -IGHG2*01, G2m.. (CH1 (125-222), bisagra (223-234), CH2 (235-343), CH3 (344-448), CHS (449-450)) (125-450)], (138-216')-disulfuro con la cadena ligera lambda (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-40*01 (96.00%) -IGLJ3*02) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226":227-227":230-230":233-233")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVESGGG VVQPGRSLRL SCAASGFTFS SYGMHWVRQA PGKGLEWVAV 50
 IWYDGSNEY Y ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVVYCARDR 100
 GYTSWYYPDA FDIWQGQTMV TVSSASTKGF SVFPLAPCSR STSESTAALG 150
 CLVKDYFPEP VTVSWNSGAL TSGVHTFPAV LQSSGLYSLS SVVTVPSSNF 200
 GTQTYTCNVD HKPSNTKVDK TVERKCCVEC PFCPPAPPVAG PSVFLFPPKP 250
 KDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNA KTKPREEQFN 300
 STFRVSVLT VVHQDWLNGK EYKCKVSNKGLPAPIEKTIIS KTRKQPREPQ 350
 VYTLPPSREE MTKNQVSLTCLVKGFYPSDI AVEWESNGQP ENNYKTTTPM 400
 LDDSGSFLY SKLTVDKSRW QQGNVFSQSV MHEALHNHYT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera
 QSVLTQPPSV SGAPGQRVTI SCTGSSNTG AGYDVHWYQQ VPGTAPKLLI 50
 YGSGNRPSGV PDRFSGSKSG TSASLAITGL QAEDADYYC QSYDSSLG 100
 VFGGGTRLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
 VAMKADSSPV KAGVETTTFS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200
 THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 151-207 264-324 370-428
 22"-96" 151"-207" 264"-324" 370"-428"
 Intra-L (C23-C104) 22'-90' 139"-198"
 22"'-90"' 139"'-198"
 Inter-H-L (CH1 10-CL 126) 138-216' 138"-216"
 Inter-H-H (h 4, h 5, h 8, h 11) 226-226" 227-227" 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 300, 300"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés

brilanestrantum
 brilanestrant


(2*E*)-3-{4-[(1*E*)-2-(2-chloro-4-fluorophenyl)-1-(1*H*-indazol-5-yl)but-1-en-1-yl]phenyl}prop-2-enoic acid

brilanestrant

acide (2*E*)-3-{4-[(1*E*)-2-(2-chloro-4-fluorophényl)-1-(1*H*-indazol-5-yl)but-1-én-1-yl]phényl}prop-2-énoïque

brilanestrant

ácido (2*E*)-3-{4-[(1*E*)-2-(2-cloro-4-fluorofenil)-1-(1*H*-indazol-5-il)but-1-en-1-il]fenil}prop-2-enoico



burosumabum #
 burosumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* FGF23 (fibroblast growth factor 23)], *Homo sapiens* monoclonal antibody;

| | |
|-----------|---|
| | <p>gamma1 heavy chain (1-447) [<i>Homo sapiens</i> VH (IGHV1-46*01 (94.90%) -(IGHD) -IGHJ3*02) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447))(118-447)], (220-213')-disulfide with kappa light chain (1'-213') [<i>Homo sapiens</i> V-KAPPA (IGKVD1-13*01 (97.90%) -IGKJ3*01) [6.3.8] (1'-106') -IGKC*01, Km3 (107'-213')]; dimer (226-226":229-229")-bisdisulfide</p> |
| burosumab | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> FGF23 (facteur de croissance des fibroblastes 23)], <i>Homo sapiens</i> anticorps monoclonal; chaîne lourde gamma1 (1-447) [<i>Homo sapiens</i> VH (IGHV1-46*01 (94.90%) -(IGHD) -IGHJ3*02) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-213')-disulfure avec la chaîne légère kappa (1'-213') [<i>Homo sapiens</i> V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ3*01) [6.3.8] (1'-107') -IGKC*01, Km3 (107'-213')]; (226-226":229-229")-bisdisulfure</p> |
| burosumab | <p>immunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> FGF23 (factor de crecimiento de los fibroblastos 23)], <i>Homo sapiens</i> anticuerpo monoclonal; cadena pesada gamma1 (1-447) [<i>Homo sapiens</i> VH (IGHV1-46*01 (94.90%) -(IGHD) -IGHJ3*02) [8.8.10] (1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-213')-disulfuro con la cadena ligera kappa (1'-213') [<i>Homo sapiens</i> V-KAPPA (IGKV1-13*02 (97.90%) -IGKJ3*01) [6.3.8] (1'-107') -IGKC*01, Km3 (107'-213')]; (226-226":229-229")-bisdisulfuro</p> |
| | <p>Heavy chain / Chaîne lourde / Cadena pesada</p> <pre> QVQLVQSGAE VKKPGASVKV SCKASGYTFT NHYMHVWRQA PGQGLEWMGI 50 INPISGSGSN AQRFGQGRVTM TRDTSTSTVY MELSSLSRSED TAVYYCARDI 100 VDADFWDGQG TMTVTVSSAST KGPSVFLPLAP SSKSTSGGTA ALGCLVKDFY 150 PEPFTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200 NVNHKPSNTK VDKKVEPKSC DKHTCTCPCP APELLGGPSV FLFPPKPKDT 250 LMISRTEPVT CVVVDVSHED PEVKFNWYVD GVEVHNARTK PREEQYNSTY 300 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK GQPREPQVYT 350 LPSPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS 400 DGSFFLYSKL TVDKSRWQQG NWFSCSVME ALHNNHYTKS LSLSPGK 447 </pre> |
| | <p>Light chain / Chaîne légère / Cadena ligera</p> <pre> AIQLTQSPSS LSASVGRDRTV ITCRASQGIS SALVWVQKQP GKAPKLLIYD 50 ASSLESQVPS RFGSGSGGTD FTLTISLQSP EDFATYYCQQ FNDYFTFGPG 100 TKVDIKRTVA APSVFIFPPS DEQLKSGTAS VVCLLNFPY REAKVQWKVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYEKHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213 </pre> |
| | <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>Intra-H (C23-C104) 22-96 144-200 261-321 367-425 22"-96" 144"-200" 261'-321' 367"-425"</p> <p>Intra-L (C23-C104) 23'-88" 133"-193' 23'''-88''' 133'''-193'''</p> <p>Inter-H-L (h 5-CL 126) 220-213" 220"-213"</p> <p>Inter-H-H (h 11, h 14) 226-226" 229-229"</p> |
| | <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 297, 297"</p> <p>Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenariós complejos fucosilados</p> |

camrelizumabum #

camrelizumab

immunoglobulin G4-kappa, anti-[*Homo sapiens* PDCD1 (programmed cell death 1, PD-1, PD1, CD279)], humanized monoclonal antibody;
gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), hinge S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (222-222":225-225")-bisdisulfide

camrélizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* PDCD1 (protéine 1 de mort cellulaire programmée, PD-1, PD1, CD279)], anticorps monoclonal humanisé;
chaîne lourde gamma4 (1-443) [VH humanisé (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), charnière S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (222-222":225-225")-bisdisulfure

camrelizumab

immunoglobulina G4-kappa, anti-[*Homo sapiens* PDCD1 (proteína 1 de muerte celular programada, PD-1, PD1, CD279)], anticuerpo monoclonal humanizado;
cadena pesada gamma4 (1-443) [VH humanizado (*Homo sapiens* IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), bisagra S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (222-222":225-225")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCAASGFTFS SYMMSWVRQA PGKGLEWVAT 50
 ISGGGANTYY PDSVKGRFTI SRDNAKNSLY LQMSNLRAED TAVVYCARQL 100
 YFDYWGQGT TTVVSSASTK GPSVFPLAPC SRSTSESTAA LGCLVKDYFP 150
 EPVTVSWSNG ALTSGVHTFP AVLQSSGLYS LSSVVTVPSS SLGKTKYTCN 200
 VDHKPSNTKV DKRVESKYGF PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
 RTPVETCVVV DVSQEDPEVQ FNWYVDGVEV HNAKTKPREE QFNSTYRVVS 300
 VLTVLHQDWL NGKEYKCKVS NGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
 QEEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSGDSF 400
 FLYSRLTVDK SRWQEGNVFS CSMVHEALHN HYTQKSLSLG LGK 443

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVIT ITCLASQTIG TWLTYQQKP GKAPKLLIYT 50
 ATSLADGVPS RFSGSGSGTD FTLTISSLQP EDFATYYCQQ VYSIPWTFGG 100
 GTKVEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYKHKH VYACEVTHQG 200
 LSSPVTKSFN RGECC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 257-317 363-421
 22"-96" 143"-199" 257"-317" 363"-421"

Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 130-214" 130"-214"
 Inter-H-H (h 8, h 11) 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 293, 293"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes
 fucosylés / glycanes de tipo CHO biantenarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traductionnelles /

Otras modificaciones post-traduccionales

H CHS K2 C-terminal lysine clipping:

443, 443"

cannabidiolum

cannabidiol

2-[(1*R*,6*R*)-3-methyl-6-(prop-1-en-2-yl)cyclohex-2-en-1-yl]-
 5-pentylbenzene-1,3-diol


cannabidiol

2-[(1*R*,6*R*)-3-méthyl-6-(prop-1-én-2-yl)cyclohex-2-én-1-yl]-
 5-pentylbenzène-1,3-diol

cannabidiol

2-[(1*R*,6*R*)-3-metil-6-(prop-1-en-2-il)ciclohex-2-en-1-il]-
 5-pentilbenceno-1,3-diol

C₂₁H₃₀O₂

**casimersenum**

casimersen



all-P-ambo-[2',3'-azanediyl-*P*-(dimethylamino)-*P*,2',3'-trideoxy-2',3'-seco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G) 5'-{*P*-[4-({2-[2-(2-hydroxyethoxy)ethoxy]ethoxy}carbonyl)piperazin-1-yl]-*N,N*-dimethylphosphonamidate}

casimersen

5'-{*P*-[4-({2-[2-(2-hydroxyéthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-*N,N*-diméthylphosphonamidate} de *tout-P-ambo*-[2',3'-azanediyl-*P*-(diméthylamino)-*P*,2',3'-tridéoxy-2',3'-séco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G)

casimersén

5'-(*P*-[4-({2-[2-(2-hidroxi)etoxi]etoxi)carbonil]piperazin-1-il]-*N,N*-dimetilfosfonamidato} de *todo-P-ambo*-[2',3'-azanediil-*P*-(dimetilamino)-*P*,2',3'-tridesoxi-2',3'-seco](2'-*N*→5')(C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G)



B(1-22):
C-A-A-T-G-C-C-A-T-C-C-T-G-G-A-G-T-T-C-C-T-G

cenegerminum #

cenegermin


human beta-nerve growth factor (beta-NGF)-(1-118)-peptide (non-covalent dimer) produced in *Escherichia coli*

cénégermine

facteur de croissance bêta des cellules nerveuses (beta-NGF)-(1-118)-peptide, humain, produit par *Escherichia coli*

cenegermina

factor de crecimiento beta de las células nerviosas (beta-NGF)-(1-118)-péptido humano (dímero no covalente), producido por *Escherichia coli*



```
SSSHPIFHRG EFSVCDSVSV WVGDKTTATD IKGKEVMVLG EVNINNSVFK 50
QYFFETKCRD PNPVDSGCRG IDSKHWNYSY TTTHTFVKAL TMDGQAAWR 100
FIRIDTACVC VLSRKA VR                                     118
```

Disulfide bridges position / Position des ponts disulfure / Posiciones de los puentes disulfuro
15-80 58-108 68-110


cenplacelum

cenplacel

Human placenta-derived adherent (PDA) cells that are culture-expanded, undifferentiated mesenchymal-like cells derived from full-term placental tissue of a human donor. Cellular identity: Mesenchymal-like stromal cell: CD34⁺, CD10⁺, CD105⁺, and CD200⁺. Cells lack the human leukocyte antigen (HLA) and costimulatory molecules on their membrane surface.

cenplacel

Cellules humaines adhérentes dérivées du placenta, en culture d'expansion, cellules semblables aux cellules mésenchymateuses non-différenciées dérivées de tissu placentaire à terme de donneur humain. identité des cellules: cellules stromales semblables aux cellules mésenchymateuses: CD34⁺, CD10⁺, CD105⁺, and CD200⁺. Les cellules sont dépourvues de l'antigène leucocytaire humain (HLA) et des molécules co-stimulantes à la surface de la membrane.

| | |
|---|--|
| cenplacel | <p>Células humanas adherentes derivadas de la placenta (PDA) expandidas por cultivo, células semejantes a las células mesenquimales no diferenciadas derivadas del tejido placentario a término.</p> <p>Identificación de las células: células estromales semejantes a las células mesenquimales: CD34⁺, CD10⁺, CD105⁺, et CD200⁺.</p> <p>Las células están desprovistas del antígeno leucocitario humano (HLA) y de las moléculas coestimulantes de la superficie de la membrana</p> |
| cibinetidum cibinetide | 5-oxo-L-prolyl-L- α -glutamyl-L-glutaminyl-L-leucyl-L- α -glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyll-L-seryl-L-serine |
| cibinéside | 5-oxo-L-prolyl-L- α -glutamyl-L-glutaminyl-L-leucyl-L- α -glutamyl-L-arginyl-L-alanyl-L-leucyl-L-asparaginyll-L-séryl-L-sérine |
| cibinetida | 5-oxo-L-proliil-L- α -glutamyl-L-glutaminil-L-leucil-L- α -glutamill-L-arginyl-L-alanyl-L-leucil-L-asparaginyll-L-seril-L-serina C ₅₁ H ₈₄ N ₁₆ O ₂₁ |
| |  <p style="text-align: center;">Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser-OH₁₀</p> |
| crizanlizumabum # crizanlizumab | <p>immunoglobulin G2-kappa, anti-[<i>Homo sapiens</i> SELP (selectin P, CD62)], humanized monoclonal antibody; gamma2 heavy chain (1-448) [humanized VH (<i>Homo sapiens</i> IGHV1-8*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -<i>Homo sapiens</i> IGHG2*02 (CH1 (123-220), hinge (221-232), CH2 K105>A (323) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-39*01 (86.90%) -IGKJ4*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218'')]; dimer (224-224":225-225":228-228":231-231")-tetrakisdisulfide</p> |
| crizanlizumab | <p>immunoglobuline G2-kappa, anti-[<i>Homo sapiens</i> SELP (sélectine P, CD62)], anticorps monoclonal humanisé; chaîne lourde gamma2 (1-448) [VH humanisé (<i>Homo sapiens</i> IGHV1-8*01 (81.60%) -(IGHD) -IGHJ4*01) [8.8.15] (1-122) -<i>Homo sapiens</i> IGHG2*02 (CH1 (123-220), charnière (221-232), CH2 K105>A (323) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-39*01 (86.90%) -IGKJ4*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218'')]; dimère (224-224":225-225":228-228":231-231")-tétrakisdisulfure</p> |

| | |
|------------------------|--|
| | <p>gamma1 heavy chain (1-446) [humanized VH (<i>Homo sapiens</i> IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -<i>Homo sapiens</i> IGHG1*01, G1m17,1 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-5*01 (84.00%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01, Km3 (107'-213'))]; dimer (225-225":228-228")-bisdisulfide</p> |
| <p>daclizumab bêta</p> | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IL2RA (sous-unité alpha du récepteur de l'interleukine 2, IL-2RA, TAC, p55, CD25)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-446) [VH humanisé (<i>Homo sapiens</i> IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -<i>Homo sapiens</i> IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfure avec la chaîne légère kappa (1'-213') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-5*01 (84.00%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01, Km3 (107'-213'))]; dimère (225-225":228-228")-bisdisulfure</p> |
| <p>daclizumab beta</p> | <p>immunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> IL2RA (subunidad alfa del receptor de la interleukina 2, IL-2RA, TAC, p55, CD25)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-446) [VH humanizado (<i>Homo sapiens</i> IGHV1-46*01 (82.70%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -<i>Homo sapiens</i> IGHG1*01, G1m17,1 (CH1 (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV1-5*01 (84.00%) -IGKJ1*01) [5.3.9] (1'-106') -<i>Homo sapiens</i> IGKC*01, Km3 (107'-213'))]; dímero (225-225":228-228")-bisdisulfuro</p> |
| | <p>Heavy chain / Chaîne lourde / Cadena pesada QVQLVQSGAE VVKPGSSVKV SCRASGYTFT SYRHHWVROA PGQGLEWIGY 50 INPSTGTYEY NQKFKDKATI TADESTNTAT MELSSLRSED TAVYFCARGG 100 GVFYWGQGT LVTVSSASTK GSFVFLAPS SKSTSGGTAA LGCLVKDYFP 150 EPVTVSWMNG ALTSQVHTFP AVLQSSGLYS LSSVVTVESS SLGTQTYICN 200 VNHKPSNTKV DKKVEPKSCD KTHTCPCCPA PELLGGPSVF LFFPKPKDTL 250 MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTRP REEQYNSTYR 300 VVSVLTVLHQ DWLNGKEYKC KVSNAKALPAP IEKTIKAKRG QPREPQVYTL 350 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQGPENNY RTTPPVLDSD 400 GSFFLYSKLT VDKSRWQQGN VFSCSVMHEA LHNHYTQKSL SLSPGK 446</p> <p>Light chain / Chaîne légère / Cadena ligera DIQMTQSFST LSASVGDRTV ITCSASSSIS YMHWYQQKPG KAPKLLIYTT 50 SNLASGVFAR FSGSGSGTEF TLTISLSLQPD DFATYYCHQR STYPLTFGQG 100 TKVEVKRTVA APSVFIPTPS DEQLKSGTAS VVCLNNFYF REARKVQWVD 150 NALQSGNSQE SVTEQDSKDS TYSLSSTLTL SKADYERHKV YACEVTHQGL 200 SSPVTKSFNR GEC 213</p> |
| | <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 143-199 260-320 366-424 22"-96" 143"-199" 260"-320" 366"-424" Intra-L (C23-C104) 23"-87" 133"-193" 23""-87"" 133""-193"" Inter-H-L (h 5-CL 126) 219-213' 219"-213" Inter-H-H (h 11, h 14) 225-225" 228-228"</p> |
| | <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84,4: 296, 296" Fucosylated complex bi-antennary NS0-type glycans with low level of high mannose glycans (sum of Man5, Man6 and Man7 <1%) / glycanes de type NS0 bi-antennaires complexes fucosylés avec un taux bas de glycanes riches en mannose (total of Man5, Man6 et Man7 <1%) / glicanos de tipo NS0 biantenaríos complejos fucosilados con una baja tasa de altas glicanos manosa (total de Man5, Man6 et Man7 <1%)</p> |

darolutamidum

darolutamide


N-{[(2*S*)-1-[3-(3-chloro-4-cyanophenyl)-1*H*-pyrazol-1-yl]propan-2-yl]-5-[(1*RS*)-1-hydroxyethyl]-1*H*-pyrazole-3-carboxamide

darolutamide

N-{[(2*S*)-1-[3-(3-chloro-4-cyanophényl)-1*H*-pyrazol-1-yl]propan-2-yl]-5-[(1*RS*)-1-hydroxyéthyl]-1*H*-pyrazole-3-carboxamide

darolutamida

N-{[(2*S*)-1-[3-(4-ciano-3-clorofenil)-1*H*-pirazol-1-il]propan-2-il]-5-[(1*RS*)-1-hidroxietil]-1*H*-pirazol-3-carboxamida

C₁₉H₁₉ClN₆O₂**depatuxizumabum #**

depatuxizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized and chimeric monoclonal antibody;
gamma1 heavy chain humanized (1-446) [humanized VH (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain chimeric (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (225-225":228-228")-bisdisulfide

dépatuxizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé et chimérique;
chaîne lourde gamma1 humanisée (1-446) [VH humanisé (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")-bisdisulfure

depatuxizumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (Receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado y quimérico;

cadena pesada gamma1 humanizada (1-446) [VH humanizado (*Homo sapiens* IGHV4-30-4*01 (84.50%) - (IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01, Km3 (108'-214'))]; dímero (225-225":228-228")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQESGPG LVKPSQTLST TCTVSGYSIS SDFAWNWIRO PPGKLEWMMG 50
 YISYSGNTRY QPSLKSRTIT SRDTSKNQFF LKLNVSVAAD TATYVCVTAG 100
 RGFPPYWGQGT LVTVSSASTK GPSVFLPLAPS SKSTSGGTTAA LGCLVKDYFP 150
 EPVTVSWNSG ALTSVGHVTFP AVLQSSGLYS LSSVVTVPSS SLGTQTYICN 200
 VNHKPSNTKV DKKVEPKSCD KHTCCPPCPA PELLGGPSVF LFPPKPKDTL 250
 MISRTPFVTC VVVDSVSHEDP EVKFNWYVDG VEVHNAKTF REEPQYNSTYR 300
 VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTIKAKG QPREPQVYTL 350
 PPSRDELTKN QVSLTCLVKG FYPSDIAVEW ESNQGQFENNY KTTTPVLDS 400
 GSFFLYSKLT VDKSRWQQGN VFSCVMHEA LHNHYTQKSL SLSPGK 446

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS MSVSVGDRVT ITCHSSQDIN SNIGWLQKPK GKSFKGLIYH 50
 GTNLDDGVPS RFSGSGSGTD YTLTISLQPE EDFATYCYVQ YAQFPWFYFG 100
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFFY PREAKVQMKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYERKH VYACEVTHQG 200
 LSSPVTKSNF RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 143-199 260-320 366-424
 22"-96" 143"-199" 260"-320" 366"-424"
 Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"
 Inter-H-L (h 5-CL 126) 219-214' 219"-214"
 Inter-H-H (h 11, h 14) 225-225" 228-228"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4;
 296, 296"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

depatuxizumabum mafodotinum #
 depatuxizumab mafodotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB)], humanized and chimeric monoclonal antibody conjugated to auristatin F;
 gamma1 heavy chain humanized (1-446) [humanized VH (*Homo sapiens* IGHV4-30-4*01 (84.50%) - (IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), hinge (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfide with kappa light chain chimeric (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214'))]; dimer (225-225":228-228")-bisdisulfide; conjugated, on an average of 4 cysteinyl, to monomethylauristatin F (MMAF), via a noncleavable maleimidocaproyl (mc) linker
 For the mafodotin part, please refer to the document "INN for pharmaceutical substances: Names for radicals, groups and others".

dépatuxizumab mafodotine

immunoglobuline G1-kappa, anti-[*Homo sapiens* EGFR (Récepteur du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erb-1, ERBB1, HER1, HER-1, ERBB)], anticorps monoclonal humanisé et chimérique conjugué à l'auristatine F;

chaîne lourde gamma1 humanisée (1-446) [VH humanisé (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), charnière (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfure avec la chaîne légère kappa chimérique (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (225-225":228-228")-bisulfure; conjugué, sur 4 cystéinyl en moyenne, au monométhylauristatine F (MMAF), via un linker maléimidocaproyl (mc) non clivable

Pour la partie *mafodotina*, veuillez-vous référer au document "INN for pharmaceutical substances: Names for radicals, groups and others".

depatuxizumab mafodotina

inmunoglobulina G1-kappa, anti-[*Homo sapiens* EGFR (Receptor del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erb-1, ERBB1, HER1, HER-1, ERBB)], anticuerpo monoclonal humanizado y quimérico conjugado con la auristatina F;

cadena pesada gamma1 humanizada (1-446) [VH humanizado (*Homo sapiens* IGHV4-30-4*01 (84.50%) -(IGHD)-IGHJ4*01) [9.7.9] (1-116) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (117-214), bisagra (215-229), CH2 (230-339), CH3 (340-444), CHS (445-446)) (117-446)], (219-214')-disulfuro con la cadena ligera kappa quimérica (1'-214') [*Mus musculus* V-KAPPA (*Mus musculus* IGKV14-100*01 -IGKJ1*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (225-225":228-228")-bisulfuro; conjugado, en 4 grupos cisteinil por término medio, con monometilauristatina F (MMAF), mediante un conector no escindible de tipo maleimidocaproyl (mc)

Por la parte *mafodotina*, por favor vaya al documento "INN for pharmaceutical substances: Names for radicals, groups and others".

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLQESGPG LVKPSQTLSL TCTVSGYSIS SDFAWNIRQ PFGKLEWNG 50
YISYSGNTRY QPSLKSRIIT SRDTSKNQFF LKLSVTRAD TATYYCVTAG 100
RGPYWGQGT LVTVSSASTK GPSVFLAPS SKSTSGGTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVTVFPSS SLGTQTYICN 200
VNHKPSNTKV DKKVEPKSCD KHTCCPPCA PELLGGPSVF LFPPKPKDTL 250
MISRTPVETC VVVVDSHEDP EVKFNWVVDG VEVHNAKTKP REEQYNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALPAP IEKTISKAKG QPREPQVYTL 350
PPSRDELTKN QVSLTCLVKG FYFSDIAVEW ESNQGPENNY KTTTPVLDSO 400
GSFFLYSKLT VDKSRWQQGN VFSCSMHEA LHNHYTQKSL SLSPGK 446

```

Light chain / Chaîne légère / Cadena ligera

```

DIQMTQSPSS MSVSVGDRVT ITCHSSQDIN SNIGWLQOKP GKSFKGLIYH 50
GTNLDLDCVPS RFGSGSGSDT YTLTISLQEP EDFATYYCVQ YAQFPWTFPG 100
GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFFY BREAKVQNKV 150
DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

| | | | | |
|--------------------|---------|-----------|-----------|-----------|
| Intra-H (C23-C104) | 22-96 | 143-199 | 260-320 | 366-424 |
| | 22"-96" | 143"-199" | 260"-320" | 366"-424" |
| Intra-L (C23-C104) | 23'-88' | 134'-194' | | |
| | 23"-88" | 134"-194" | | |

Inter-H-L (h 5-CL 126)* 219-214' 219"-214"

Inter-H-H (h 11, h 14)* 225-225" 228-228"

*Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

dexisometheptenum


dexisometheptene

(2*R*)-*N*,6-dimethylhept-5-en-2-amine

dexisométhéptène

(2*R*)-*N*,6-diméthylhept-5-én-2-amine

dexisometepteno

(2*R*)-*N*,6-dimetilhept-5-en-2-aminaC₉H₁₉N**dezamizumabum #**

dezamizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* APCS (amyloid P component serum, serum amyloid P component, SAP, pentraxin-2, PTX2)], humanized monoclonal antibody;
 gamma1 heavy chain (1-452) [humanized VH (*Homo sapiens* IGHV1-69*02 (85.70%) -(IGHD)-IGHJ5*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (123-220), hinge (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (231-231":234-234")-bisdisulfide

dézamizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* APCS (composant amyloïde P du sérum, composant amyloïde P sérique, APS, pentraxine-2, PTX2)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-452) [VH humanisé (*Homo sapiens* IGHV1-69*02 (85.70%) -(IGHD)-IGHJ5*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (123-220), charnière (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (231-231":234-234")-bisdisulfure

dezamizumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* APCS (componente amiloide P del suero, componente amiloide P serico, APS, pentraxina-2, PTX2)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-452) [VH humanizado (*Homo sapiens* IGHV1-69*02 (85.70%) -(IGHD)-IGHJ5*01) [8.8.15] (1-122) -*Homo sapiens* IGHG1*01, G1m17,1 (CH1 (123-220), bisagra (221-235), CH2 (236-345), CH3 (346-450), CHS (451-452)) (123-452)], (225-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (231-231":234-234")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGSSVKV SCKASGFTFA TYNMHWRQA PGQGLEWMGY 50
 IYPGDGNANY NQQPKGRVTI TADKSTSTAY MELSSLRSED TAVVYCARGD 100
 FFDYGGYYFD SWGQGLTVTV SSASTKGPSV PFLAPSSKST SGGTAALGCL 150
 VKDYFPEPVV SVWNSGALTS GVHTFPAVLQ SSGLYSLSSV VIVPSSSLGT 200
 QTYICNVNHK PSNTKVDKVK EPKSCDKTHT CPPCPAPELL GGPSVFLPPP 250
 KPKDTLMISR TPEVTCVVVD VSHEDEPKVF NNYVDGVEVH NAKTKPREEQ 300
 YNSTYRVVSV LTVLHQDWLN GKEYKCKVSN KALPAPIEKT ISKAKGQPRE 350
 PQVYTLPPSR DELTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP 400
 PVLDSGSEFF LYSKLTVDKS RWQQGNVFC SVMHEALHNN YTKSLSLSP 450
 GK 452

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRVTI ITCRASENIY SYLAWYQQKPK GKAPKLLIHN 50
 AKTLAEQVPS RFGSGSGSDT FTLTISSLQP EDFATYYCQH HYGAPLTFGQ 100
 GTKLEIKRVT AAPSVFIFPP SDEQLKSGTA SVVCLLNIFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSSTLT LSKADYERHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430
 22"-96" 149"-205" 266"-326" 372"-430"

Intra-L (C23-C104) 23"-88" 134"-194"
 23"-88" 134"-194"

Inter-H-L (h 5-CL 126) 225-214" 225"-214"

Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

dinutuximabum beta #

dinutuximab beta

immunoglobulin G1-kappa, anti-[*Homo sapiens* ganglioside GD2 (disialoganglioside GD2)], chimeric monoclonal antibody;

gamma1 heavy chain (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dimer (222-222":225-225")-bisdisulfide

dinutuximab bêta



immunoglobuline G1-kappa, anti-[*Homo sapiens* ganglioside GD2 (disialoganglioside GD2)], anticorps monoclonal chimérique;

chaîne lourde gamma1 (1-443) [*Mus musculus* VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (114-211), charnière (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfure avec la chaîne légère kappa (1'-220') [*Mus musculus* V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -*Homo sapiens* IGKC*01, Km3 (114'-220')]; dimère (222-222":225-225")-bisdisulfure

dinutuximab beta

inmunoglobulina G1-kappa, anti-[*Homo sapiens* gangliósido GD2 (disialogangliósido GD2)], anticuerpo monoclonal quimérico;

| | |
|--|--|
| dinutuximab bêta | <p>gamma1 heavy chain (1-443) [<i>Mus musculus</i> VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -<i>Homo sapiens</i> IGHG1*03, G1m3 (CH1 (114-211), hinge (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfide with kappa light chain (1'-220') [<i>Mus musculus</i> V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -<i>Homo sapiens</i> IGKC*01, Km3 (114'-220'')]; dimer (222-222'':225-225'')-bisdisulfide</p> |
| dinutuximab beta | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> ganglioside GD2 (disialoganglioside GD2)], anticorps monoclonal chimérique; chaîne lourde gamma1 (1-443) [<i>Mus musculus</i> VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -<i>Homo sapiens</i> IGHG1*03, G1m3 (CH1 (114-211), charnière (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfure avec la chaîne légère kappa (1'-220') [<i>Mus musculus</i> V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -<i>Homo sapiens</i> IGKC*01, Km3 (114'-220'')]; dimère (222-222'':225-225'')-bisdisulfure</p> <p>immunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> gangliósido GD2 (disialogangliósido GD2)], anticuerpo monoclonal quimérico; cadena pesada gamma1 (1-443) [<i>Mus musculus</i> VH (IGHV1S135*01 -(IGHD)-IGHJ4*01) [8.8.6] (1-113) -<i>Homo sapiens</i> IGHG1*03, G1m3 (CH1 (114-211), bisagra (212-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (114-443)], (216-220')-disulfuro con la cadena ligera kappa (1'-220') [<i>Mus musculus</i> V-KAPPA (IGKV1-110*01 -IGKJ5*01) [11.3.10] (1'-113') -<i>Homo sapiens</i> IGKC*01, Km3 (114'-220'')]; dimero (222-222'':225-225'')-bisdisulfuro</p> |
| | <p>Heavy chain / Chaîne lourde / Cadena pesada</p> <pre> EVQLQSGPE LEKFGASVMI SCKASGSSFT GYNNMWRQIN IGKSLWIGA 50 IDPYVGGFSY NQKFKGRATL TVDKSSSTAF MHLKLTSEED SAVYCVSGM 100 EYWGQCTSVT YSASTKGFPS VFPLAPSKKS TSGGTALGC LVKDYFPEPV 150 TVSWNSGALT SGVHTFFAVL QSSGLYSLSG VVTVPSSSLG TQTYICNVNH 200 KPSNTKVDKR VEPKSCDKTH TCFPCPAPEL LGGFSVFLFP KPKDPTLMIS 250 RTEVETCVVV DVSHEDPEVK FNNYVDGVEV HNAKTKPREE QYNSTYRVVS 300 VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS 350 REEMTKNQVS LTCLVKGFYP SDIAVEWESN QQPENNYKTT PPVLDSDGSP 400 FLYSKLTVDK SRWQGNVFS CSMVHEALHN HYTQKSLSLG PGK 443 </pre> <p>Light chain / Chaîne légère / Cadena ligera</p> <pre> EIVMTQSPAT LSVSPGERAT LSCRSSQSLV HRNGNTYLHW YLQKPGQSPK 50 LLIHKVSNRF SGVPDRFSGS GSGTDFTLKI SRVEAEDLGV YFCSQSTHVP 100 PLTFGAGTKL ELKRTVAAPS VFIFPPSDEQ LKSGTASVVC LLNNFYPREA 150 KVQWKVDNAL QSGNSQESVT EQDSKSTYS LSSTLTLSKA DYEKHKVYAC 200 EVTHQGLSSP VTKSFNRGEC 220 </pre> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro</p> <p>Intra-H (C23-C104) 22-96 140-196 257-317 363-421 22"-96" 140"-196" 257"-317" 363"-421"</p> <p>Intra-L (C23-C104) 23"-93" 140"-200" 23"-93" 140"-200"</p> <p>Inter-H-L (h 5-CL 126) 216-220' 216"-220" Inter-H-H (h 11, h 14) 222-222" 225-225"</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 293, 293'</p> <p>Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados</p> |
| dioximeli fumaras dioximel fumarate | <p>2-(2,5-dioxopyrrolidin-1-yl)ethyl methyl (2E)-but-2-enedioate</p> |

| | |
|-------------------------|---|
| fumarate de diroximel | (2E)-but-2-ènedioate de 2-(2,5-dioxopyrrolidin-1-yl)éthyle et de méthyle |
| fumarato de diroximel | (2E)-but-2-enodioato de 2-(2,5-dioxopirrolidin-1-il)etilo y de metilo |
| | C ₁₁ H ₁₃ NO ₆ |
| |  |
| elacestrantum | |
| elacestrant | (6R)-6-{2-[ethyl({4-[2-(ethylamino)ethyl]phenyl)methyl}amino)-4-methoxyphenyl]-5,6,7,8-tetrahydronaphthalen-2-ol |
| élacestrant | (6R)-6-{2-[éthyl({4-[2-(éthylamino)éthyl]phényl)méthyl}amino)-4-méthoxyphényl]-5,6,7,8-tétrahydronaphtalén-2-ol |
| elacestrant | (6R)-6-{2-[etil({4-[2-(etilamino)etil]fenil}metil)amino]-4-metoxifenil]-5,6,7,8-tetrahidronaftalen-2-ol |
| | C ₃₀ H ₃₈ N ₂ O ₂ |
| |  |
| elapegademasum # | |
| elapegademasum | [Cys ⁷⁴ >Ser,Ala ²⁴⁵ >Thr]adenosine deaminase (<i>Bos taurus</i> , bovine)-(1-356)-peptide, produced in <i>Escherichia coli</i> , substituted on N ² of the N-terminal alanyl residue (A ¹) and on N ⁶ of lysyl residues (K) with an average of approximately 13 ω-methoxypoly(oxyethylene)-α-carbonyl groups (~5 kDa each) |
| élapégadémase | [Cys ⁷⁴ >Ser,Ala ²⁴⁵ >Thr]adénosine déaminase (<i>Bos taurus</i> , bovine)-(1-356)-peptide, produit par <i>Escherichia coli</i> , substitué sur les N ² du résidu alanyl N-terminal (A ¹) et sur les N ⁶ des résidus lysyl (K) avec en moyenne 13 groupes ω-métoxi-poli(oxyéthylène)-α-carbonyle (~5 kDa chacun) approximativement |

elapegademasa

[Cys⁷⁴>Ser,Ala²⁴⁵>Thr]adenosina deaminasa (*Bos taurus*, bovino)-(1-356)-péptido, producido por *Escherichia coli*, sustituido en los N^o del resto alanilN-terminal (A¹) y en los N^o de los restos lisil (K) con una media de 13 grupos ω-metoxipoli(oxietileno)-α-carbonilo (~5 kDa cada uno de ellos) de forma aproximada


Sequence / Séquence / Secuencia

```

AQTFAFNKFK VELHVHLDGA IKPETILYYG RKRGIALPAD TPEELQNIIG 50
MDKFLSLPEF LAKFDYMPA IAGSREAVKR IAYEFVEMKA KDGVVYVEVR 100
YSPHLLANSK VEPFIPWQAE GDLTPEVVS LVNQGLQEGE RDFGVKVRSI 150
LCCMRHQPSW SSEVVELCKK YREQTVVAID LAGDETIEGS SLFPGHVKAY 200
AEAVKSGVHR TVHAGEVGS A NVVKEAVDTL KTERLGHGYH TLEDFTLYNR 250
LRQENMHFEV CPWSSYLTA WKPDTHEPVV RFRNDQVNYS LNTDDPLIFK 300
STLDTDYQMT KNEMGFTEEE FKRLNINAAK SSFLPEDEKK ELLDLLLYKAY 350
GMPSPA

```

Potential pegylated residues / Résidus pégylés potentiels / Restos pegilados potenciales

elezanumabum #
elezanumab

immunoglobulin G1-lambda1, anti-[*Homo sapiens* RGMA (repulsive guidance molecule family member a, repulsive guidance molecule A, RGMA)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-450) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13](1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), hinge (219-233), CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfide with lambda1 light chain (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimer (229-229'';232-232'')-bisdisulfide

élézanumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* RGMA (membre a de la famille de molécules d'orientation répulsive, molécule d'orientation répulsive A, RGMA)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-450) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), charnière (219-233), CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfure avec la chaîne légère lambda1 (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dimère (229-229'';232-232'')-bisdisulfure

elezanumab

immunoglobulina G1-lambda1, anti-[*Homo sapiens* RGMA (miembro de la familia de moléculas de orientación repulsiva, molécula de orientación repulsiva A, RGMA)], *Homo sapiens* anticuerpo monoclonal;

cadena pesada gamma1 (1-450) [*Homo sapiens* VH (IGHV1-18*01 (92.90%) -(IGHD) -IGHJ6*03) [8.8.13] (1-120) -IGHG1*01, Gm17,1 (CH1 (121-218), bisagra (219-233), CH2 L1.2>A (238), L1.3>A (237), T14>Q (253) (234-343), CH3 M107>L (431) (344-448), CHS (449-450)) (121-450)], (223-214')-disulfuro con la cadena ligera lambda1 (1'-215') [*Homo sapiens* V-LAMBDA (IGLV2-11*01 (89.90%) -IGLJ2*01) [9.3.9] (1'-109') -IGLC2*01 (110'-215')]; dímero (229-229":232-232")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVQSGAE VKKPGASVKV SCKASGYTFT SHGISWVRQA PGQGLDWMGW 50
 ISPYSGNTNY AQLQGRVTM TTDSTSTAY MELSSLRSED TAVYCARVG 100
 SGPIYYMDVW GQGLTVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSGV HTPFPAVLQSS GLYSLSSVVT VFSSSLGTQT 200
 YICNVNPKPS NTKVDKKEVE KSCDKTHTCP PCPAPAAAGG PSVFLPPPKP 250
 KDQLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VHLGQDNLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ 350
 VYTLPPSREE MTKNQVSLTLC LVKGFYPSDI AVEWESNGQP ENNYKTTPEV 400
 LDSGGSFFLY SKLTVDKSRW QQGNVFCSCV LHEALHNYHT QKSLSLSPGK 450

Light chain / Chaîne légère / Cadena ligera

QSALTQPRSV SGSPGQSVTI SCTGTSSSVG DSIYVSWYQQ HPGKAPKMLL 50
 YDVKRPSGV PDRFSGSKSG NTASLTISGL QAEDEADYYC YSYAGTDTLF 100
 GGGTKVTVLG QPKAAPSVTL FPPSSSEELQA NKATLVCLIS DFYPGAIVTA 150
 WKADSSPVKA GVETTTPSKQ SNNKYAASSY LSLTPEQWKS HRSYSCQVTH 200
 EGSTVEKTVV PTECS 215

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
 22"-96" 147"-203" 264"-324" 370"-428"
 Intra-L (C23-C104) 22'-90' 137'-196'
 22"'-90"' 137"'-196"
 Inter-H-L (h 5-CL 126) 223-214' 223"-214"
 Inter-H-H (h 11, h 14) 229-229' 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 300, 300"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

elivaldogenum tavalentivum #
 elivaldogene tavalentivec

A VSV-G*-pseudotyped self-inactivating HIV-1-derived lentiviral vector (pLBP100 hALD) encoding human adrenoleukodystrophy (ALD) protein (ABCD1 gene) under the control of a modified myeloproliferative sarcoma virus promoter (MND**)

* VSV-G = vesicular stomatitis virus G envelope protein
 ** MND = myeloproliferative sarcoma virus enhancer with negative control region deleted, dl587rev primer-binding site substituted


élivaldogène tavalentivec

vecteur lentiviral dérivé du VIH-1 auto-inactifant (pLBP100 hALD) pseudotypé VSV-G*, codant pour la protéine humaine (gène ABCD1) de l'adrénoleucodystrophie (ALD), sous le contrôle d'un promoteur du virus du sarcome myéloprolifératif modifié (MND**)

* VSV-G = glycoprotéine G de l'enveloppe du virus de la stomatite vésiculaire
 ** MND = promoteur du virus du sarcome myéloprolifératif dont la région de contrôle négatif a été supprimée, le site de liaison de l'amorce substitué par dl587rev

| | |
|---|---|
| elivaldogén tavalentivec | <p>vector lentiviral derivado del VIH-1 auto-inactivante (pLBP100 hALD) pseudotipo VSV-G*, que codifica para la proteína humana (gen ABCD1) de la adrenoleucodistrofia (ALD), bajo el control de un promotor del virus del sarcoma mieloproliferativo modificado (MND**)</p> <p>* VSV-G = glicoproteína G del virus de la estomatitis vesicular</p> <p>** MND = promotor del virus del sarcoma mieloproliferativo bajo la región de control negativo ha sido suprimido, el sitio de enlace del inicio substituido por dI587rev</p> |
| eltrapudencelum eltrapudencel | <p>Autologous dendritic cells loaded with antigen from self-renewing, proliferating autologous irradiated tumour cells, in a solution of granulocyte-macrophage colony stimulating factor (GM-CSF).</p> <p>Patient's monocytes are collected from peripheral blood by leukocyte apheresis, led to differentiate into dendritic cells in culture and incubated with expanded irradiated autologous self-renewing, cancer-initiating cells (CICs).</p> |
| eltrapudencel | <p>cellules dendritiques autologues chargées avec un antigène de cellules tumorales autologues, auto-renouvellantes, proliférantes et irradiées, dans une solution de facteur de stimulation des colonies de granulocytes et de macrophages (GM-CSF).</p> <p>Les monocytes des patients sont recueillis par leucaphérèse à partir de sang périphérique, conduits à se différencier en cellules dendritiques par culture et incubés avec des cellules initiatrices de cancer (CICs) autologues ayant des propriétés d'auto-renouvellement.</p> |
| eltrapudencel | <p>células dendríticas autólogas cargadas con un antígeno de células tumorales autólogas, autorenovables, proliferantes e irradiadas, en una solución de factor de estimulación de colonias de granulocitos y de macrófagos (GM-CSF).</p> <p>Los monocitos de los pacientes se recogen por leucofèresis a partir de sangre periférica, conducidos a diferenciarse en células dendríticas para el cultivo e incubados con las células iniciadoras de cáncer (CICs) autólogas con las propiedades de autorenovación.</p> |
| emapalumabum # emapalumab | <p>immunoglobulin G1-lambda1, anti-[<i>Homo sapiens</i> IFNG (interferon gamma, IFN gamma)], <i>Homo sapiens</i> monoclonal antibody;</p> <p>gamma1 heavy chain (1-453) [<i>Homo sapiens</i> VH (IGHV3-23*01 -(IGHD) -IGHJ5*02) [8.8.16] (1-123) -IGHG1*03, Gm17,1 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-216')-disulfide with lambda1 light chain (1'-217') [<i>Homo sapiens</i> V-LAMBDA (IGLV6-57*01 (99.00%) -IGLJ3*02) [8.3.10] (1'-111') -IGLC2*01 (112'-217')]; dimer (232-232":235-235")-bisdisulfide</p> |

| | |
|---------------------|---|
| émapalumab | <p>immunoglobuline G1-lambda1, anti-[<i>Homo sapiens</i> IFNG (interféron gamma, IFN gamma)], <i>Homo sapiens</i> anticorps monoclonal;</p> <p>chaîne lourde gamma1 (1-453) [<i>Homo sapiens</i> VH (IGHV3-23*01 -(IGHD) -IGHJ5*02) [8.8.16] (1-123) -IGHG1*03, Gm17,1 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-216')-disulfure avec la chaîne légère lambda1 (1'-217') [<i>Homo sapiens</i> V-LAMBDA (IGLV6-57*01 (99.00%) -IGLJ3*02) [8.3.10] (1'-111') -IGLC2*01 (112'-217')]; dimère (232-232":235-235")-bisdisulfure</p> |
| emapalumab | <p>inmunoglobulina G1-lambda1, anti-[<i>Homo sapiens</i> IFNG (interferón gamma, IFN gamma)], <i>Homo sapiens</i> anticuerpo monoclonal;</p> <p>cadena pesada gamma1 (1-453) [<i>Homo sapiens</i> VH (IGHV3-23*01 -(IGHD) -IGHJ5*02) [8.8.16] (1-123) -IGHG1*03, Gm17,1 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453)) (124-453)], (226-216')-disulfuro con la cadena ligera lambda1 (1'-217') [<i>Homo sapiens</i> V-LAMBDA (IGLV6-57*01 (99.00%) -IGLJ3*02) [8.3.10] (1'-111') -IGLC2*01 (112'-217')]; dímero (232-232":235-235")-bisdisulfuro</p> <p>Heavy chain / Chaîne lourde / Cadena pesada EVQLLESGGG LVQPGGSLRL SCAASGFTFS SYAMSWVRQA PGKGLEWVSA 50 ISGSGGSTIY ADSVKGKRFIT SRDNSKNTLY LQMNSLRAED TAVYCAKDG 100 SSGWYVPHWF DPWQGGLTMT VSSASTKGFV VFPLAPSSKS TSGGTAALGC 150 LVKDYFPEPV TVSWNSGALT SGVHTFFAVL QSSGLYSLSS VVTFPSSSLG 200 TQTYICNVNH KFSNPKVDKR VEPKSCDKH TCFPFAPEL LGGSVFLFP 250 PKPKDILMIS RFPETCVVY DVSHDEEVK FMYVVDGVEV HNAKTPREE 300 QYNSTYRWVS VLTVLHQDWL NGKEYKCKYS NKALPAPIEK TISKAKGQR 350 EPQVYTLPPS REEMTKNOVS LTCLVKGFPY SDIAVEWESN GQPENNYKTT 400 PFVLDSDGSP FLYSKLTVDK SRWQGNVFS CSMVHEALHN HYTEKSLSLG 450 PGK 453</p> <p>Light chain / Chaîne légère / Cadena ligera NFMLTQPHSV SESPGKVTI SCTRSSGSIA SNYVQWYQDR PGSSPTTVIY 50 EDNQRFSGVF DRFSGSIDSS SNSASLTISG LKTEDEADYD CQSYDGSNRW 100 MFGGDTKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150 VAWKAQSSPV KAGVETTTFS KQSNNKYAA S YLSLTPEDW KSHRSYSCQV 200 THEGSTVEKT VAPTECS 217</p> <p>Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro Intra-H (C23-C104) 22-96 150-206 267-327 373-431 Intra-L (C23-C104) 22-96" 150"-206" 267-327" 373"-431" Intra-L (C23-C104) 22-91' 139'-198' 22"-91" 139"-198" Inter-H-L (h 5-CL 126) 226-216' 226"-216" Inter-H-H (h 11, h 14) 232-232' 235-235"</p> <p>N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación H CH2 N84.4: 303,303"</p> <p>Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados</p> |
| ensartinibum | |
| ensartinib | 6-amino-5-[(1 <i>R</i>)-1-(2,6-dichloro-3-fluorophenyl)ethoxy]- <i>N</i> -{4-[(3 <i>R</i> ,5 <i>S</i>)-3,5-dimethylpiperazine-1-carbonyl]phenyl}pyridazine-3-carboxamide |
| ensartinib | 6-amino-5-[(1 <i>R</i>)-1-(2,6-dichloro-3-fluorophényl)éthoxy]- <i>N</i> -{4-[(3 <i>R</i> ,5 <i>S</i>)-3,5-diméthylpiperazine-1-carbonyl]phényl}pyridazine-3-carboxamide |
| ensartinib | 6-amino-5-[(1 <i>R</i>)-1-(2,6-dicloro-3-fluorofenil)etoxi]- <i>N</i> -{4-[(3 <i>R</i> ,5 <i>S</i>)-3,5-dimetilpiperazina-1-carbonil]fenil}piridazina-3-carboxamida |

C₂₆H₂₇Cl₂FN₆O₃**enzaptovirum**

enzaptovir


(10aR)-1-(3-méthyl-1,2-oxazole-4-carbonyl)-10a-(6-méthylpyridin-3-yl)-2,3,10,10a-tétrahydro-1H,5H-imidazo[1,2-a]pyrrolo[1,2-d]pyrazin-5-one

enzaptovir

(10aR)-1-(3-méthyl-1,2-oxazole-4-carbonyl)-10a-(6-méthylpyridin-3-yl)-2,3,10,10a-tétrahydro-1H,5H-imidazo[1,2-a]pyrrolo[1,2-d]pyrazin-5-one

enzaptovir

(10aR)-1-(3-méthyl-1,2-oxazole-4-carbonyl)-10a-(6-méthylpyridin-3-yl)-2,3,10,10a-tétrahydro-1H,5H-imidazo[1,2-a]pyrrolo[1,2-d]pyrazin-5-one

C₂₀H₁₉N₅O₃**eptinibum**

eptinib


N-{3-chloro-4-[(3-fluorophényl)méthoxy]phényl}-6-[(1Z)-N-[(3R)-morpholin-3-yl]méthoxy]but-2-ynimidoyl]quinazolin-4-amine

éptinib

N-{3-chloro-4-[(3-fluorophényl)méthoxy]phényl}-6-[(1Z)-N-[(3R)-morpholin-3-yl]méthoxy]but-2-ynimidoyl]quinazolin-4-amine

eptinib

N-{3-chloro-4-[(3-fluorophényl)méthoxy]phényl}-6-[(1Z)-N-[(3R)-morpholin-3-yl]méthoxy]but-2-ynimidoyl]quinazolin-4-amine

C₃₀H₂₇ClFN₅O₃

| | |
|---|---|
| <p>eptinezumabum # eptinezumab</p> | <p>immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> CALCA (calcitonin related polypeptide alpha) calcitonin gene-related peptide 1, CGRP1, 83-119 and <i>Homo sapiens</i> CALCB (calcitonin related polypeptide beta) calcitonin gene-related peptide 2, CGRP2, 82-118], humanized monoclonal antibody; gamma1 heavy chain (1-441) [humanized VH (<i>Homo sapiens</i> IGHV3-66*01 (81.40%) -(IGHD)-IGHJ3*02) [8.7.5] (1-111) -<i>Homo sapiens</i> IGHG1*03 (CH1 K119>A (156) (112-209), hinge (210-224), CH2 N84.4>A (291) (225-334), CH3 (335-439), CHS (440-441)) (112-441)], (214-219')-disulfide with kappa light chain (1'-219') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-27*01 (86.20%) -IGKJ4*01) [8.3.13] (1'-112') -<i>Homo sapiens</i> IGKC*01, Km3 (113'-219')]; dimer (220-220":223-223")-bisdisulfide</p> |
| <p>eptinezumab</p> | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> CALCA (polypeptide alpha apparenté à la calcitonine) peptide 1 apparenté au gène de la calcitonine, CGRP1, 83-119 et <i>Homo sapiens</i> CALCB (polypeptide bêta apparenté à la calcitonine) peptide 2 apparenté au gène de la calcitonine, CGRP2, 82-118], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-441) [VH humanisé (<i>Homo sapiens</i> IGHV3-66*01 (81.40%) -(IGHD)-IGHJ3*02) [8.7.5] (1-111) -<i>Homo sapiens</i> IGHG1*03 (CH1 K119>A (156) (112-209), charnière (210-224), CH2 N84.4>A (291) (225-334), CH3 (335-439), CHS (440-441)) (112-441)], (214-219')-disulfure avec la chaîne légère kappa (1'-219') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-27*01 (86.20%) -IGKJ4*01) [8.3.13] (1'-112') -<i>Homo sapiens</i> IGKC*01, Km3 (113'-219')]; dimère (220-220":223-223")-bisdisulfure</p> |
| <p>eptinezumab</p> | <p>inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> CALCA (polipéptido alfa relacionado con la calcitonina) péptido 1 relacionado con el gen de la calcitonina, CGRP1, 83-119 y <i>Homo sapiens</i> CALCB (polipéptido beta relacionado con la calcitonina) péptido 2 relacionado con el gen de la calcitonina, CGRP2, 82-118], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-441) [VH humanizado (<i>Homo sapiens</i> IGHV3-66*01 (81.40%) -(IGHD)-IGHJ3*02) [8.7.5] (1-111) -<i>Homo sapiens</i> IGHG1*03 (CH1 K119>A (156) (112-209), bisagra (210-224), CH2 N84.4>A (291) (225-334), CH3 (335-439), CHS (440-441)) (112-441)], (214-219')-disulfuro con la cadena ligera kappa (1'-219') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV1-27*01 (86.20%) -IGKJ4*01) [8.3.13] (1'-112') -<i>Homo sapiens</i> IGKC*01, Km3 (113'-219')]; dímero (220-220":223-223")-bisdisulfuro</p> |

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAVSGIDL S GYYMNVWRQA PGKGLEWGV 50
 IGINATYYA SWAKGRFTIS RDNSKTTVYL QMNSLRAEDT AVYFCARGDI 100
 WGQGLTLTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV 150
 SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ TYICNVNHKP 200
 SNTKVDARVE PKSCDKTHTC PFCPEPELLG GPSVFLFPFK PKDTLMISRT 250
 PEVTCVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY ASTYRVVSVL 300
 TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKRKGQPREP QVYTLPPSRE 350
 EMTKNQVSLT CLVKGFPYPSD IAVEWESNGQ PENNYKTTFP VLSDSGSFFL 400
 YSKLTVDKSR WQQQNVFSCS VMHEALHNHY TQKSLSLSPG K 441

Light chain / Chaîne légère / Cadena ligera
 QVLTQSPSSL SASVGDRTYI NCQASQSVYH NTYLAWYQQK PGKVPKQLIY 50
 DASTLASGVP SRFSGSGSGT DFTLTISLQ PEDVATYIYCL GSYDCTNGDC 100
 FVFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVYVCL LNNFYPREAK 150
 VQWKVDNALQ SGNSQESVTE QDSKSTYSL SSTLTLSKAD YEKHKVYACE 200
 VTHQGLSSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22°-95' 138°-194' 255°-315' 361°-419'
 22°-95' 138°-194' 255°-315' 361°-419'
 Intra-L (C23-C104) 22°-89' 139°-199' Intra-L 95°-100'
 22°-89' 139°-199' (C110-C115) 95°-100"
 Inter-H-L (h 5-CL 126) 214-219' 214°-219"
 Inter-H-H (h 11, h 14) 220-220' 223-223"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4>A (291, 291");
 No N-glycosylation sites / pas de sites de N-glycosylation / ningún posición de N-glicosilación

erenumabum #
 erenumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* CALCRL (calcitonin receptor like receptor, calcitonin gene-related peptide receptor, CGRPR, CGRP-R, CRLR)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-456) [*Homo sapiens* VH (IGHV3-30*03 (93.90%) -(IGHD) -IGHJ6*01) [8.8.23] (1-130) -IGHG2*01, G2m.. (CH1 (131-228), hinge (229-240), CH2 (241-349), CH3 (350-454), CHS (455-456)) (131-456)], (144-215')-disulfide with lambda light chain (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (98.00%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC1*01 (111'-216')]; dimer (232-232":233-233":236-236":239-239")-tetrakisdisulfide

érenumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* CALCRL (récepteur analogue au récepteur de la calcitonine, récepteur du peptide apparenté au gène de la calcitonine, CGRPR, CGRP-R, CRLR)], *Homo sapiens* anticorps monoclonal; chaîne lourde gamma2 (1-456) [*Homo sapiens* VH (IGHV3-30*03 (93.90%) -(IGHD) -IGHJ6*01) [8.8.23] (1-130) -IGHG2*01, G2m.. (CH1 (131-228), charnière (229-240), CH2 (241-349), CH3 (350-454), CHS (455-456)) (131-456)], (144-215')-disulfure avec la chaîne légère lambda (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (98.00%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC1*01 (111'-216')]; dimère (232-232":233-233":236-236":239-239")-tétrakisdisulfure

erenumab

immunoglobulina G2-lambda, anti-[*Homo sapiens* CALCRL (receptor análogo del receptor de la calcitonina, receptor del péptido relacionado con el gen de la calcitonina, CGRPR, CGRP-R, CRLR)], *Homo sapiens* anticuerpo monoclonal;

cadena pesada gamma2 (1-456) [*Homo sapiens* VH (IGHV3-30*03 (93.90%) -(IGHD) -IGHJ6*01) [8.8.23] (1-130) -IGHG2*01, G2m.. (CH1 (131-228), bisagra (229-240), CH2 (241-349), CH3 (350-454), CHS (455-456)) (131-456)], (144-215')-disulfuro con la cadena ligera lambda (1'-216') [*Homo sapiens* V-LAMBDA (IGLV1-51*01 (98.00%) -IGLJ2*01) [8.3.11] (1'-110') -IGLC1*01 (111'-216')]; dímero (232-232":233-233":236-236":239-239")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVESGGG VVQPRSLRL SCAASGFTFS SFGMHWVRQA PGKGLEWVAV 50
ISFDGSIKYS VDSYKGRFTI SRDNSKNTLF LQMNSLRAED TAVYICARDR 100
LNYDSSGY HYKYGMVAV GQGTTVTVSS ASTKGPSVFP LAPCSRSTSE 150
STAAALGCLVK DYFPEPTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT 200
VPSNFGTQT YTCNVDRKPS NTKVDKTVR KCCVCPCCP APPVAGPSVF 250
LFPKPKDTL MISRTEVTC VVVDVSHEDP EVQFNWYVDG VEVHNAKTKP 300
REEQFNSTFR VVSVLTVVHQ DWLNGKEYKC KVSNGKLPAP IEKTIKTKG 350
QPREPQVYTL PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQPEPNY 400
KTTPEMLDSD GSFFLYSKLT VDKSRNQQGN VFSCVMHEA LHNHYTKSL 450
SLSPGK 456

Light chain / Chaîne légère / Cadena ligera

QSVLTQPPSV SAAPGQKVTI SCSGSSSNIG NNYVSWYQQL PGTAPKLLIY 50
DNNKRPSEGIP DRFSGSKSGT STTLGITGLQ TGDEADYICG TWDSRLSAVV 100
FGGKTLTVL GQPKANPTVT LFPSSSEELQ ANKATLVCLI SDFYPAVTV 150
AWKADGSPVK AGVETTKPSK QSNKYAASS YLSLTFEQWK SHRSYSCQVT 200
HEGSTVERTV APTECS 216

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 157-213 270-330 376-434
22"-96" 157"-213" 270"-330" 376"-434"

Intra-L (C23-C104) 22"-89" 138"-197"
22"-89" 138"-197"

Inter-H-L (CH1 10-CL 126) 144-215' 144"-215"

Inter-H-H (h 4, h 5, h 8, h 11) 232-232" 233-233" 236-236" 239-239"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

306, 306"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

eretidigenum velentivecum #

eretidigene velentivec

Recombinant, non-replicating, lentiviral vector w1.6_hWAS_WPREmut6 (VSV-G*) encoding the human Wiskott-Aldrich syndrome (WAS) gene under the control of its native promoter, post-transcriptionally-regulated by a modified WPRE (mut6 WPRE**)

* VSV-G = vesicular stomatitis virus G envelope protein

** WPRE m6 = WPRE mut6 = mut6 = mut6 WPRE: mutated woodchuck hepatitis virus posttranscriptional regulatory element

éretidigène vélentivec

vecteur lentiviral recombinant sans capacité de réplication w1.6_hWAS_WPREmut6 (VSV-G*) contenant le gène humain du syndrome de Wiskott-Aldrich sous le contrôle de son promoteur natif, régulé en post-transcription par WPRE** modifié (mut6 WPRE**)

* VSV-G = glycoprotéine G du virus de la stomatite vésiculaire

**WPRE m6 = WPRE mut6 = mut6 = mut6 WPRE: élément muté de régulation post-transcriptionnelle du virus de l'hépatite de la marmotte d'Amérique

eretidigén velentivec

vector lentiviral recombinante no replicativo w1.6_hWAS_WPREmut6 (VSV-G*) que contiene el gen humano del síndrome de Wiskott-Aldrich bajo el control de su promotor nativo, regulado post-transcripcionalmente por WPRE** modificado (mut6 WPRE**)

* VSV-G = glicoproteína G del virus de la estomatitis vesicular

**WPRE m6 = WPRE mut6 = mut6 = mut6 WPRE: elemento mutado de regulación post-transcriptional del virus de la hepatitis de la marmota de América

evobrutinibum

evobrutinib


1-[4-({[6-amino-5-(4-phenoxyphenyl)pyrimidin-4-yl]amino)methyl}piperidin-1-yl]prop-2-en-1-one

évobrutinib

1-[4-({[6-amino-5-(4-phénoxyphényl)pyrimidin-4-yl]amino)méthyl}pipéridin-1-yl]prop-2-én-1-one

evobrutinib

1-[4-({[6-amino-5-(4-fenoxifenil)pirimidin-4-il]amino}metil)piperidin-1-il]prop-2-en-1-ona

 $C_{25}H_{27}N_5O_2$
**fezolinetantum**

fezolinetant


(4-fluorophenyl)[(8*R*)-8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]methanone

fézolinétant

(4-fluorophényl)[(8*R*)-8-méthyl-3-(3-méthyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-1,2,4-triazolo[4,3-*a*]pyrazin-7(8*H*)-yl]méthanone

fezolinetant


(4-fluorofenil)[(8*R*)-8-metil-3-(3-metil-1,2,4-tiadiazol-5-il)-5,6-dihidro-1,2,4-triazolo[4,3-*a*]pirazin-7(8*H*)-il]metanona

 $C_{16}H_{15}FN_6OS$
**flurdihydroergotaminum**

flurdihydroergotamine

5'α-benzyl-12'-hydroxy-2'-methyl-2-(trifluoromethyl)-(10α)-9,10-dihydroergotaman-3',6',18-trione

| | |
|-----------------------|--|
| flurdihydroergotamine | 5'α-benzyl-12'-hydroxy-2'-méthyl-2-(trifluorométhyl)-(10α)-9,10-dihydroergotamane-3',6',18-trione |
| flurdihydroergotamina | 5'α-bencil-12'-hidroxi-2'-metil-2-(trifluorometil)-(10α)-9,10-dihydroergotaman-3',6',18-triona C ₃₄ H ₃₆ F ₃ N ₅ O ₅ |



follitropinum epsilon #
follitropin epsilon

heterodimer of human glycoprotein hormones alpha chain and follitropin subunit beta (FSH-beta), follicle-stimulating hormone, produced in human chronic myelogenous leukaemia cells, glycoform epsilon

follitropine epsilon

hétérodimère constitué de la chaîne alpha des hormones glycoprotéiques et de la sous-unité bêta de la follitropine (HFS-bêta) humaines, hormone folliculostimulante, produite dans des cellules humaines de leucémie myéloïde chronique, forme glycosylée epsilon

follitropina épsilon

heterodímero constituido por la cadena alfa de las hormonas glicoproteicas y la subunidad beta de la follitropina (HFS-beta) humanas, hormona estimulante del folículo, producida en células humanas de la leucemia mielóide crónica, forma glicosilada épsilon

alpha chain / chaîne alpha / cadena alfa

APDVQDCPEC TLQENPFSSQ PGAPILQCMG CCFSTRAYTP LRSKKTMLVQ 50
KNVTSESTCC VAKSYNRVTV MGGFKVENHT ACHCSTCYHH KS 92

beta chain / chaîne bêta / cadena beta

NSCELTNITI AIEKEECRFC ISINTTWCAG YCYTRDLVYK DPARPKIQKT 50'
CTFKELVYET VRVPGCAHHA DSLYTYPVAT QCHGKCDSD STDCTVRGLG 100'
PSYCSFGEMK E 111'

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

7-31 10-60 28-82 32-84 59-87
3'-51' 17'-66' 20'-104' 28'-82' 32'-84' 87'-94'

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)

Asn-52 Asn-78 Asn-7' Asn-24'

fostemsavirum
fostemsavir


{3-[(4-benzoylpiperazin-1-yl)-oxoacetyl]-4-methoxy-7-(3-methyl-1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[2,3-*c*]pyridin-1-yl)methyl dihydrogen phosphate

fostemsavir

dihydrogénophosphate de {3-[(4-benzoylpipérazin-1-yl)-oxoacétyl]-4-méthoxy-7-(3-méthyl-1*H*-1,2,4-triazol-1-yl)-1*H*-pyrrolo[2,3-*c*]pyridin-1-yl)méthyle

fostemsavir

dihidrogenofosfato de {3-[(4-benzoilpiperazin-1-il)-oxoacetil]-4-metoxi-7-(3-metil-1*H*-1,2,4-triazol-1-il)-1*H*-pirrolo[2,3-*c*]piridin-1-il}metilo

 $C_{25}H_{26}N_7O_8P$


fremanezumabum #
fremanezumab

immunoglobulin G2-kappa, anti-[*Homo sapiens* CALCA (calcitonin related polypeptide alpha) calcitonin gene-related peptide 1, CGRP1, 83-119 and *Homo sapiens* CALCB (calcitonin related polypeptide beta) calcitonin gene-related peptide 2, CGRP2, 82-118], humanized monoclonal antibody;
gamma2 heavy chain (1-448) [humanized VH (*Homo sapiens* IGHV3-7*01 (85.70%) -(IGHD) -IGHJ4*01) [8.10.13] (1-122) -*Homo sapiens* IGHG2*01, G2m..(CH1 (123-220), hinge (221-232), CH2 A115>S (331), P116>S (332) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (224-224'':225-225'':228-228'':231-231'')-tetrakisdisulfide

frémanezumab

immunoglobuline G2-kappa, anti-[*Homo sapiens* CALCA (polypeptide alpha apparenté à la calcitonine) peptide 1 apparenté au gène de la calcitonine, CGRP1, 83-119 et *Homo sapiens* CALCB (polypeptide bêta apparenté à la calcitonine) peptide 2 apparenté au gène de la calcitonine, CGRP2, 82-118], anticorps monoclonal humanisé;
chaîne lourde gamma2 (1-448) [VH humanisé (*Homo sapiens* IGHV3-7*01 (85.70%) -(IGHD) -IGHJ4*01) [8.10.13] (1-122) -*Homo sapiens* IGHG2*01, G2m..(CH1 (123-220), charnière (221-232), CH2 A115>S (331), P116>S (332) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV3-11*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (224-224'':225-225'':228-228'':228-228'':231-231'')-tétrakisdisulfure

fremanezumab

immunoglobulina G2-kappa, anti-[*Homo sapiens* CALCA (polipéptido alfa relacionado con la calcitonina) péptido 1 relacionado con el gen de la calcitonina, CGRP1, 83-119 y *Homo sapiens* CALCB (polipéptido beta relacionado con la calcitonina) péptido 2 relacionado con el gen de la calcitonina, CGRP2, 82-118], anticuerpo monoclonal humanizado;

cadena pesada gamma2 (1-448) [VH humanizado (*Homo sapiens*IGHV3-7*01 (85.70%) -(IGHD) -IGHJ4*01) [8.10.13] (1-122) -*Homo sapiens*IGHG2*01, G2m.. (CH1 (123-220), bisagra (221-232), CH2 A115>S (331), P116>S (332) (233-341), CH3 (342-446), CHS (447-448)) (123-448)], (136-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens*IGKV3-11*01 (85.30%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens*IGKC*01, Km3 (108'-214'); dímero (224-224":225-225":228-228":231-231")-tetrakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQFGGSLRL SCAASGFTFS NYWISWRQA PGKLEWVAE 50
IRSESDASAT HYAEAVKGRF TISRDNAKNS LYLQMNLSRA EDTAVYYCLA 100
YFDYGLAIQN YWQGGLTVTV SSASTKGPSV FFLAPCSRST SESTAALGCL 150
VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SGLYLSLSSV VTPSSNPGT 200
QTYTCNVDPK PSNTKVDKTV ERKCCVECP CPAPFVAGPS VFLEPPKPKD 250
TLMISRTPEV TCVVVDVSHS DPEVQFNWYV DGVVHNNAKT KPREEQFNST 300
FRVSVLTVV HQDWLNGKEY KCKVSNKGLP SSIEKTIKST KGQPREPQVY 350
TLPFSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTPEMLD 400
SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNNHYTK SLSLSPGK 448
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPAT LSLSPGERAT LSCASKRVT TYVSWYQQK GPAPRLLIYG 50
ASNRYLGIPA RFGSGSGSDT FTLTISLLEP EDFAVYYCSQ SYNYPYFPGQ 100
GTKLEIKRTV AAPSVEFIAPP SDEQLKSGTA SVVCLLNIFY PREAKVQWVK 150
DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
LSSPVTKSFN RGEK 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-98 149-205 262-322 368-426
22"-98" 149"-205" 262"-322" 368"-426"

Intra-L (C23-C104) 23'-88' 134'-194"
23"-88" 134"-194"

Inter-H-L (CH1 10-CL 126) 136-214' 136"-214"

Inter-H-H (h 4, h 5, h 8, h 11) 224-224" 225-225" 228-228" 231-231"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

gemtuzumabum ozogamicinum #
gemtuzumab ozogamicin

immunoglobulin G4-kappa, anti-[*Homo sapiens* CD33 (sialic acid binding Ig-like lectin 3, SIGLEC3, SIGLEC-3, gp67, p67)], humanized monoclonal antibody conjugated to *N*-acetyl-gamma calicheamicin;
gamma4 heavy chain (1-443) [humanized VH (*Homo sapiens*IGHV1-3*01 (72.90%) -(IGHD) -IGHJ5*01) [8.8.9] (1-116)), IGHG4*01 (CH1 (117-214), hinge S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443)) (117-443)], (130-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens*IGKV1-5*01 (81.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens*IGKC*01, Km3 (112'-218'); dimer (232-232":235-235")-bisdisulfide; conjugated, on an average of 2 or 3 lysyl (0-6), to *N*-acetyl-*S*'-des(methylsulfanyl)-*S*'-(4-hydrazinyl-2-methyl-4-oxobutan-2-yl)calicheamicin γ_1 via a bifunctional 4-(4-acetylphenoxy)butanoyl (AcBut) linker

gemtuzumab ozogamicine

immunoglobuline G4-kappa, anti-[*Homo sapiens* CD33 (lectine 3 de type Ig-like liant l'acide sialique, SIGLEC3, SIGLEC-3, gp67, p67)], anticorps monoclonal humanisé conjugué à la *N*-acétyl-gamma calichéamicine;
chaîne lourde gamma4 chain (1-443) [VH humanisé (*Homo sapiens*IGHV1-3*01 (72.90%) -(IGHD) -IGHJ5*01) [8.8.9] (1-116)), IGHG4*01 (CH1 (117-214), charnière S10>P (224) (215-226), CH2 (227-336), CH3 (337-441),

CHS (442-443) (117-443)], (130-218')-disulfure avec la chaîne légère (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-5*01 (81.90%) - IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218'))]; dimère (232-232':235-235')-bisdisulfure; conjugué, sur 2 ou 3 lysyl en moyenne (0-6), à la *N*-acétyl-*S*'-dés(méthylsulfanyl)-*S*'-(4-hydrazinyl-2-méthyl-4-oxobutan-2-yl)calicheamicine γ_1 via un linker bifonctionnel 4-(4-acétylphénoxy)butanoyle (AcBut)

gemtuzumab ozogamicina

inmunoglobulina G4-kappa, anti-[*Homo sapiens* CD33 (lectina de tipo inmunoglobulina 3 que se une al ácido siálico, SIGLEC3, SIGLEC-3, gp67, p67)], anticuerpo monoclonal humanizado conjugado con la *N*-acetil-gamma calicheamicina; cadena pesada gamma4 cadena (1-443) [VH humanizado (*Homo sapiens* IGHV1-3*01 (72.90%) -(IGHD) -IGHJ5*01) [8.8.9] (1-116)), IGHG4*01 (CH1 (117-214), bisagra S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442-443) (117-443))], (130-218')-disulfuro con la cadena ligera (1'-218') [V-KAPPA humanizada (*Homo sapiens* IGKV1-5*01 (81.90%) -IGKJ1*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218'))]; dímero (232-232':235-235')-bisdisulfuro; conjugado, sobre 2 o 3 lisil por término medio (0-6), a la *N*-acetil-*S*'-des(metilsulfanil)-*S*'-(4-hidrazinil-2-metil-4-oxobutan-2-il)calicheamicina γ_1 mediante un enlace bifuncional 4-(4-acetilfenoxi)butanoil (AcBut)

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGSSVKV SCKASGYTIT DSNIHWRQA PGQSLEWIGY 50
IYPYNGGTDY NQKFKNRATL TVDNPTNTAY MELSSLRSED TAFYVCVNGN 100
PWLAYWGGQT LVTVSSASTK GPSVFPLAPC SRSTSESTAA LGGLKDYDFP 150
EPVTVSWNSG ALTSGVHTFP AVLQSSGLYS LSSVTVFVPS SLGKTYTCN 200
VDHKPSTNKV DKRVESKYGP PCPPCPAPEF LGGPSVFLFP PKPKDTLMIS 250
RTPEVTCVVV DVSQEDPEVQ FNWYVDGVEF HNAKTKPREE QFNSTYRVVS 300
VLTVLHQDWL NGKEYKCKVS NKGLPSSIEK TISKAKGQPR EPQVYTLPPS 350
QEMTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSGDSF 400
FLYSRLTVDK SRWQEGNVFS CSVMHEALHN HYTKSLSLS LGK 443
```

Light chain / Chaîne légère / Cadena ligera

```
DIQLTQSPST LSASVGRVIT ITCRAESLD NYGIRFLTWF QQKPKAPKL 50
LMYAAASNGS GVPSRFSGSG SGTEFTLTIS LQPDDFATY YCQTKVEPW 100
SFGQGTKEVE KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NMFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
THQGLSSPVT KSFNRGEC 218
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 257-317 363-421
 22'-96" 143'-199" 257'-317" 363"-421"
 Intra-L (C23-C104) 23'-92" 138'-198"
 23"-92" 138"-198"

Inter-H-L (CH1 10-CL 126) 130-218" 130"-218"

Inter-H-H (h 8, h 11) 222-222" 225-225"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

HCH2N84.4:

293, 293"

Fucosylated complex bi-antennary N50-type glycans / glycanes de type NS0 bi-antennaires complexes

fucosylés / glicanos de tipo NS0 biantenarios complejos fucosilados


Other post-translational modifications / Autres modifications post-traductionnelles / Otras modificaciones post-traduccionales

HCHS K2 C-terminal lysine clipping:

443, 443"

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales

An average of 2 or 3 lysyl are substituted. 2 or 3 lysyl sont substitués en moyenne. 2 o 3 lisil estan sustituidos pro término medio.



golodirsenum

golodirsén


all-P-ambo-[2',3'-azanediyil-*P*-(diméthylamino)-*P*,2',3'-trideoxy-2',3'-seco](2'-*N*→5')(G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C) 5'-{*P*-[4-({2-[2-(2-hydroxyéthoxy)éthoxy]éthoxy}carbonyl)piperazin-1-yl]-*N,N*-diméthylphosphonamidate}

golodirsén

tout-P-ambo-5'-{*P*-[4-({2-[2-(2-hydroxy-éthoxy)éthoxy]éthoxy}carbonyl)pipérazin-1-yl]-*N,N*-diméthylphosphonamidate} de [2',3'-azanediyil-*P*-(diméthylamino)-*P*,2',3'-trideoxy-2',3'-seco](2'-*N*→5')(G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C)

golodirsén

todo-P-ambo-5'-{*P*-[4-({2-[2-(2-hydroxiétoxi)étoxi]étoxi}carbonyl)piperazin-1-il]-*N,N*-diméthilfosfonamidato} de [2',3'-azanediyil-*P*-(diméthylamino)-*P*,2',3'-trideoxi-2',3'-seco](2'-*N*→5')(G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C)

C₃₀₅H₄₈₁N₁₃₈O₁₁₂P₂₅

n = 1 - 24

B(1-25):

G-T-T-G-C-C-T-C-C-G-G-T-T-C-T-G-A-A-G-G-T-G-T-T-C

hemoglobinum betafumarilum (bovinum) #

hemoglobin betafumaril (bovine)

S^{3,β92}, S^{3,β92}-bis(2-amino-2-oxoéthyl)-N^{6,β81}, N^{6,β81}-[(2E)-(but-2-enedioyl)]bovine hemoglobin (α₂β₂ tetramer)

hémoglobine bêtafumaril (bovine)

S^{3,β92}, S^{3,β92}-bis(2-amino-2-oxoéthyl)-N^{6,β81}, N^{6,β81}-[(2E)-(but-2-ènedioyl)]hémoglobine bovine (tétramère α₂β₂)

hemoglobina betafumarilo (bovina)

S^{3,β92}, S^{3,β92}-bis(2-amino-2-oxoetil)-N^{6,β81}, N^{6,β81}-[(2E)-(but-2-enedioil)]hemoglobina bovina (tetramero α₂β₂)



Alpha chain / Chaîne alpha / Cadena alfa

VLSAADKGNV KAANGKVGGH AAEYGAEALE RMFLSFPTTK TYFPHFDLSH 50
GSAQVKGHGA KVAAALTKAV EHLDDLPGAL SELSDLHAHK LRVDPVNFKL 100
LSHSLLVTLA SHLPSDFTPA VHASLDKFLA NVSTVLTSKY R 141

Beta chain / Chaîne bêta / Cadena beta

MLTAEKAQAV TAFWGVKVD EVGGEALGRL LVVYPWTQRF FESFGDLSTA 50
DAVMNPKVK AHGKKVLDSE SNGMKHLDDL KGTFAALSEL HCDKLVDPDE 100
NEFKLLGNLVV VVLARNFGKE FTPVLQADFQ KVVAGVANAL AHRYH 145

Modified residues / Résidus modifiés / Restos modificados

C_{β92}, C_{β'92}K_{β81-fumaryl}-K_{β'81}

ifabotuzumabum #

ifabotuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* EPHA3 (ephrin receptor A3, EPH receptor A3, ephrin type-A receptor 3, tyrosine protein kinase TYR04, tyrosine-protein kinase receptor REK4, ETK, ETK1, HEK, HEK4)], humanized monoclonal antibody;
 gamma1 heavy chain (1-449) [humanized VH (*Homo sapiens* IGHV1-2*02 (91.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (119-216), hinge (217-231), CH2 (232-341), CH3 (342-447), CHS (448-449)) (119-448)], (221-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (*Homo sapiens* IGKV1D-16*01 (91.60%) -IGKJ2*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimer (227-227":230-230")-bisdisulfide

ifabotuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* EPHA3 (récepteur A3 d'éphrine, récepteur A3 d'EPH, récepteur 3 type-A d'éphrine, protéine tyrosine kinase TYR04, récepteur tyrosine-protéine kinase REK4, ETK, ETK1, HEK, HEK4)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-449) [VH humanisé (*Homo sapiens* IGHV1-2*02 (91.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (119-216), charnière (217-231), CH2 (232-341), CH3 (342-447), CHS (448-449)) (119-448)], (221-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (*Homo sapiens* IGKV1D-16*01 (91.60%) -IGKJ2*01) [6.3.9] (1'-107') - *Homo sapiens* IGKC*01 (108'-214')]; dimère (227-227":230-230")-bisdisulfure

ifabotuzumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* EPHA3 (receptor A3 de efrina, receptor A3 d'EPH, receptor 3 tipo-A de efrina, tirosina protein kinasa TYR04, receptor tirosina-protein kinasa REK4, ETK, ETK1, HEK, HEK4)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-449) [VH humanizado (*Homo sapiens* IGHV1-2*02 (91.80%) -(IGHD)-IGHJ6*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, Gm3 (CH1 (119-216), bisagra (217-231), CH2 (232-341), CH3 (342-447), CHS (448-449)) (119-448)], (221-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (*Homo sapiens* IGKV1D-16*01 (91.60%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')]; dímero (227-227":230-230")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYWMNWVQA PGQGLEWMDG 50
 IYPGSGNTNY DEKFGQGRVTM TRDTSISTAY MELSRRLRSD TAVYVCARGG 100
 YYEDFDSWGQ GTTIVTVSSAS TKGPSVFPLA PSSKSTSGGT AALGCLVKDY 150
 FPEPVTVSWN SGALTSVGHVHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
 CNVNHKPSNT KVDKRVEPKS CDKHTCTPCP PAPELLGGPS VFLFPPKPKD 250
 TLMISRTPEV TCVVVDVSHS DPEVKFNWYV DGVEVHNAKT KPREEQYNST 300
 YRVVSVLTVL HQDWLNGKEY KCKVSNKALP APIEKTI SKA KGQPREPQVY 350
 TLPPSREEMT KNQVSLTCLV KGFYPSDIAV EWESNGQPEN NYKTTTTPVLD 400
 SDGSFFLYSK LTVDKSRWQQ GNVFSCSVMH EALHNNHYTQR SLSLSPGK 448

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSF LSASVGDRTV ITCRASQGI SYLAWYQQKPK EKAPKRLIYA 50
 ASSLQSGVPS RFGSGSGSTE FTLTISLQLP EDFATYYCGQ YANYPYTFGQ 100
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWVK 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 262-322 368-426
 22"-96" 145"-201" 262"-322" 368"-426"
 Intra-L (C23-C104) 23'-88" 134'-194"
 23"'-88"' 134"'-194"
 Inter-H-L (h 5-CL 126) 221-214" 221"-214"
 Inter-H-H (h 11, h 14) 227-227" 230-230"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

298, 298"

Afucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes afucosylés / glicanos de tipo CHO biantennarios complejos no fucosilados

ilmetropii iodidum

ilmetropium iodide


(1*R*,3*r*,5*S*)-3-[[*(2R,S)*-2-(hydroxymethyl)-
 2-phenylbutanoyl]oxy]-8,8-dimethyl-
 8-azabicyclo[3.2.1]octanium iodide

iodure d'ilmétropium

iodure de (1*R*,3*r*,5*S*)-3-[[*(2R,S)*-2-(hydroxyméthyl)-
 2-phénylbutanoyl]oxy]-8,8-diméthyl-
 8-azabicyclo[3.2.1]octanium

ioduro de ilmetropio

ioduro de (1*R*,3*r*,5*S*)-3-[[*(2R,S)*-2-fenil-
 2-(hidroximetil)butanoil]oxi]-8,8-dimetil-
 8-azabicyclo[3.2.1]octanio

 $C_{20}H_{30}INO_3$
**imlatoclxum**

imlatoclx


4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-en-
 1-yl]methyl]piperazin-1-yl)-*N*-(4-[[*(trans*-4-hydroxy-
 4-methylcyclohexyl)methyl]amino]-3-nitrobenzenesulfonyl)-
 2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide

imlatoclx

4-(4-[[2-(4-chlorophényl)-4,4-diméthylcyclohex-1-én-
 1-yl]méthyl]pipérazin-1-yl)-*N*-(4-[[*(trans*-4-hydroxy-
 4-méthylcyclohexyl)méthyl]amino]-3-nitrobenzenesulfonyl)-
 2-[(1*H*-pyrrolo[2,3-*b*]pyridin-5-yl)oxy]benzamide

imlatoclx

4-(4-[[2-(4-clorofenil)-4,4-dimetilciclohex-1-en-
 1-il]metil]piperazin-1-il)-*N*-(4-[[*(trans*-4-hidroxil-
 4-metilciclohexil)metil]amino]-3-nitrobenzenosulfonyl)-
 2-[(1*H*-pirrolo[2,3-*b*]piridin-5-il)oxi]benzamida



inotersenum
inotersen

all-P-ambo-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioguanilyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioadenilyl-(3'→5')-2'-deoxy-5-methyl-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioadenilyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanilyl-(3'→5')-2'-deoxy-P-thioadenilyl-(3'→5')-2'-deoxy-P-thioadenilyl-(3'→5')-2'-O-(2-methoxyethyl)-P-thioadenilyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiouridylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methyl-P-thiocytidylyl-(3'→5')-2'-O-(2-methoxyethyl)-5-methylcytidine

inotersen


tout-P-ambo-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioguanilyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioadényl-(3'→5')-2'-déoxy-5-méthyl-P-thiocytidylyl-(3'→5')-2'-déoxy-P-thioadényl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-déoxy-P-thioguanilyl-(3'→5')-2'-déoxy-P-thioadényl-(3'→5')-2'-déoxy-P-thioadényl-(3'→5')-2'-O-(2-méthoxyéthyl)-P-thioadényl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiouridylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthyl-P-thiocytidylyl-(3'→5')-2'-O-(2-méthoxyéthyl)-5-méthylcytidine

inotersén

todo-P-ambo-5-metil-2'-O-(2-metoxietil)-P-tiouridilil-(3'→5')-5-metil-2'-O-(2-metoxietil)-P-tiocitidilil-(3'→5')-5-metil-2'-O-(2-metoxietil)-P-tiouridilil-(3'→5')-5-metil-2'-O-(2-metoxietil)-P-tiouridilil-(3'→5')-2'-O-(2-metoxietil)-P-tioguanilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-P-tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-5-metil-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-O-(2-metoxietil)-P-tioadenilil-(3'→5')-5-metil-2'-O-(2-metoxietil)-P-tiouridilil-(3'→5')-5-metil-2'-O-(2-metoxietil)-P-tiocitidilil-(3'→5')-5-metil-2'-O-(2-metoxietil)-P-tiocitidilil-(3'→5')-2'-O-(2-metoxietil)-5-metilcitidina

C₂₃₀H₃₁₈N₆₉O₁₂₁P₁₉S₁₉

(3'-5')(P-thio)(mUmoe-mCmoe-mUmoe-mUmoe-Gmoe-dG-dT-dT-dA-mdC-dA-dT-dG-dA-dA-Amoe-mUmoe-mCmoe-mCmoe-mCmoe)



itacitinibum
itacitinib


(1-{1-[3-fluoro-2-(trifluoromethyl)pyridine-4-carbonyl]piperidin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetid-3-yl)acetonitrile

itacitinib

(1-{1-[3-fluoro-2-(trifluorométhyl)pyridine-4-carbonyl]pipéridin-4-yl}-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azétidin-3-yl)acetonitrile

itacitinib

(1-{1-[3-fluoro-2-(trifluorometil)piridina-4-carbonil]piperidin-4-il}-3-[4-(7H-pirrolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il]azetid-3-il)acetonitrile

C₂₆H₂₃F₄N₉O


larotrectinibum
larotrectinib

(3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide

larotrectinib

(3S)-N-{5-[(2R)-2-(2,5-difluorophényl)pyrrolidin-1-yl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxypyrrolidine-1-carboxamide

larotrectinib

(3*S*)-*N*-{5-[(2*R*)-2-(2,5-difluorofenil)pirrolidin-1-il]pirazolo[1,5-*a*]pirimidin-3-il]-3-hidroxi-1-pirrolidina-1-carboxamida $C_{21}H_{22}F_2N_6O_2$ **lisavanbulinum**


lisavanbulin

(2*S*)-2,6-diamino-*N*-[4-[2-(2-{4-[(2-cyanoethyl)amino]-1,2,5-oxadiazol-3-yl}-1*H*-benzimidazol-1-yl)acetyl]phenyl]hexanamide

lisavanbuline

(2*S*)-2,6-diamino-*N*-[4-[2-(2-{4-[(2-cyanoéthyl)amino]-1,2,5-oxadiazol-3-yl}-1*H*-benzimidazol-1-yl)acétyl]phényl]hexanamide

lisavanbulina

(2*S*)-2,6-diamino-*N*-[4-[2-(2-{4-[(2-cianoetil)amino]-1,2,5-oxadiazol-3-il}-1*H*-benzimidazol-1-il)acetil]fenil]hexanamida $C_{26}H_{29}N_9O_3$ **lumicitabinum**

lumicitabine



4'-C-(chloromethyl)-2'-deoxy-2'-fluorocytidine
3',5'-bis(2-methylpropanoate)

lumicitabine

3',5'-bis(2-méthylpropanoate) de 4'-C-(chlorométhyl)-2'-déoxy-2'-fluorocytidine

lumicitabina

3',5'-bis(2-metilpropanoato) de 4'-C-(clorometil)-2'-desoxi-2'-fluorocitidina



lupartumabum #
lupartumab

immunoglobulin G1-lambda1, anti-[*Homo sapiens* LYPD3 (Ly6/PLAUR domain containing 3, GPI-anchored cell-surface protein C4.4a, C4.4A)], *Homo sapiens* monoclonal antibody;
gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfide with lambda1 light chain (1'-217')] [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimer (226-226":229-229")-bisdisulfide

lupartumab

immunoglobuline G1-lambda1, anti-[*Homo sapiens* LYPD3 (protéine 3 contenant un domaine Ly6/PLAUR, protéine C4.4a GPI-ancrée à la surface cellulaire, C4.4A)], *Homo sapiens* anticorps monoclonal;
chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfure avec la chaîne légère lambda1 (1'-217')] [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dimère (226-226":229-229")-bisdisulfure

lupartumab

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* LYPD3 (proteína 3 que contiene un dominio Ly6/PLAUR, proteína C4.4a GPI-ancrada en la superficie celular, C4.4A)], *Homo sapiens* anticuerpo monoclonal;
cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfuro con la cadena ligera lambda1 (1'-217')] [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLLESGGG LVQPGGSLRL SCAASGFTFS NAWMSWVRQA PGKGLEWVSY 50
 ISSSGSTIYY ADSVKGRPTI SRDNSKNTLY LQMNSLRAED TAVVYCAREG 100
 LWAFDYWGQG TLVTVSSAST KGPSVFPFLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPFVTSWNS GALTSVGHVF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
 NVNHKPSNTK VDKKVEPKSC DKHTCPCPC APELLGGPSV FLFPPKPKDT 250
 LMSRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREBQYNSTY 300
 RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK GQPREPQVYT 350
 LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTTPVLDS 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPG 446

Light chain / Chaîne légère / Cadena ligera

ESVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYVVHWYQQ LPGTAPKLLI 50
 YDNNKRPSGV PDRFSGKSG TSASLAISGL RSEDEADYYC AAWDDRINGP 100
 VFGGGTKLTV LGQPKAAPSV TLFPSSSEEL QANKATLVCL ISDFYPGAVT 150
 VAWKADSSPV KAGVETTPS KQSNKYAAS SYLSLTPEQW KSHRSYSCQV 200
 THEGSTVEKT VAPTECS 217

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"
 Intra-L (C23-C104) 22'-90' 139'-198"
 22"'-90"' 139"'-198"
 Inter-H-L (h 5-CL 126) 220-216' 220"-216"
 Inter-H-H (h 11, h 14) 226-226' 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

lupartumabum amadotinum #
 lupartumab amadotin

immunoglobulin G1-lambda1, anti-[*Homo sapiens* LYPD3 (Ly6/PLAUR domain containing 3, GPI-anchored cell-surface protein C4.4a, C4.4A)], *Homo sapiens* monoclonal antibody conjugated to an auristatin W derivative; gamma1 heavy chain (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfide with lambda1 light chain (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]]; dimer (226-226":229-229")-bisdisulfide; S-substituted on an average of 4 reduced cysteinyl by reaction with *N*-demethyl-*N*-[4-(6-maleimidohexanohydrazido)-4-oxobutyl]auristatin W amide

lupartumab amadotine

immunoglobuline G1-lambda1, anti-[*Homo sapiens* LYPD3 (protéine 3 contenant un domaine Ly6/PLAUR, protéine C4.4a GPI-ancrée à la surface cellulaire, C4.4A)], *Homo sapiens* anticorps monoclonal conjugué à un dérivé de l'auristatine W; chaîne lourde gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), charnière (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfure avec la chaîne légère lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]]; dimère (226-226":229-229")-bisdisulfure; S-substitué, sur 4 cystéines réduits en moyenne, par réaction avec *N*-desméthyl-*N*-[4-(6-maléimidohexanohydrazido)-4-oxobutyl]auristatine W amide

lupartumab amadotina

inmunoglobulina G1-lambda1, anti-[*Homo sapiens* LYPD3 (proteína 3 que contiene un dominio Ly6/PLAUR, proteína C4.4a GPI-anclada a la superficie celular, C4.4A)], *Homo sapiens* anticuerpo monoclonal conjugado con un derivado de la auristatina W;

cadena pesada gamma1 (1-446) [*Homo sapiens* VH (IGHV3-48*03 (92.90%) -(IGHD) -IGHJ4*01) [8.8.10](1-117) -IGHG1*01, Gm17,1 (CH1 (118-215), bisagra (216-230), CH2 (231-340), CH3 (341-445), CHS K>del (446)) (118-446)], (220-216')-disulfuro con la cadena ligera lambda1 (1'-217') [*Homo sapiens* V-LAMBDA (IGLV1-47*01 (87.90%) -IGLJ2*01) [9.3.11] (1'-111') -IGLC2*01 (112'-217')]; dímero (226-226''-229-229'')-bisdisulfuro; S-sustituido, en 4 grupos cisteinil reducidos por término medio, por reacción con *N*-desmetil-*N*-[4-(6-maleimidohexanohidrazido)-4-oxobutil]auristatina W amida

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLLESGGG LVQPGGSLRL SCAASGFTFS NAMMSWVRQA PGKLEWVSY 50
ISSSGSTIYY ADSVKGRFTI SRDNSKNTLY LQMNLSRAED TAVYYCAREG 100
LWAFDYWGQG TLTVTSSAST KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF 150
PEPVTYVWNS GALTSGVHTF PAVLQSSGLY SLSSVVTVPS SSLGTQTYIC 200
NVNHKPSNTK VDKKVEPKSC DKHTCTPPCP APELLGGPSV FLFPPKPKDT 250
LMISRTPEVT CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY 300
RVVSVLTVLH QDWLNGKEYK CKVSNKALPA PIEKTIKAK GQPREPQVYT 350
LPPSRDELTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTTPVLDS 400
DGSFFLYSKL TVDKSRWQQG NWFSCSVHHE ALHNHYTQKS LSLSPG 446
```

Light chain / Chaîne légère / Cadena ligera

```
ESVLTQPPSV SGAPGQRVTI SCTGSSSNIG AGYVVHWYQQ LPGTAPKLLI 50
YDNNKRPSGV PDRFSGSKSG TSASLAISGL RSEDEADYYC AAWDDRNLNGP 100
VFGGDKLTV LGQPKAAPSV TLFPPSSEEL QANKATLVCL ISDFYPGAVT 150
VAWKADSSPV KAGVETTPFS KQSNNKYAAS SYLSLTPEQW KSHRSYSCQV 200
THEGSTVEKT VAPTECS 217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"
 Intra-L (C23-C104) 22'-90' 139'-198'
 22"'-90"' 139"'-198"

Inter-H-L (h 5-CL 126)* 220-216' 220"-216"

Inter-H-H (h 11, h 14)* 226-226' 229-229"

*Two or three of the inter-chain disulfide bridges are not present, an average of 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


H CH2 N84.4:

297, 297"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales

C*
 214', 214"', 223, 223",
 229, 229', 232, 232"



lutikizumabum #

lutikizumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* IL1A (interleukin 1 alpha) and *Homo sapiens* IL1B (interleukin 1 beta, IL-1B, 1L1F2)], humanized monoclonal antibody, tetravalent bispecific;
 gamma1 heavy chain (1-577) [humanized VH anti-IL1B (*Homo sapiens* IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125) -*Homo sapiens* VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -*Homo sapiens* IGHG1*01 (CH1 (248-345), hinge (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfide with kappa light chain (1'-327') [humanized V-KAPPA anti-IL1B (*Homo sapiens* IGKV1-27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker -*Homo sapiens* V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -*Homo sapiens* IGKC*01, Km3 (221'-327')]; dimer (356-356":359-359")-bisdisulfide

lutikizumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* IL1A (interleukine 1 alpha) et *Homo sapiens* IL1B (interleukine 1 bêta, IL-1B, 1L1F2)], anticorps monoclonal humanisé, tétravalent bispécifique;
 chaîne lourde gamma1 chaîne (1-577) [VH humanisé anti-IL1B (*Homo sapiens* IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -6-mer linker (120-125) -*Homo sapiens* VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -*Homo sapiens* IGHG1*01 (CH1 (248-345), charnière (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfure avec la chaîne légère (1'-327') [V-KAPPA humanisé anti-IL1B (*Homo sapiens* IGKV1-27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') -7-mer linker -*Homo sapiens* V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -*Homo sapiens* IGKC*01, Km3 (221'-327')]; dimère (356-356":359-359")-bisdisulfure

lutikizumab

immunoglobulina G1-kappa, anti-[*Homo sapiens* IL1A (interleukina 1 alfa) y *Homo sapiens* IL1B (interleukina 1 beta, IL-1B, 1L1F2)], anticuerpo monoclonal humanizado, tetravalente biespecífico;
 cadena pesada gamma1 cadena (1-577) [VH humanizado anti-IL1B (*Homo sapiens* IGHV3-23*04 (80.60%) -(IGHD)-IGHJ4*01) [8.8.12] (1-119) -linker 6-mer (120-125) -*Homo sapiens* VH anti-IL1A (IGHV3-30*03 (88.80%) -(IGHD)-IGHJ1*01) [8.8.15] (126-247) -*Homo sapiens* IGHG1*01 (CH1 (248-345), bisagra (346-360), CH2 L1.3>A (364), L1.2>A (365), (361-470), CH3 (471-575), CHS (576-577)) (248-577)], (350-327')-disulfuro con la cadena ligera (1'-327') [V-KAPPA humanizado anti-IL1B (*Homo sapiens* IGKV1-27*01 (82.10%) -IGKJ2*01) [6.3.9] (1'-106') linker 7-mer -*Homo sapiens* V-KAPPA anti-IL1A (IGKV1-12*01 (92.60%) -IGKJ4*01) [6.3.9] (114'-220') -*Homo sapiens* IGKC*01, Km3 (221'-327')]; dímero (356-356":359-359")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG VVQPGKSLRL SCSASGFTFS RYDMSWVRQA PGKGLEWVAY 50
 ISHGGAGTYY PDSVKGRFTI SRDMSKNTLF LQMDSLRPED TGVYFCARGG 100
 VTKGYFDVWG QGTPVTVSSA STKGPQVQLV ESGGGVVPQG RSLRLSCTAS 150
 GFTFSMFGVH WVRQAPGKGL EWVAVSYDG SNKYAESVK GRFTISRDN 200
 KNILFLQMDL LRLEDTAVY CARGRPKVI PAPLAHWGQG TLVTFSSAST 250
 KGPSVFPLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS GALTSGVHTF 300
 PAVLQSSGLY SLSSVTVTPS SSLGTQTYIC NVNHKPSNTK VDKKVEPKSC 350
 DKHTCPCPC APEAAGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSHED 400
 PEVTFENWYD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH QDWLNGKEYK 450
 CKVSNKALPA PIEKTIKAK GQPREPQVYI LPPSREEMTK NQVSLTCLVK 500
 GFYPSDIAVE WESNGQPENN YKTTTPVLDL DGSFFLYSKL TVDKSRWQQG 550
 NVFCSVMHE ALHNHYTQKS LSLSPGK 577

Light chain / Chaîne légère / Cadena ligera

DIQMTQSPSS LSASVGRDVT ITCRASGNH NYLTWYQQTP GKAPKLLIYN 50
 AKTLADGVPS RFGSGSGTD YFTTISLQP EDIATYYCQH FWSIPYTPGQ 100
 GTKLQITRTV AAPDIQMTQS PSSVSASVGD RVTITCRASG GISSWLAWYQ 150
 QKPGKAPKLL IYEASNLETG VPSRFGSGGS GSDFTLTISS LQPEDEPATYY 200
 CQQTSSFLLS FGGGKVEHK RTVAAPSVFI FPPSDEQLKS GTASVVCLLN 250
 NFYPREAKVQ WKVDNALQSG NSQESVTEQD SKDSTYSLSS TLTLSKADYE 300
 KHKVYACEVT HQGLSSPVTK SFNRGEC 327

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-221 274-330 391-451 497-555
 22"-96" 147"-221" 274"-330" 391"-451" 497"-555"

Intra-L (C23-C104) 23-88" 136"-201" 247"-307"
 23"-88" 136"-201" 247"-307"

Inter-H-L (h 5-CL 126) 350-327" 350"-327"

Inter-H-H (h 11, h 14) 356-356" 359-359"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

427, 427"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

miridesapum

miridesap

1,1'-hexanedioyldi-D-proline


miridésap

1,1'-hexanedioyldi-D-proline

miridesap

1,1'-hexanodioildi-D-prolina

C₁₆H₂₄N₂O₆

**mivebresibum**

mivebresib

N-[4-(2,4-difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1*H*-pyrrolo[2,3-*c*]pyridin-4-yl)phenyl]ethanesulfonamide


mivébrésib

N-[4-(2,4-difluorophénoxy)-3-(6-méthyl-7-oxo-6,7-dihydro-1*H*-pyrrolo[2,3-*c*]pyridin-4-yl)phényl]éthanesulfonamide

mivebresib

N-[4-(2,4-difluorofenoxi)-3-(6-metil-7-oxo-6,7-dihidro-1*H*-pirrolo[2,3-*c*]piridin-4-il)fenil]etanosulfonamida

C₂₂H₁₉F₂N₃O₄S



nacubactamum

nacubactam

(1*R*,2*S*,5*R*)-2-[(2-aminoethoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yl hydrogen sulfate


nacubactam

hydrogénosulfate de (1*R*,2*S*,5*R*)-2-[(2-aminoéthoxy)carbamoyl]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-yle

nacubactam

hidrogenosulfato de (1*R*,2*S*,5*R*)-2-[(2-aminoetoxi)carbamoiil]-7-oxo-1,6-diazabicyclo[3.2.1]octan-6-ilo

C₉H₁₆N₄O₇S



naquotinibum

naquotinib

6-ethyl-3-{4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino}-5-[[3*R*]-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide


naquotinib


6-éthyl-3-{4-[4-(4-méthylpipérazin-1-yl)pipéridin-1-yl]anilino}-5-[[3*R*]-1-(prop-2-énoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide

naquotinib

6-etil-3-{4-[4-(4-metilpiperazin-1-il)piperidin-1-il]anilino}-5-[[3*R*]-1-(prop-2-enoil)pirrolidin-3-il]oxi}pirazina-2-carboxamida

C₃₀H₄₂N₈O₃



C₂₇H₄₁F₂N₅O**obicetrapibum**

obicetrapib


4-[[2-([3,5-bis(trifluorométhyl)phényl]méthyl)](2*R*,4*S*)-1-(éthoxycarbonyl)-2-éthyl-6-(trifluorométhyl)-1,2,3,4-tétrahydroquinolin-4-yl]amino]pyrimidin-5-yl]oxy}butanoïque

obicétrapib

acide 4-[[2-([3,5-bis(trifluorométhyl)phényl]méthyl)](2*R*,4*S*)-1-(éthoxycarbonyl)-2-éthyl-6-(trifluorométhyl)-1,2,3,4-tétrahydroquinoléin-4-yl]amino]pyrimidin-5-yl]oxy}butanoïque

obicetrapib

ácido 4-[[2-([3,5-bis(trifluorometil)fenil]metil)](2*R*,4*S*)-2-etil-1-(etoxicarbonil)-6-(trifluorometil)-1,2,3,4-tetrahydroquinolein-4-il]amino]pirimidin-5-il]oxi}butanoico

C₃₂H₃₁F₉N₄O₅**ofranerгенum obadenovecum #**

ofranerгенe obadenovec

A recombinant non-replicating adenovirus type 5 vector carrying a fas-chimera transgene consisting of fas and human tumour necrosis factor receptor 1 (TNFR1), under transcriptional control of a murine pre-pro-endothelin promoter (PPE-1-3X*)

*PPE-1-3X = modified PPE-1 promoter that contains three copies of the endothelial cells (EC)-positive regulatory elements.

ofranerгенe obadenovec

vecteur adenoviral 5 recombinant sans capacité de réplіcation, contenant un transgène chimérique-fas constitué du fas et du récepteur 1 du facteur de nécrose tumorale humaine (TNFR1), sous le contrôle transcriptionnel d'un promoteur pré-pro-endothéline murin (PPE-1-3X*)

*PPE-1-3X = promoteur pré-pro-endothéline modifié contenant trois copies d'éléments de régulation positive provenant des cellules endothéliales

| | |
|-----------------------------------|---|
| ofranergén obadenovec | vector adenoviral 5 recombinante no replicante, que contiene un transgec quimérico-fas constituido del fas y del receptor 1 del factor de necrosis tumoral humano (TNFR1), bajo el control transcripcional de un promotor pre-pro-endotelina murino (PPE-1-3X*) *PPE-1-3X = promotor pre-pro-endotelina modificado que contiene tres copias de elementos de regulación positiva que proviene de las células endoteliales |
| padsevonilum padsevonil | (4R)-4-(2-chloro-2,2-difluoroethyl)-1-[[2-(methoxymethyl)-6-(trifluoromethyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]methyl]pyrrolidin-2-one |
| padsévonil | (4R)-4-(2-chloro-2,2-difluoroéthyl)-1-[[2-(méthoxyméthyl)-6-(trifluorométhyl)imidazo[2,1-b][1,3,4]thiadiazol-5-yl]méthyl]pyrrolidin-2-one |
| padsevonil | (4R)-4-(2-cloro-2,2-difluoroetil)-1-[[2-(metoximetil)-6-(trifluorometil)imidazo[2,1-b][1,3,4]tiadiazol-5-il]metil]pirrolidin-2-ona C ₁₄ H ₁₄ ClF ₅ N ₄ O ₂ S |
| | |
| palucorcelum palucorcel | allogeneic human umbilical tissue derived cells (hUTC) obtained by enzymatic digestion of post-partum blood-free umbilical cord tissue and <i>ex vivo</i> expansion. Cells secrete trophic factors and do not express markers of endothelial cells (CD31), cord blood cells (CD45), epithelial cells (E-cadherin) and fibroblasts (FSP-1). |
| palucorcel | cellules humaines allogéniques dérivées de tissu ombilical (hUTC) obtenues par réactions enzymatiques de tissu de cordon ombilical post-partum exsangue et par expansion <i>ex vivo</i> . Les cellules secrètent des facteurs trophiques et n'expriment pas les marqueurs des cellules endothéliales (CD31), des cellules sanguines du cordon (CD45), des cellules épithéliales (cadhérine E) ni des fibroblastes (FSP-1). |
| palucorcel | células humanas alogénicas derivadas de tejido umbilical (hUTC) obtenidas por reacciones enzimáticas de tejido de cordón umbilical posparto libre de sangre y por expansión <i>ex vivo</i> . Las células secretan los factores tróficos y no expresan los marcadores de las células endoteliales (CD31), las células sanguíneas del cordón (CD45), las células epiteliales (cadherina E) y los fibroblastos (FSP-1). |

pegunigalsidasum alfa #
pegunigalsidase alfa

glycyl-human α -galactosidase-L-seryl-L- α -glutamyl-L-lysyl-L- α -aspartyl-L- α -glutamyl-L-leucine, non-covalent dimer, glycosylated with plant glycans, produced in *Nicotiana tabacum* cells, substituted with an average of eight 4-({ α -[2-(3-carboxypropanamido)ethyl]poly(oxyethylene)- ω -yl}amino)-4-oxobutanoyl groups (2 kDa each) and cross-linking (polyethylene glycol-O,O'-diyl)bis[ethane-2,1-diylazanediy] (1,4-dioxobutane-4,1-diyl)] bridges (2 kDa each) per dimeric protein on Gly¹-N and Lys-N⁶ sites

pégunigalsidase alfa

glycyl- α -galactosidase humain-L-séryl-L- α -glutamyl-L-lysyl-L- α -aspartyl-L- α -glutamyl-L-leucine, dimère non covalent, glycosylé avec des glycanes de plantes, produit par des cellules de *Nicotiana tabacum*, substitué avec une moyenne de 8 groupes 4-({ α -[2-(3-carboxypropanamido)éthyl]poly(oxyéthylène)- ω -yl}amino)-4-oxobutanoyle (2 kDa chacun) et lié par des ponts (polyéthylène glycol-O,O'-diyl)bis[éthane-2,1-diylazanediy] (1,4-dioxobutane-4,1-diyl)] (2 kDa chacun) par deux monomères sur les sites Gly¹-N et Lys-N⁶

pegunigalsidasa alfa

glicil- α -galactosidase humano-L-seril-L- α -glutamyl-L-lisil-L- α -aspartil-L- α -glutamyl-L-leucina, dímero no covalente, glicosilado con los glicanos de plantas, producido por las células de *Nicotiana tabacum*, sustituido con una media de 8 grupos 4-({ α -[2-(3-carboxipropanamido)etil]poli(oxiétileno)- ω -il}amino)-4-oxobutanoilo (2 kDa cada uno de ellos) y unido por los puentes (polietileno glicol-O,O'-diil)bis[etano-2,1-diilazanedil] (1,4-dioxobutano-4,1-diil)] (2 kDa cada uno de ellos) por ambos monómeros sobre los lugares Gly¹-N y Lys-N⁶

Monomer / Monomère / Monómero

```
GLDNLGARTP TMGWLHWERF MCNLDQCQEEP DSCISEKLFM EMAELMVSEG 50
WKDAGYEYLC IDDCWMAPOQ DSEGRLQADP QRFPHGIROL ANYVHSGGLK 100
LGIYADVGNK TCAGFPGSFG YYDIDAQTFD DWGVLLKFD GCYCDLENL 150
ADGYKHMSLA LNRTGRSIVY SCEWFLYMPF FQKPNYTEIR QYCNHWRNFA 200
DIDDSWKSIL SILDWTSFNQ ERIVDVAGPG GWNDFMLVI GNEGLSNNQQ 250
VTQMALWAIM AAPLFMSNDL RHISPOKAL LQDKDVIAIN QDPLGKQGYQ 300
LRQGDNFVW ERPLSGLAWA VAMINRQEIG GPRSITYAVA SLGKGVACNP 350
ACFITQLLPV KRKLGFEYWT SRLRSHINPT GTVLLQLENT MQMSLKDLLS 400
EKDEL 405
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
22-64 26-33 112-142 172-193 348-352


Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)



Asn-109 Asn-162 Asn-185 Asn-378

Potential N-substituted residues with pegylated radical Gly-1 and N-6 of lysines

Résidus potentiellement N-subsitués par le radical pegylé Gly-1 et N-6 des lysines

Restos potencialmente N-subsituados por el radical pegilado Gly-1 y N-6 de las lisinas





poseltinibum
poseltinib



N-[3-({2-[4-(4-methylpiperazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl}oxy)phenyl]prop-2-enamide

poseltinib

N-[3-({2-[4-(4-méthylpipérazin-1-yl)anilino]furo[3,2-d]pyrimidin-4-yl}oxy)phényl]prop-2-énamide

poseltinib

N-[3-({2-[4-(4-metilpiperazin-1-il)anilino]furo[3,2-d]pirimidin-4-il}oxi)fenil]prop-2-enamida



ranevetmabum #
ranevetmab

immunoglobulin G1-kappa, anti-[*Mus musculus* NGF (nerve growth factor, nerve growth factor beta polypeptide, NGFB, beta-NGF)], caninized monoclonal antibody; gamma1 heavy chain (1-453) [caninizedVH (*Rattus norvegicus* IGHV5S13*01 (71.40%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Canis lupus familiaris* IGHG1*01 (CH1 (123-219), hinge (220-233), CH2 (234-343), CH3 (344-451), CHS (452-453)) (123-453)], (137-213')-disulfide with kappa light chain (1'-217') [caninizedV-KAPPA (*Rattus norvegicus* IGKV12S34*01 (76.80%) -IGKJ2-3*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGKC*01 (108'-213') -4-mer (214'-217')]; dimer (224-224":226-226":232-232")-tridisulfide

ranévetmab

immunoglobuline G2-kappa, anti-[*Mus musculus* NGF (facteur de croissance du nerf, facteur de croissance du nerf polypeptide bêta, NGFB, bêta-NGF)], anticorps monoclonal caninisé; chaîne lourde gamma2 (1-453) [VH caninisé (*Rattus norvegicus* IGHV5S13*01 (71.40%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Canis lupus familiaris* IGHG1*01 (CH1 (123-219), charnière (220-233), CH2 (234-343), CH3 (344-451), CHS (452-453)) (123-453)], (137-213')-disulfure avec la chaîne légère kappa (1'-217') [V-KAPPA caninisé (*Rattus norvegicus* IGKV12S34*01 (76.80%) -IGKJ2-3*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGKC*01 (108'-213') -4-mer (214'-217')]; dimère (224-224":226-226":232-232")-tridisulfure

ranevetmab

inmunoglobulina G2-kappa, anti-[*Mus musculus* NGF (factor de crecimiento de los nervios, factor de crecimiento de nervios polipéptido beta, NGFB, beta-NGF)], anticuerpo monoclonal caninizado;
cadena pesada gamma2 (1-453) [VH caninizado (*Rattus norvegicus* IGHV5S13*01 (71.40%) -(IGHD)-IGHJ4*01) [8.7.16] (1-122) -*Canis lupus familiaris* IGHG1*01 (CH1 (123-219), bisagra (220-233), CH2 (234-343), CH3 (344-451), CHS (452-453)) (123-453)], (137-213')-disulfuro con la cadena ligerakappa (1'-217') [V-KAPPA caninizado (*Rattus norvegicus* IGKV12S34*01 (76.80%) -IGKJ2-3*01) [6.3.9] (1'-107') -*Canis lupus familiaris* IGKC*01 (108'-213') -4-mer (214'-217''); dímero (224-224"-226-226"-232-232")-trisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGGSLRL SCVASGFSLT NNNVNWVQA PGKLEWVGG 50
VWAGGATDYN SALKSRFTIS RDNKNTVFL QMHSLRSEDT AVYYCARDGG 100
YSSSTLYAMD AWQGQTSVTV SSASTTAPSV FPLAPSCGST SGSTVALACL 150
VSGYFPEPVT VSNNGSLTS GVHTFPSVLQ SGLHLSLSM VIVPSSRWFS 200
ETFTCNVHP ASNTKVKPV FNECRCTDP PCVPPEPLGG PSVLIFFPKP 250
KDILRITRTP EVTCVVLDLG REDPEVQISW FVDGKEVHTA KTQSRQQFEN 300
GTYRVVSVLP IEHQDWLTKG EFKRCVNHID LPSPIERTIS KARGRAHKPS 350
VYVLEPSPKE LSSSDTVSIT CLIKDFYPPD IDVEWQSNQ QPERKHRMT 400
PPQLDEDEGSY FLYSKLSVDK SRWQQGDFPT CAVMHETLQN HYTDLSLSHS 450
PGK 453
```

Light chain / Chaîne légère / Cadena ligera

```
DIVMTQSPAS LLSQGETVT ITCRASEDIY NALAWYQKP QAPKLLIYN 50
TDTLHTGVPS RFSGSGGTD FSLTISLEP EDVAVYVYCOH YFHYPRTPGQ 100
GTKVELKRND AQPAYLFPQ SPDLHTGSA SVVCLLNSFY PKDINVKWKV 150
DGIQDGTGIQ ESVTEQDKDS TYSLSTLTM SSTEYLSHEL YSCEITHKSL 200
PSTLIKSFQR SECQRVD 217
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-95 149-205 264-324 371-431
22"-95" 149"-205" 264"-324" 371"-431"
Intra-L (C23-C104) 23"-88" 134"-193"
23"-88" 134"-193"
Inter-H-L (CH1 I1-CL 126) 137-213" 137"-213"
Inter-H-H (h 14, h 17) 224-224" 226-226" 232-232"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
300, 300"
Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

ravoxertinibum

ravoxertinib


1-[(1S)-1-(4-chloro-3-fluorophenyl)-2-hydroxyethyl]-
4-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-
4-yl}pyridin-2(1H)-one

ravoxertinib

1-[(1S)-1-(4-chloro-3-fluorophényl)-2-hydroxyéthyl]-
4-{2-[(1-méthyl-1H-pyrazol-5-yl)amino]pyrimidin-
4-yl}pyridin-2(1H)-one

ravoxertinib

1-[(1S)-1-(4-cloro-3-fluorofenil)-2-hidroxietil]-4-{2-[(1-metil-
1H-pirazol-5-il)amino]pirimidin-4-il}piridin-2(1H)-ona



recanaclotidum
recanaclotide



S¹, S⁶:S², S¹⁰:S⁵, S¹³-tricyclo(L-cysteinyl-L-cysteinyl-O-phosphono-L-seryl-L-leucyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteine)

récanaclotide

S¹, S⁶:S², S¹⁰:S⁵, S¹³-tricyclo(L-cystéinyl-L-cystéinyl-O-phosphono-L-séryl-L-leucyl-L-cystéinyl-L-cystéinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cystéinyl-L-thréonylglycyl-L-cystéine)

recanaclotida

S¹, S⁶:S², S¹⁰:S⁵, S¹³-tricyclo(L-cisteinil-L-cisteinil-O-fosfono-L-seril-L-leucil-L-cisteinil-L-cisteinil-L-asparaginil-L-profil-L-alanil-L-cisteinil-L-treonilglicil-L-cisteína)



reltecimodum
reltecimod



D-alanyl-[T-cell-specific surface glycoprotein CD28-(8-15)-peptide]-D-alanine:
D-alanyl-L-seryl-L-prolyl-L-methionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl-D-alanine

reltécimod

D-alanyl-[(8-15)-peptide de glycoprotéine de surface CD28 spécifique des cellules T]-D-alanine:
D-alanyl-L-séryl-L-prolyl-L-méthionyl-L-leucyl-L-valyl-L-alanyl-L-tyrosyl-L-α-aspartyl-D-alanine



reltecimod

D-alanil-[(8-15)-péptido de glicoproteína de superficie CD28 específica de las células T]-D-alanina:
D-alanil-L-seril-L-prolil-L-metionil-L-leucil-L-valil-L-alanil-L-tirosil-L-α-aspartil-D-alanina



remetinostatum

| | |
|--------------|--|
| remetinostat | methyl 4-[[8-(hydroxyamino)-8-oxooctanoyl]oxy]benzoate |
| rémétinostat | 4-[[8-(hydroxyamino)-8-oxooctanoyl]oxy]benzoate de méthyle |
| remetinostat | 4-[[8-(hidroxiamino)-8-oxooctanoil]oxi]benzoato de metilo |

**remtolumabum #**

| | |
|------------|--|
| remtolumab | <p>immunoglobulin G1-kappa, anti-[<i>Homo sapiens</i> IL17A (interleukin 17A, IL-17A) and <i>Homo sapiens</i> TNF (tumor necrosis factor (TNF) superfamily member 2, TNFSF2, TNF-alpha, TNFA)], <i>Homo sapiens</i> monoclonal antibody, tetravalent bispecific;</p> <p>gamma1 heavy chain (1-587) [<i>Homo sapiens</i> VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tetraglycyl-seryl) linker (122-132) -<i>Homo sapiens</i> VH' anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), hinge (356-370), CH2 (371-480), CH3 (481-585), CHS (586-587)) (258-587)], (360-331')-disulfide with kappa light chain (1'-331')] [<i>Homo sapiens</i> V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]]; dimer (366-366":369-369")-bisdisulfide</p> |
| remtolumab | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> IL17A (interleukine 17A, IL-17A) et <i>Homo sapiens</i> TNF (facteur de nécrose tumorale membre 2 de la superfamille du TNF, TNFSF2, TNF-alpha, TNFA)], <i>Homo sapiens</i> anticorps monoclonal, tétravalent bispécifique;</p> <p>chaîne lourde gamma1 (1-587) [<i>Homo sapiens</i> VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tétraglycyl-séryl) linker (122-132) -<i>Homo sapiens</i> VH' anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), charnière (356-370), CH2 (371-480), CH3 (481-585), CHS (586-587)) (258-587)], (360-331')-disulfure avec la chaîne légère kappa (1'-331')] [<i>Homo sapiens</i> V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]]; dimère (366-366":369-369")-bisdisulfure</p> |
| remtolumab | <p>inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> IL17A (interleukina 17A, IL-17A) y <i>Homo sapiens</i> TNF (factor de necrosis tumoral miembro 2 de la superfamilia del TNF, TNFSF2, TNF-alfa, TNFA)], <i>Homo sapiens</i> anticuerpo monoclonal, tetravalente biespecifico;</p> |

cadena pesada gamma1 (1-587) [*Homo sapiens* VH anti-TNF (IGHV3-9*01 (93.90%) -(IGHD) -IGHJ4*01) [8.8.14] (1-121) -10-mer bis(tetraglicil-seril) linker (122-132) -*Homo sapiens* VH' anti-IL17A (IGHV1-69*01 (85.70%) -(IGHD) -IGHJ6*01) [8.8.19] (132-257) -IGHG1*01, G1m17,1 (CH1 (258-355), bisagra (356-370), CH2 (371-480), CH3 (481-585), CHS (586-587)) (258-587)], (360-331')-disulfuro con la cadena ligera kappa (1'-331') [*Homo sapiens* V-KAPPA anti-TNF (IGKV1-27*01 (95.80%) -IGKJ2*01) [6.3.9] (1'-107') -*Homo sapiens* V-KAPPA anti-IL17A (IGKV6-21*01 (90.50%) -IGKJ3*01) [6.3.9] (118'-224') -IGKC*01, Km3 (225'-213')]; dímero (366-366":369-369")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVESGGG LVQPGRSLRL SCAASGFTFD DYAMHWVRQA PGKGLEWVSA 50
ITWNSGHIDY ADSVEGRFTI SRDNAKNSLY LQMNSLRAED TAVYYCAKVS 100
YLTASSLDY WQGTTLVTVS SGGGGSGGGG SEVQLVQSGA EVKKPGSSVK 150
VSCKASGGSF GGYGIGWVRQ APGQGLEWMG GITPPFGFAD YAQKFGGRVT 200
ITADESTTTA YMELSGLTSD DTAVYYCARD PNEFWNGYYS THDFDSWGQG 250
TTVTVSSAST KGPSVFLAP SSKSTSGGTA ALGCLVKDYF PEPVTVSWNS 300
GALTSGVHTF PAVLQSSGLY SLSSVTVVPS SSLGTQTYIC NVNHKPSNTK 350
VDKKVEPKSC DKHTCPCPC APELLGGPSV FLFPPKPKDT LMSIRTPPEVT 400
CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREEQYNSTY RVVSVLTVLH 450
QDWLNGKEYK CKVSNKALPEA PIEKTIKAK GQPREPQVYT LPPSRDELTK 500
NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDL DGSFFFLYSKL 550
TVDKSRWQQG NVFSCSVME ALHNHYTQKS LLSLSPGK 587
```

Light chain / Chaîne légère / Cadena ligera

```
DIQMTQSPSS LSASVGRVIT ITCRASQGIS NYLAWYQQKPK GKAPKLLIYA 50
ASTLQSGVPS RFGSGSGCTD FTLTISSLPQ EDVATYYCQR YNRAPYTFGQ 100
GTKVEIKRGG SGGGGSGEIV LTQSPDFQSV TPKEKVTITC RASQDIGSEL 150
HWYQQKPDQP PALLIKYASH STSGVPSRFS GSGSGTDFTL TINGLEAEDA 200
GTYIYCHQDTS LPYTFPGPTK VDIKRTVAAP SVFI PPSDE QLKSGTASVV 250
CLLNMFYPRE AKVQWKVDNA LQSGNSQESV TEQDSKSDSTY SLSSTLTLSK 300
ADYEKHKVYA CEVTHQGLSS PVTRKSNRGE C 331
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 153-227 284-340 401-461 507-565
 22"-96" 153"-227" 284"-340" 401"-461" 507"-565"
 Intra-L (C23-C104) 23"-88" 140"-205" 251"-311"
 23"-88" 140"-205" 251"-311"
 Inter-H-L (h 5-CL 126) 360-331' 360"-331"
 Inter-H-H (h 11, h 14) 366-366" 369-369"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 437, 437"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

rogaratinibum

rogaratinib


4-[[4-amino-6-(methoxymethyl)-5-(7-methoxy-5-methyl-1-benzothiophen-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]methyl]piperazin-2-one

rogaratinib

4-[[4-amino-6-(méthoxyméthyl)-5-(7-méthoxy-5-méthyl-1-benzothiophén-2-yl)pyrrolo[2,1-f][1,2,4]triazin-7-yl]méthyl]pipérazin-2-one

rogaratinib

4-[[4-amino-5-(5-metil-7-metoxi-1-benzotiofen-2-il)-6-(metoximetil)pirrolo[2,1-f][1,2,4]triazin-7-il]metil]piperazin-2-ona

C₂₃H₂₆N₆O₃S**rosiptorum**


rosiptor

7-amino-17-methylidene-6,7-seco-5 α -androstane-3 β ,6-diol

rosiptor

7-amino-17-méthylidène-6,7-séco-5 α -androstane-3 β ,6-diol

rosiptor

7-amino-17-metilideno-6,7-seco-5 α -androstan-3 β ,6-diolC₂₀H₃₅NO₂**rosmantuzumabum #**

rosmantuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* RSPO3 (R-spondin 3, thrombospondin type I (TSP1) domain containing protein 2, THSD2)], humanized monoclonal antibody;
 gamma1 heavy chain (1-447) [humanized VH (*Homo sapiens* IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01 [8.8.10] (1-117) -*Homo sapiens* IGHG1*03, (CH1 (118-215), hinge (216-230), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)), (220-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV1-39*01 (83.80%) -IGKJ4*01 [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218'))]; dimer (226-226":229-229")-bisdisulfide

rosmantuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* RSPO3 (R-spondine 3, protéine 2 contenant un domaine thrombospondine de type I (TSP1), THSD2)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-447) [VH humanisé (*Homo sapiens* IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01 [8.8.10] (1-117) -*Homo sapiens* IGHG1*03, (CH1 (118-215), charnière (216-230),), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)), (220-218')-disulfure avec la chaîne légère (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV1-39*01 (83.80%) -IGKJ4*01 [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218'))]; dimère (226-226":229-229")-bisdisulfure

rosmantuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* RSPO3 (R-espondina 3, proteína 2 que contiene un dominio tromboespondina de tipo I (TSP1), THSD2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-447) [VH humanizado (*Homo sapiens* IGHV1-46*01 (84.50%) -(IGHD)-IGHJ4*01 [8.8.10] (1-117) -*Homo sapiens* IGHG1*03, (CH1 (118-215), bisagra (216-230),), CH2 (231-340), CH3 (341-445), CHS (446-447)) (118-447)], (220-218')-disulfuro con la cadena ligera (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV1-39*01 (83.80%) -IGKJ4*01 [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218'))]; dímero (226-226":229-229")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLVQSGAE VKKPGASVKV SCKASGYTFT DYSIHWRQA PGQGLEWIGY 50
 IYPSNGDSGY NQKFKNRVTM TRDTSSTAY MELSLRSED TAVYYCATYF 100
 ANNFYWGQG TLTIVSSAST KGPSVFLAP SSKSTSGGTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVTPS SSLGTQTYIC 200
 NVNHKPSNTK VDKRVEPKSC DKHTCPCPE APELLGGPSV FLPPPKKDT 250
 LMSRTPVET CVVVDVSHED PEVKFNWYVD GVEVHNAKTK PREBEQNSTY 300
 RVVSVLTVLH QDVLNGKEYK CKVSNKALPA PIEKTIKAK GPPEPQVYT 350
 LPPSREEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTTPVLDS 400
 DGSFFLYSKL TVDKSRWQQG NVFSCSVMHE ALHNHYTQKS LSLSPGK 447

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRVIT ITCKASQSVY YDGDSYMNWY QPKPKAPKL 50
 LIYAASNLES GVPSRFGSGG SGTDFLTIS PVQAEDFATY YCQQSNEDPL 100
 TFGAGTKLEL KRTVAAPSVF IFPPSDEQLK SGTASVVCLL NNFYPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYLS SLTLTSKADY EKHKVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 144-200 261-321 367-425
 22"-96" 144"-200" 261"-321" 367"-425"
 Intra-L (C23-C104) 23'-92' 138"-198"
 23'"-92'" 138'"-198'"
 Inter-H-L (h 5-CL 126) 220-218' 220"-218"
 Inter-H-H (h 11, h 14) 226-226" 229-229"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 297, 297"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

Other post-translational modifications / Autres modifications post-traduccionnelles / Otras modificaciones post-traduccionales
 H CHS K2 C-terminal lysine clipping:
 447, 447"

rosomidnarum
 rosomidnar

DNA oligonucleotide sequence that is complementary to a region upstream of the B-cell lymphoma (BCL-2) gene:
 2'-deoxycytidyl-(3'→5')-2'-deoxyadenyl-(3'→5')-2'-
 deoxycytidyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-
 deoxycytidyl-(3'→5')-2'-deoxyadenyl-(3'→5')-2'-
 deoxycytidyl-(3'→5')-2'-deoxyguanylyl-(3'→5')-2'-
 deoxycytidyl-(3'→5')-2'-deoxyadenyl-(3'→5')-thymidyl-
 (3'→5')-2'-deoxycytidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-
 2'-deoxycytidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-
 deoxyguanylyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-
 deoxycytidyl-(3'→5')-2'-deoxycytidyl-(3'→5')-2'-
 deoxyguanylyl-(3'→5')-thymidyl-(3'→5')-2'-
 deoxyguanosine

| | |
|---|---|
| rosomidnar | <p>séquence oligonucléotide d'ADN complémentaire d'une région en amont du gène (BCL-2) lymphome formé de lymphocytes B:</p> <p>2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyadénylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxycytidylyl-(3'→5')-2'-déoxyguanylyl-(3'→5')-thymidylyl-(3'→5')-2'-déoxyguanosine</p> |
| rosomidnar | <p>secuencia de oligonucleótidos de ADN complementaria de una región ascendente del gen (BCL-2) de linfomas de células B:</p> <p>2'-desoxicetidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiadenilil-(3'→5')-timidilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxicetidilil-(3'→5')-2'-desoxiguanilil-(3'→5')-timidilil-(3'→5')-2'-desoxiguanosina</p> <p>$C_{227}H_{291}N_{88}O_{141}P_{23}$</p> <p>(3'-5')d(C-A-C-G-C-A-C-G-C-G-C-A-T-C-C-C-C-G-C-C-C-G-T-G)</p> |
| rozanolixizumabum # rozanolixizumab | <p>immunoglobulin G4-kappa, anti-[<i>Homo sapiens</i> FCGRT (Fc fragment of IgG receptor and transporter, neonatal Fc receptor, FcRn, transmembrane alpha chain of the neonatal receptor)], humanized and chimeric monoclonal antibody;</p> <p>gamma4 heavy chain (1-444) humanized [humanized VH (<i>Homo sapiens</i>IGHV3-7*01 (86.50%) -(IGHD) -IGHJ4*01 [8.8.10] (1-117)), <i>Homo sapiens</i>IGHG4*01 (CH1 (118-215), hinge S10>P (225) (216-227),CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfide with kappa light chain chimeric (1'-219') [synthetic V-KAPPA (<i>Homo sapiens</i>IGKV1-9*01 (76.00%) -<i>Homo sapiens</i>IGKJ2*01) [11.3.9] (1'-112') -<i>Homo sapiens</i>IGKC*01, Km3 (113'-219')]; dimer (223-223":226-226")-bisdisulfide</p> |

rozanolixizumab

immunoglobuline G4-kappa, anti-[*Homo sapiens* FCGRT (récepteur du fragment Fc des IgG et transporteur, récepteur Fc néonatal, FcRn, chaîne alpha transmembranaire du récepteur néonatal)], anticorps monoclonal humanisé et chimérique; chaîne lourde gamma4 humanisée (1-444) [VH humanisé (*Homo sapiens*IGHV3-7*01 (86.50%) -(IGHD) -IGHJ4*01 [8.8.10] (1-117)), *Homo sapiens*IGHG4*01 (CH1 (118-215), charnière S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfure avec la chaîne légère kappa chimérique (1'-219') [V-KAPPA synthétique (*Homo sapiens*IGKV1-9*01 (76.00%) -*Homo sapiens*IGKJ2*01) [11.3.9] (1'-112') - *Homo sapiens*IGKC*01, Km3 (113'-219'))]; dimère (223-223":226-226")-bisdisulfure

rozanolixizumab

inmunoglobulina G4-kappa, anti-[*Homo sapiens* FCGRT (receptor del fragmento Fc de las IgG y transportador, receptor Fc neonatal, FcRn, cadena alfa transmembranaria del receptor neonatal)], anticuerpo monoclonal humanizado y quimérico; cadena pesada gamma4 humanizada (1-444) [VH humanizado (*Homo sapiens*IGHV3-7*01 (86.50%) - (IGHD) -IGHJ4*01) [8.8.10] (1-117)), *Homo sapiens*IGHG4*01 (CH1 (118-215), bisagra S10>P (225) (216-227), CH2 (228-337), CH3 (338-442), CHS (443-444)) (118-444)], (131-219')-disulfuro con la cadena ligera kappa quimérica (1'-219') [V-KAPPA sintético (*Homo sapiens*IGKV1-9*01 (76.00%) -*Homo sapiens*IGKJ2*01) [11.3.9] (1'-112') -*Homo sapiens*IGKC*01, Km3 (113'-219'))]; dímero (223-223":226-226")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVPLVESGGG LVQPGGSLRL SCAVSGTFFS NYGMVWVRQA PGKGLEWVAY 50
 IDSDGDNTYY RDSVKGRTI SRDNAKSSLY LQMSNLAED TAVYYCTTGI 100
 VRPFYLGQGG TLTVSSAST KGPSVFLAP CSRSTSESTA ALGCLVKDYF 150
 PEPVTVSWNS GALTSGVHTF PAVLQSSGLY SLSSVTVTPS SSLGKTYTTC 200
 NVDHKPSNTK VDKRVESKYG PPCPPCPAPE FLGGPSVFLF PPKPKDTLMI 250
 SRTEEVTCVV VDVQEDPEV QFNWYVDGVE VHNAKTKPRE EQFNSTYRVV 300
 SVLTVLHQDW LNGKEYKCKV SNKGLPSSIE KTISKAKGQP REPQVYTLPP 350
 SQEEMTKNQV SLTCLVKGfy PSDIAVWES NGQPENNYKT TTPVLDSDGS 400
 FFLYSRLTVD KSRWQEGNVF SCSVMHEALH NHYTQKSLSL SLGK 444

Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSASVGRVIT ITCKSSQSLV GASGKTYLYW LFKQPGKAPK 50
 RLIVLVSTLD SGIPSRFSGS GSGTEFTLI SSLQPEDFAT YYCLQGTHFP 100
 HTPFGQTKLE IKRTVAAPS FIPPPSDEQL KSGTASVCL LNNFYPREAK 150
 VQWKVDNALQ SGNQSQESVTE QDSKDYTSL SSTLTLSKAD YEKHKVYACE 200
 VTHQGLSSPV TKSFNREGC 219

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 144-200 258-318 364-422
 22"-96" 144"-200" 258"-318" 364"-422"
 Intra-L (C23-C104) 23'-93' 139'-199'
 23"'-93"' 139"'-199"
 Inter-H-L (CH1 10-CL 126) 131-219' 131"-219"
 Inter-H-H (h 8, h 11) 223-223" 226-226"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 294, 294"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

sacituzumabum #

sacituzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* TACSTD2 (tumor-associated calcium signal transducer 2, membrane component chromosome 1 surface marker 1, M1S1, gastrointestinal tumor-associated antigen GA7331, pancreatic carcinoma marker protein GA733-1, epithelial glycoprotein-1, EGP-1, trophoblast antigen-2, cell surface glycoprotein Trop-2, TROP2)], humanized monoclonal antibody;
 gamma1 heavy chain (1-451) [humanized VH (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (122-219), hinge (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfide with kappa light chain (1'-214')] [humanized V-KAPPA (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimer (230-230":233-233")-bisdisulfide

sacituzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* TACSTD2 (transducteur 2 de signaux calciques associé aux tumeurs, composant membranaire du chromosome 1 marqueur de surface 1, M1S1, antigène GA7331 associé aux tumeurs gastrointestinales, protéine GA733-1 marqueur de carcinomes pancréatiques, glycoprotéine épithéliale 1, EGP-1, antigène 2 du trophoblaste, glycoprotéine Trop-2 à la surface des cellules, TROP2)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-451) [VH humanisé (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (122-219), charnière (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfure avec la chaîne légère kappa (1'-214')] [V-KAPPA humanisé (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dimère (230-230":233-233")-bisdisulfure

sacituzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* TACSTD2 (transductor 2 de señales cálcicas asociado a los tumores, componente membranario del cromosoma 1 marcador de superficie 1, M1S1, antígeno GA7331 asociado a todos los tumores gastrointestinales, proteína GA733-1 marcador de carcinomas pancreáticos, glicoproteína epitelial 1, EGP-1, antígeno 2 de trofoblasto, glicoproteína Trop-2 de la superficie de las células, TROP2)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-451) [VH humanizado (*Homo sapiens* IGHV7-4-1*02 (85.70%) -(IGHD)-IGHJ2*01) [8.8.14] (1-121) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (122-219), bisagra (220-234), CH2 (235-344), CH3 (345-449), CHS (450-451)) (122-451)], (224-214')-disulfuro con la cadena ligera kappa (1'-214')] [V-KAPPA humanizado (*Homo sapiens* IGKV1-9*01 (82.20%) -IGKJ4*01) [6.3.9] (1'-107') -*Homo sapiens* IGKC*01, Km3 (108'-214')]; dímero (230-230":233-233")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 QVQLQQSGSE LKKPGASVKV SCKASGYTFT NYGMNWKQA PGQGLKWMGW 50
 INTYTGPEPT TDDFKGRFAF SLDTSVSTAY LQISLTKADD TAVYFCARGG 100
 FGSSYWYFDV WGGGSLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV 150
 KDYFPEPVTV SWNSGALTSQ VHTFPAVLQS SGLYLSLSSVV TVPSSSLGTQ 200
 TYICNVNHPK SNTKVDKRVK PKSCDKHTC PPCAPELLG GPSVFLFPFK 250
 PKDTLMIBRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY 300
 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPRPE 350
 QVYTLPPSRE EMTKNQVSLT CLVKGFPYPSD IAEWESNGQ PENNYKTPFP 400
 VLDSGDSGFFL YSKLTVDKSR WQQGNVFCSS VMHEALHNHY TQKSLSLSPG 450
 K 451

Light chain / Chaîne légère / Cadena ligera
 DIQLTQSPSS LSASVGRVRS ITCKASQDVS IAWAWYQQKP GKAPKLLIYS 50
 ASYRYTGVPD RFGSGSGGTD FTLTISLQPD EDFAVYVCQQ HYITPLTFGA 100
 GTKVEIKRTV AAPSVPFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWVK 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEV 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 148-204 265-325 371-429
 22"-96" 148"-204" 265"-325" 371"-429"
 Intra-L (C23-C104) 23'-88" 134'-194"
 23"'-88"' 134"'-194"
 Inter-H-L (h 5-CL 126) 224-214" 224"-214"
 Inter-H-H (h 11, h 14) 230-230" 233-233"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 301, 301"
 Fucosylated complex bi-antennary Sp2/0-type glycans / glycanes de type Sp2/0 bi-antennaires complexes fucosylés / glicanos de tipo Sp2/0 biantenaricos complejos fucosilados

satoreotidum
 satoreotide

S², S⁷-cyclo{4-chloro-L-phenylalanyl-D-cysteiny-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phenylalanyl-4-(carbamoylamino)-D-phenylalanyl-L-lysyl-L-threonyl-L-cysteiny-4-D-tyrosinamide}


satoréotide

S², S⁷-cyclo{4-chloro-L-phénylalanyl-D-cystéiny-4-[(4S)-2,6-dioxo-1,3-diazinane-4-carboxamido]-L-phénylalanyl-4-(carbamoylamino)-D-phénylalanyl-L-lysyl-L-thréonyl-L-cystéiny-4-D-tyrosinamide}

satoreotida



S², S⁷-ciclo{4-cloro-L-fenilalanil-D-cisteinil-4-[(4S)-2,6-dioxo-1,3-diazinano-4-carboxamido]-L-fenilalanil-4-(carbamoylamino)-D-fenilalanil-L-lisil-L-treonil-L-cisteinil-D-tyrosinamida}


C₅₈H₇₂ClN₁₅O₁₄S₂



seladelparum
 seladelpar

[4-(((2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl)sulfanyl)-2-methylphenoxy]acetic acid

| | |
|----------------------|--|
| séladelpar | acide [4-(((2 <i>R</i>)-2-éthoxy-3-[4-(trifluorométhyl)phénoxy]propyl)sulfanyl)-2-méthylphénoxy]acétique |
| seladelpar | ácido [4-(((2 <i>R</i>)-2-etoxi-3-[4-(trifluorometil)fenoxi]propil)sulfanil)-2-metilfenoxi]acético |
| | $C_{21}H_{23}F_3O_5S$ |
| |  |
| seltorexantum | |
| seltorexant | [(3 <i>aR</i> ,6 <i>aS</i>)-5-(4,6-diméthylpyrimidin-2-yl)hexahydropyrrolo[3,4- <i>c</i>]pyrrol-2(1 <i>H</i>)-yl][2-fluoro-6-(2 <i>H</i> -1,2,3-triazol-2-yl)phényl]méthanone |
| seltorexant | [(3 <i>aR</i> ,6 <i>aS</i>)-5-(4,6-diméthylpyrimidin-2-yl)hexahydropyrrolo[3,4- <i>c</i>]pyrrol-2(1 <i>H</i>)-yl][2-fluoro-6-(2 <i>H</i> -1,2,3-triazol-2-yl)phényl]méthanone |
| seltorexant | [(3 <i>aR</i> ,6 <i>aS</i>)-5-(4,6-diméthylpirimidin-2-il)hexahidropirrolo[3,4- <i>c</i>]pirrol-2(1 <i>H</i>)-il][2-fluoro-6-(2 <i>H</i> -1,2,3-triazol-2-il)fenil]metanona |
| | $C_{21}H_{22}FN_7O$ |
| |  |
| serabelisibum | |
| serabelisib | [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2- <i>a</i>]pyridin-3-yl](morpholin-4-yl)méthanone |
| sérabélisib | [6-(2-amino-1,3-benzoxazol-5-yl)imidazo[1,2- <i>a</i>]pyridin-3-yl](morpholin-4-yl)méthanone |
| serabelisib | [6-(2-amino-1,3-benzoxazol-5-il)imidazo[1,2- <i>a</i>]piridin-3-il](morfolin-4-il)metanona |

C₁₉H₁₇N₅O₃

sofpironii bromidum
sofpironium bromide


1-*ambo*-(3*R*)-3-[[*R*)-(cyclopentyl)hydroxy(phenyl)acetyl]oxy]-1-(2-ethoxy-2-oxoethyl)-1-methylpyrrolidinium bromide

bromure de sofpironium

bromure de 1-*ambo*-(3*R*)-3-[[*R*)-(cyclopentyl)hydroxyl(phényl)acétyl]oxy]-1-(2-éthoxy-2-oxoéthyl)-1-méthylpyrrolidinium

bromuro de sofpironio

bromuro de 1-*ambo*-(3*R*)-3-[[*R*)-(ciclopentil)hidroxi(fenil)acetil]oxi]-1-(2-etoxi-2-oxoetil)-1-metilpirrolidinio

C₂₂H₃₂BrNO₅

somatogonum #
somatogon

fusion protein of human choriogonadotropin subunit β (CG- β)-(118-145)-peptide (1-28) with human somatotropin (growth hormone, GH) (29-219) and two tandem copies of human choriogonadotropin subunit β (CG- β)-(118-145)-peptide (220-247, 248-275), O-glycosylated on 12-18 serines, produced in Chinese hamster ovary (CHO) cells

somatogon

sous-unité bêta de la choriogonadotrophine humaine (CG- β)-(118-145)-peptide (1-28) protéine de fusion avec la somatotropine humaine (hormone de croissance, GH) (29-219) protéine de fusion avec deux copies de la sous-unité bêta de la choriogonadotrophine humaine (CG- β)-(118-145)-peptide (1-28), 12-18 sérines sont O-glycosylées, produite par des cellules ovariennes de hamster chinois (CHO)

somatogón

subunidad beta de la coriogonadotropina humana (CG- β)-(118-145)-péptido (1-28) proteína de fusión con la somatotropina humana (hormona de crecimiento, GH) (29-219) proteína de fusión con ambas copias de la subunidad beta de la coriogonadotropina humana (CG- β)-(118-145)-péptido (1-28), 12-18 serinas O-glicosiladas, producidas por las células de ovario de hamster chino (CHO)

Sequence / Séquence / Secuencia

SSSSKAPPPS LPSFSRLPGP SDTPILPQFP TIPLSRLFDN AMLRAHRLHQ 50
 LAFDTYQEF EAYIPKEQKY SPLQNPQTSL CFSESIPTPS NREETQQKSN 100
 LELLRLISLLL IQSWLEPVQF LRSVFNANSLV YGASDSNVYD LLKDLEEGIQ 150
 TLMGRLEDGS PRTGQIFKQT YSKFDTNSHN DDALLKNYGL LYCFRKDMDK 200
 VETFLRIVQC RSVEGSCGFS SSSKAPPPSL PSFSRLPGFS DTPILPQSSS 250
 SKAPPPSLFS PSRLPGFS DT PILPQ 275

Disulfide bridges location / Position des ponts disulfures / Posiciones de los puentes disulfuro
 81-193 210-217

Potential glycosylation sites / Sites potentiels de glycosylation / Sitios potenciales de glicosilación

Ser-1* Ser-2* Ser-3* Ser-4* Ser-10 Ser-13 Ser-15 Ser-21
 Ser-220* Ser-221* Ser-222* Ser-223* Ser-229 Ser-232 Ser-234 Ser-240
 Ser-248* Ser-249* Ser-250* Ser-251* Ser-257 Ser-260 Ser-262 Ser-268

* when two serines are linked together, only one can be glycosylated.
 quand deux sérines sont liées l'une à l'autre, une seule peut être glycosylée.
 cuando dos serinas están ligadas una al otra, una sola puede ser glicosilada.

suptavumabum #
 suptavumab

immunoglobulin G1-kappa, anti-[human respiratory syncytial virus (RSV) fusion glycoprotein F], *Homo sapiens* monoclonal antibody;
 gamma1 heavy chain (1-453) [*Homo sapiens* VH (IGHV3-9*01 (87.90%) -(IGHD) -IGHJ6*01) [8.8.16](1-123) -IGHG1*01, G1m17,1 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453))(124-453)], (226-214')-disulfide with kappa light chain (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107')-IGKC*01, Km3 (108'-214')]; dimer (232-232':235-235')-bisdisulfide

suptavumab

immunoglobuline G1-kappa, anti-[glycoprotéine de fusion F du virus respiratoire syncytial (VRS) humain], *Homo sapiens* anticorps monoclonal;
 chaîne lourde gamma1 (1-453) [*Homo sapiens* VH (IGHV3-9*01 (87.90%) -(IGHD) -IGHJ6*01) [8.8.16] (1-123) -IGHG1*01, G1m17,1 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453))(124-453)], (226-214')-disulfure avec la chaîne légère kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dimère (232-232':235-235')-bisdisulfure

suptavumab

inmunoglobulina G1-kappa, anti-[glicoproteína de fusión F del virus respiratorio sincitial (VRS) humano], *Homo sapiens* anticuerpo monoclonal;
 cadena pesada gamma1 (1-453) [*Homo sapiens* VH (IGHV3-9*01 (87.90%) -(IGHD) -IGHJ6*01) [8.8.16] (1-123) -IGHG1*01, G1m17,1 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 (347-451), CHS (452-453))(124-453)], (226-214')-disulfuro con la cadena ligera kappa (1'-214') [*Homo sapiens* V-KAPPA (IGKV3-15*01 (94.70%) -IGKJ4*01) [6.3.9] (1'-107') -IGKC*01, Km3 (108'-214')]; dímero (232-232':235-235')-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGD LVQPGRSLRL SCVASGFTFD DYAMHWVROA PGKLEWVSG 50
 VSWSGSTVGY ADSVKGRFTV SRDNAQKSLY LQMNLSRAED TALYYCVKDA 100
 YKFNYYYYGL DWVGQGTVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
 LVKDYFFPEPV TVSWNSGALT SGVHTFPAVL QSSGLYSLSS VVTVPSSSLG 200
 TQTYICNVNH KPSNTRKVDK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
 PKPKDTLMIS RTPVETCVVV DVSHEDPEVK FNWYVDCVEV HNAKTKPREE 300
 QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
 EPQVYTLPPS RDELTKNQVS LTCLVKGFPY SDIAVEWESN GQPENNYKTT 400
 PPLVDSGDSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSL 450
 PGK 453

Light chain / Chaîne légère / Cadena ligera
 EIVMTQSPAT LSVSPGERAT LSCRASQTIL SNLAWYLQKP GQAPRLLIYG 50
 ASTRATGLPA RFSGSGSGTE FTLTISLQSQ EDFAVYYCQQ YNNWPLTFGG 100
 GTKVEIKRTV AAPSVPFIPP SDEQLKSGTA SVVCLLNFFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
 Intra-H (C23-C104) 22-96 150-206 267-327 373-431
 22"-96" 150"-206" 267"-327" 373"-431"
 Intra-L (C23-C104) 23'-88" 134'-194'
 23"-88" 134"-194"
 Inter-H-L (h 5-CL 126) 226-214' 226"-214"
 Inter-H-H (h 11, h 14) 232-232" 235-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación
 H CH2 N84.4:
 303, 303"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

telisotuzumabum #
 telisotuzumab

immunoglobulin G1-kappa, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody; gamma1 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216), hinge K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (223-223":225-225":228:228")-tridisulfide

télisotuzumab

immunoglobuline G1-kappa, anti-[*Homo sapiens* MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé; chaîne lourde gamma1 (1-445) [VH humanisé (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216), charnière K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimère (223-223":225-225":228:228")-tridisulfure

telisotuzumab

inmunoglobulina G1-kappa, anti-[*Homo sapiens* MET (proto-oncogen met, receptor del factor de crecimiento de hepatocitos, HGFR, receptor del factor de dispersión, receptor del HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de células renales 2, RCCP2)], anticuerpo monoclonal humanizado; cadena pesada gamma1 (1-445) [VH humanizado (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216), bisagra K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dímero (223-223":225-225":228:228")-trisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```

QVQLVQSGAE VKKPGASVKV SCKASGYLFT AYTMHWRQA PGQGLEWMGW 50
IKPNNGLANY AQKFGQGRVTM TRDTSISTAY MELSLRLRSD TAVYVCARSE 100
ITTEFDYWGQ GTLVTVSSAS TKGPSVFFLA PSSKSTISGGT AALGCLVKDY 150
FPEPTVSWN SGALTSVHT FPAVLQSSGL YSLSSVTVTP SSSLGTQTYI 200
CNVNHKPSNT KVDKRVPEKS CDCHCPPCA PELGGGSPVF LFPPKPKDTL 250
MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTP REEQNSTYR 300
VVSVLTVLHQ DWLNGKEYKC KVSNKALFAP IEKTISKAKG QREPOVYTL 350
PPSREEMTKN QVSLTCLVKG FYPYSDIAVEW ESNGQPENNY KTTTPVLDSD 400
GSFLYSLKLT VDKSRWQQN VFSCSVMHEA LHNHYTQKSL SLSPG 445

```

Light chain / Chaîne légère / Cadena ligera

```

DIVMTQSPDS LAVSLGERAT INCKSSESVD SYANSFLHWY QQKPGQPPKL 50
LIYRSTRES GVDFRFGSGG SGTDETLTIS SLQAEADVAV YCQSKEDDFL 100
TFGGGTKVEI KRTVAAPSVE IFFPSDEQLK SGTASVVCLL NNFYPREAKV 150
QWKVDNALQS GNSQESVTEQ DSKDSTYLSL STLTLSKADY EKHKVIACEV 200
THQGLSPVPT KSFNRGEC 218

```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 145-201 260-320 366-424
 22"-96" 145"-201" 260"-320" 366"-424"
 Intra-L (C23-C104) 23"-92" 138"-198"
 23"-92" 138"-198"
 Inter-H-L (h 5-CL 126) 221-218' 221"-218"
 Inter-H-H (h 11, h 14) 225-225" 228-228" (h 8>C) 223-223"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 296, 296"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenarijos complejos fucosilados

telisotuzumabum vedotinum #
telisotuzumab vedotin

immunoglobulin G1-kappa, anti-[*Homo sapiens* MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)], humanized monoclonal antibody conjugated to auristatin E; gamma1 heavy chain (1-445) [humanized VH (*Homo sapiens* IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -*Homo sapiens* IGHG1*03, G1m3 (CH1 (119-216), hinge K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfide with kappa light chain (1'-218') [humanized V-KAPPA (*Homo sapiens* IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -*Homo sapiens* IGKC*01, Km3 (112'-218')]; dimer (223-223":225-225":228:228")-trisdisulfide; conjugated, on an average of 3 cysteinyl, to

| | |
|------------------------|--|
| | <p>monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-<i>p</i>-aminobenzoyloxycarbonyl (mc-val-cit-PABC) type linker For the <i>vedotin</i> part, please refer to the document "<i>INN for pharmaceutical substances: Names for radicals, groups and others</i>".</p> |
| télisotuzumab védotine | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> MET (proto-oncogène met, récepteur du facteur de croissance hépatocytaire, HGFR, récepteur du facteur de dispersion, récepteur de l'HGF/SF, récepteur protéine-tyrosine kinase c-Met, carcinome papillaire à cellules rénales 2, RCCP2)], anticorps monoclonal humanisé conjugué à l'auristatine E; chaîne lourde gamma1 (1-445) [VH humanisé (<i>Homo sapiens</i> IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -<i>Homo sapiens</i> IGHG1*03, G1m3 (CH1 (119-216), charnière K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfure avec la chaîne légère kappa (1'-218') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218')]; dimère (223-223":225-225":228:228")-trisdifure; conjugué, sur 3 cystéinyl en moyenne, au monométhylauristatine E (MMAE), via un linker clivable de type maléimidocaproyl-valyl-citrullinyl-<i>p</i>-aminobenzoyloxycarbonyl (mc-val-cit-PABC) Pour la partie <i>védotine</i>, veuillez-vous référer au document "<i>INN for pharmaceutical substances: Names for radicals, groups and others</i>".</p> |
| telisotuzumab vedotina | <p>inmunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> MET (protooncogén met, receptor del factor de crecimiento de los hepatocitos, HGFR, receptor del factor de dispersión, receptor del HGF/SF, receptor proteína-tirosina kinasa c-Met, carcinoma papilar de las células renales 2, RCCP2)], anticuerpo monoclonal humanizado conjugado con la auristatina E; cadena pesada gamma1 (1-445) [VH humanizado (<i>Homo sapiens</i> IGHV1-2*02 (92.90%) -(IGHD)-IGHJ4*01) [8.8.11] (1-118) -<i>Homo sapiens</i> IGHG1*03, G1m3 (CH1 (119-216), bisagra K7>del, T8>C (223), T10>del (217-229), CH2 (230-339), CH3 (340-444), CHS K>del (445)) (119-445)], (221-218')-disulfuro con la cadena ligera kappa (1'-218') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV4-1*01 (85.10%) -IGKJ4*01) [10.3.9] (1'-111') -<i>Homo sapiens</i> IGKC*01, Km3 (112'-218')]; dímero (223-223":225-225":228:228")-trisdifuro; conjugado, sobre una media de 3 cisteinil, a la monometilauristatina E (MMAE), mediante un enlace escindible de tipo maléimidocaproyl-valil-citrulinil-<i>p</i>-aminobenciloxicarbonil (mc-val-cit-PABC) Para la fracción <i>vedotina</i> se pueden referir al documento "<i>INN for pharmaceutical substances: Names for radicals, groups and others</i>".</p> |

Heavy chain / Chaîne lourde / Cadena pesada

QVQLVQSGAE VVKPGASVKV SCKASGYIFT AYTMMHWRQA PGQGLEWMGW 50
 IKPNNGLANY AOKPQGRVTM TRDTSISTAY MELSLRLSDD TAVYYCARSE 100
 ITTEFDYWGQ GTLVTVSSAS TKGPSVFPLA PSSKSTSGT AALGCLVKDY 150
 FPEPVTWSWN SGALTSVHHT FPAVLQSSGL YSLSSVVTVP SSSLGTQTYI 200
 CNVNHKPSNT KVDRKVEPKS CDCHCPGCPA PELLGGPSVF LFPPKPKDTL 250
 MISRTPEVTC VVVDVSHEDP EVKFNWYVDG VEVHNAKTRP REEQNSTYTR 300
 VVSVLTVLHQ DNLNGKEYKC KVSNKALPAP IEKTSKAKG QPREPQVYTL 350
 PPSREEMTKN QVSLTCLVKG FYPSDIAVEW ESNQQPENNY KTTPEVLDSD 400
 GSFFLYSKLT VDKSRWQQGN VFSCVMHEA LHNHYTQKSL SLSPG 445

Light chain / Chaîne légère / Cadena ligera

DIVMTQSPDS LAVSLGERAT INCKSSSEVD SYANSFLHWY QOKPGQPPKL 50
 LIYRASTRES GVPDRFSGSG SGTDFTLTIS SLQAEDVAVY YCQQSKEDPL 100
 TFGGGTKVEI KRTVAAPSVF IFPPSDEQLK SGTASVCLL NNFYPREAKV 150
 QWKVDNALQS GNSQESVTEQ DSKDSTYSLS STLTLSKADY EKHKVYACEV 200
 THQGLSSPVT KSFNRGEC 218

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22"-96" 145"-201" 260"-320" 366"-424"
 22"-96" 145"-201" 260"-320" 366"-424"
 Intra-L (C23-C104) 23"-92" 138"-198"
 23"-92" 138"-198"

Inter-H-L (h 5-CL 126)* 221"-218" 221"-218"

Inter-H-H (h 11, h 14)* 225"-225" 228"-228" (h 8>C) 223"-223"

*Two or three of the inter-chain disulfide bridges are not present, an average of 3 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 3 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 3 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

296, 296*

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

tenofovirum exalidexum

tenofovir exalidex

3-(hexadecyloxy)propyl hydrogen {{{(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy)methyl}phosphonate


ténofovir exalidex

{{{(2*R*)-1-(6-amino-9*H*-purin-9-yl)propan-2-yl]oxy)méthyl}hydrogénophosphonate de 3-(hexadécyloxy)propyle

tenofovir exalidex

{{{(2*R*)-1-(6-amino-9*H*-purin-9-il)propan-2-il]oxi]metil}hidrogenofosfonato de 3-(hexadeciloxi)propilo

C₂₈H₅₂N₅O₅P

**tirabrutinibum**

tirabrutinib


6-amino-9-[(3*R*)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phenoxyphenyl)-7,9-dihydro-8*H*-purin-8-one

tirabrutinib

6-amino-9-[(3*R*)-1-(but-2-ynoyl)pyrrolidin-3-yl]-7-(4-phénoxyphényl)-7,9-dihydro-8*H*-purin-8-one

tirabrutinib

6-amino-9-[(3*R*)-1-(but-2-inoil)pirrolidin-3-il]-7-(4-fenoxifenil)-7,9-dihidro-8*H*-purin-8-ona



tonabacasum #
tonabacase

Staphylococcus aureus phage 1 (SAP-1)-derived soluble endolysin (*Staphylococcus aureus* phage lysin-1, bacteriolysin SAL-1), produced in *Escherichia coli*

tonabacase

endolysine soluble dérivée du phage 1 de *Staphylococcus aureus* (lysine du phage 1 de *Staphylococcus aureus*, bactériolysine SAL-1), produite par *Escherichia coli*

tonabacasa

endolisina soluble derivada del fago 1 de *Staphylococcus aureus* (lisina del fago 1 de *Staphylococcus aureus*, bacteriolisina SAL-1), producida por *Escherichia coli*

Sequence / Séquence / Secuencia
 AKTQAEINKR LDAYAKGTV D SPYRIKKATS YDPSFGVMEA GAIDADGYHH 50
 AQCQDLITDY VLWLTDNKVR TWGNAKDQIK QSYGTGFKIH ENKPTSTVPKK 100
 GWIAVFTSGS YQQWGHIGIV YDGGNTSTFT ILEQNWNGYA NKKPTKRVDN 150
 YYGLTHFIEI PVKAGTTVKK ETAKKSASKT PAPKKKATLK VSKNHINYTM 200
 DKRGGKPEGM VIHNDAGRSS GQQYENSLAN AGYARYANGI AHYYGSEGVY 250
 WEALDAKNQI AWHTGDGTGA NSGNFRFAGI EVCQSMSASD AQFLKNEQAV 300
 FQFTAELKFE WGLTPNKRKV RLMHFEFVPTA CPHRSMVLHT GFNPVTQGRP 350
 SQAIMNKLKD YFIKQIKNYM DKGTSSTVV KDKTSSAST PATRPVTSW 400
 KKNQYGTWYK PENATFVNGN QPVTIRIGSP FLNAPVGGNL PAGATIVYDE 450
 VCIQAGHIWI GYNAYNGNRV YCPVRTCQGV PPNHIGVAW GVFK 494

tonongenconcelum #
tonongenconcel

Allogeneic primary human chondrocytes transduced with a retroviral vector expressing human transforming growth factor-beta1 (TGF-β1). A master cell bank of primary human chondrocytes, grown from cartilage tissue obtained from the surgical excision of a polydactyly finger from a three-year-old female donor, was prepared. After transduction of cells from the master cell bank, a single clonal population was selected using limiting dilution and submitted to irradiation. Cells express TGF-β1, Type I and Type II collagen as well as Type I and Type II TGF-β1 receptors; they lack expression of gag and pol genes.

tonongenconcel

Chondrocytes humains primaires allogéniques transduits par un vecteur rétroviral exprimant le facteur de croissance transformant-bêta1 (TGF-β1). Une banque de cellules primaires a été préparée à partir de tissu cartilagineux obtenu par excision chirurgicale d'un doigt surnuméraire d'un donneur âgé de 3 ans et de sexe féminin. Après transduction des cellules de la banque de cellules primaires, un seul clone a été sélectionné en utilisant une dilution limitative et en le soumettant à une irradiation. Les cellules expriment le TGF-β1, du collagène de type I et II ainsi que les récepteurs de type I et II du TGF-β1; elles sont dépourvues d'expression de gènes gag et pol.

tonogenconcel

Condrocitos humanos primarios alogénicos transducidos por un vector retroviral que expresa el factor de crecimiento transformador-beta1 (TGF-β1). Un banco de células primarias preparado a partir de tejido cartilaginoso obtenido por escisión quirúrgica de un dedo adicional de un donante de 3 años de edad y de sexo femenino. Después de la transducción de las células del banco de células primarias, se selecciona un único clon utilizando una dilución limitante y se somete a radiación. Las células que expresan el TGF- β1, del colágeno de tipo I y II así como los receptes de tipo I y II del TGF- β1; ellas carecen de la expresión de los genes gag y pol.

tozuleristidum

tozuleristide

$N^{6,27}$ -[6-(2-((1*E*,2*E*,4*E*,6*E*)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)-1*H*-benzo[*e*]indol-3-ium-2-yl]hepta-2,4,6-trien-1-ylidene)-1,1-dimethyl-1,2-dihydro-3*H*-benzo[*e*]indol-3-yl)hexanoyl]-[Lys¹⁵>Arg,Lys²³>Arg]chlorotoxin (*Leiurus quinquestriatus quinquestriatus*) (Egyptian scorpion)

tozuléristide

$N^{6,27}$ -[6-(2-((1*E*,2*E*,4*E*,6*E*)-7-[1,1-diméthyl-3-(4-sulfonatobutyl)-1*H*-benzo[*e*]indol-3-ium-2-yl]hepta-2,4,6-trién-1-ylidène)-1,1-diméthyl-1,2-dihydro-3*H*-benzo[*e*]indol-3-yl)hexanoyl]-[Lys¹⁵>Arg,Lys²³>Arg]chlorotoxine de *Leiurus quinquestriatus quinquestriatus* (scorpion égyptien)

tozuleristida


$N^{6,27}$ -[6-(2-((1*E*,2*E*,4*E*,6*E*)-7-[1,1-dimetil-3-(4-sulfonatobutil)-1*H*-benzo[*e*]indol-3-ium-2-il]hepta-2,4,6-trien-1-ilideno)-1,1-dimetil-1,2-dihidro-3*H*-benzo[*e*]indol-3-il)hexanoil]-[Lys¹⁵>Arg,Lys²³>Arg]clorotoxina de *Leiurus quinquestriatus quinquestriatus* (escorpión egipcio)
C₂₀₃H₂₉₆N₅₈O₅₂S₁₂

Sequence / Sequence / Secuencia

MCMPCFTTTH QMARRCDDCC GGRGRGKCYG PQCLCR 36

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro
2-19 5-28 16-33 20-35

Modified residue / Résidu modifié / Resto modificado



trastuzumabum duocarmazinum #

trastuzumab duocarmazine

immunoglobulin G1-kappa, anti-[*Homo sapiens* ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185-erbB2, NEU, CD340)], humanized monoclonal antibody conjugated to the pro-drug *seco*-duocarmycin-hydroxybenzamide-azaindole (*seco*-DUBA);

| | |
|--------------------------|---|
| | <p>gamma1 heavy chain (1-449) [humanized VH (<i>Homo sapiens</i> (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -<i>Homo sapiens</i> IGHG1*01, G1m17, nG1m1 (CH1 (121-218), hinge (219-233), CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>del (449)) (121-449)], (223-214')-disulfide with kappa light chain (1'-214') [humanized V-KAPPA (<i>Homo sapiens</i> IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dimer (229-229":232-232")-bisdisulfide, conjugated on an average of 2 or 4 cysteines, to <i>seco</i>-DUBA via the cleavable linker <i>N</i>-[2-(2-maleimidoethoxy)ethoxycarbonyl]-L-valyl-L-citrullinyl-<i>p</i>-aminobenzoyloxycarbonyl-<i>N</i>-[2-(2-hydroxyethoxy)ethyl]-<i>N</i>-[2-(methylamino)ethyl]carbamoyl</p> |
| trastuzumab duocarmazine | <p>immunoglobuline G1-kappa, anti-[<i>Homo sapiens</i> ERBB2 (récepteur 2 du facteur de croissance épidermique, récepteur tyrosine-protéine kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticorps monoclonal humanisé conjugué à la pro-drogue <i>seco</i>-duocarmicine-hydroxybenzamide-azaindole (<i>seco</i>-DUBA); chaîne lourde gamma1 (1-449) [VH humanisé (<i>Homo sapiens</i> (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -<i>Homo sapiens</i> IGHG1*01, G1m17, nG1m1 (CH1 (121-218), charnière (219-233), CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>del (449)) (121-449)], (223-214')-disulfure avec la chaîne légère kappa (1'-214') [V-KAPPA humanisé (<i>Homo sapiens</i> IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dimère (229-229":232-232")-bisdisulfure, conjugué sur une moyenne de 2 ou 4 cystéines au <i>seco</i>-DUBA via le linker clivable <i>N</i>-[2-(2-maleimidoéthoxy)éthoxycarbonyl]-L-valyl-L-citrullinyl-<i>p</i>-aminobenzoyloxycarbonyl-<i>N</i>-[2-(2-hydroxyéthoxy)éthyl]-<i>N</i>-[2-(méthylamino)éthyl]carbamoyl</p> |
| trastuzumab duocarmazina | <p>immunoglobulina G1-kappa, anti-[<i>Homo sapiens</i> ERBB2 (receptor 2 del factor de crecimiento epidérmico, receptor tirosina-proteína kinasa erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], anticuerpo monoclonal humanizado conjugado con el profármaco <i>seco</i>-duocarmicina-hidroxibenzamida-azaíndol (<i>seco</i>-DUBA); cadena pesada gamma1 (1-449) [VH humanizado (<i>Homo sapiens</i> (IGHV3-66-*01 (81.60%) -(IGHD)-IGHJ6*01) [8.8.13] (1-120) -<i>Homo sapiens</i> IGHG1*01, G1m17, nG1m1 (CH1 (121-218), bisagra (219-233), CH2 (234-343), CH3 D12>E (359), L14>M (361) (344-448), CHS K>del (449)) (121-449)], (223-214')-disulfuro con la cadena ligera kappa (1'-214') [V-KAPPA humanizado (<i>Homo sapiens</i> IGKV1-39*01 (86.30%) -IGKJ1*01) [6.3.9] (1'-107') -<i>Homo sapiens</i> IGKC*01, Km3 (108'-214')]; dímero (229-229":232-232")-bisdisulfuro; conjugado en 2 o 4 cisteínas, por término medio con <i>seco</i>-DUBA mediante el enlace escindible <i>N</i>-[2-(2-maleimidoetoxi)etoxicarbonil]-L-valil-L-citrulinil-<i>p</i>-aminobenciloxicarbonil-<i>N</i>-[2-(2-hidroxiétoxi)etil]-<i>N</i>-[2-(metilamino)etil]carbamoilo</p> |

Heavy chain / Chaîne lourde / Cadena pesada
 EVQLVESGGG LVQPGGSLRL SCAASGFNIK DTYIHWVRQA PCKGLEWVAR 50
 IYPTNGYTRY ADSVKGRTFI SADTKSNTAY LQMNSLRAED TAVYICSRWG 100
 GDGFYAMDYW GQGTLVTVSS ASTKGPVFP LAPSSKSTSG GTAALGCLVK 150
 DYFPEPVTVS WNSGALTSVG HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT 200
 YICNVNPKFS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP 250
 KDTLMSRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN 300
 STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIIS KAKGQPREPQ 350
 VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVENESNGQP ENNYKTTTPPV 400
 LDSGSEFELY SKLTVDKSRW QQGNVFCSCV MHEALHNYHT QKSLSLSPG 449
 Light chain / Chaîne légère / Cadena ligera
 DIQMTQSPSS LSAGVGDVVT ITCRASQDVN TAVAWYQQKPK GKAPKLLIYS 50
 ASFLYSGVPS RFGSRSRSGTD FTLTISSLQP EDFATYYCQQ HYTTPPTFGQ 100
 GTKVEIKRTV AAPSVEIFPP SDEQLKSGTA SVVCLLNNFY PRAKQVQWKV 150
 DNALQSGNSQ ESVTEQDSKD STYLSLSLTL LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEC 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 147-203 264-324 370-428
 22^o-96^o 147^o-203^o 264^o-324^o 370^o-428^o

Intra-L (C23-C104) 23^o-88^o 134^o-194^o
 23^o-88^o 134^o-194^o

Inter-H-L (h 5-CL 126)* 223-214^o 223^o-214^o

Inter-H-H (h 11, h 14)* 229-229^o 232-232^o

*Two or three of the inter-chain disulfide bridges are not present, on average 2 or 4 cysteinyl being conjugated each via a thioether bond to a drug linker.

*Deux ou trois des ponts disulfures inter-chaînes ne sont pas présents, 2 or 4 cystéinyl en moyenne étant chacun conjugué via une liaison thioéther à un linker-principe actif.

*Faltan dos o tres puentes disulfuro inter-catenarios, una media de 2 o 4 cisteinil está conjugada a conectores de principio activo.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación


H CH2 N84.4:

300, 300^o

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados

Potential modified residues / résidus modifiés potentiels / restos modificados potenciales

C*
 214^o, 214^o, 223, 223^o,
 229, 229^o, 232, 232^o



tucidinostatam

tucidinostat

N-(2-amino-4-fluorophenyl)-4-[(2*E*)-3-(pyridin-3-yl)prop-2-enamido]methylbenzamide


tucidinostat

N-(2-amino-4-fluorophényl)-4-[(2*E*)-3-(pyridin-3-yl)prop-2-énamido]méthylbenzamide

tucidinostat

N-(2-amino-4-fluorofenil)-4-[(2*E*)-3-(piridin-3-il)prop-2-enamido]metilbenzamida

C₂₂H₁₉FN₄O₂



upadacitinibum


upadacitinib

(3*S*,4*R*)-3-ethyl-4-(3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pyrazin-8-yl)-*N*-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide

upadacitinib (3*S*,4*R*)-3-éthyl-4-(3*H*-imidazo[1,2-*a*]pyrrolo[2,3-*e*]pirazin-8-yl)-*N*-(2,2,2-trifluoroéthyl)pyrrolidine-1-carboxamide

upadacitinib (3*S*,4*R*)-3-etil-4-(3*H*-imidazo[1,2-*a*]pirrolo[2,3-*e*]pirazin-8-il)-*N*-(2,2,2-trifluoroetil)pirrolidina-1-carboxamida

C₁₇H₁₉F₃N₆O



uprifosbuvirum

uprifosbuvir

propan-2-yl *N*-[(*R*)-{[(2*R*,3*R*,4*R*,5*R*)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3-hydroxy-4-méthyloxolan-2-yl]méthoxy}phénoxyphosphoryl]-*D*-alaninate


uprifosbuvir

N-[(*R*)-{[(2*R*,3*R*,4*R*,5*R*)-4-chloro-5-(2,4-dioxo-3,4-dihydropyrimidin-1(2*H*)-yl)-3-hydroxy-4-méthyloxolan-2-yl]méthoxy}phénoxyphosphoryl]-*D*-alaninate de propan-2-yle

uprifosbuvir

N-[(*R*)-{[(2*R*,3*R*,4*R*,5*R*)-4-cloro-5-(2,4-dioxo-3,4-dihidropirimidin-1(2*H*)-il)-3-hidroxi-4-metiloxolan-2-il]metoxi}fenoxifosforil]-*D*-alaninato de propan-2-ilo

C₂₂H₂₉ClN₃O₉P



utomilumabum #

utomilumab

immunoglobulin G2-lambda, anti-[*Homo sapiens* TNFRSF9 (tumor necrosis factor receptor (TNFR) superfamily member 9, 4-1BB, T cell antigen ILA, CD137)], *Homo sapiens* monoclonal antibody; gamma2 heavy chain (1-442) [*Homo sapiens* VH (IGHV5-10-1*04 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG2*01, G2m.. (CH1 (117-214), hinge (215-226), CH2 (227-335), CH3 (336-440), CHS (441-442)) (117-442)], (130-213')-disulfide with lambda light chain (1'-214')] [*Homo sapiens* V-LAMBDA (IGLV3-1*01 (90.00%) -IGLJ7*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimer (218-218":219-219":222-222":225-225")-tetrakisdisulfide

utomilumab

immunoglobuline G2-lambda, anti-[*Homo sapiens* TNFRSF9 (membre 9 de la superfamille des récepteurs du facteur de nécrose tumorale, 4-1BB, antigène ILA de lymphocyte T, CD137)], *Homo sapiens* anticorps monoclonal;

utumilumab

chaîne lourde gamma2 (1-442) [*Homo sapiens* VH (IGHV5-10-1*04 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG2*01, G2m.. (CH1 (117-214), charnière (215-226), CH2 (227-335), CH3 (336-440), CHS (441-442)) (117-442)], (130-213')-disulfure avec la chaîne légère lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-1*01 (90.00%) -IGLJ7*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dimère (218-218":219-219":222-222":225-225")-tétrakisdisulfure

inmunoglobulina G2-lambda, anti-*[Homo sapiens* TNFRSF9 (miembro 9 de la superfamilia de los receptores del factor de necrosis tumoral, 4-1BB, antígeno ILA de linfocito T, CD137)], *Homo sapiens* anticuerpo monoclonal; cadena pesada gamma2 (1-442) [*Homo sapiens* VH (IGHV5-10-1*04 (94.90%) -(IGHD)-IGHJ4*01) [8.8.9] (1-116) -IGHG2*01, G2m.. (CH1 (117-214), bisagra (215-226), CH2 (227-335), CH3 (336-440), CHS (441-442)) (117-442)], (130-213')-disulfuro con la cadena ligera lambda (1'-214') [*Homo sapiens* V-LAMBDA (IGLV3-1*01 (90.00%) -IGLJ7*01) [6.3.11] (1'-108') -IGLC2*01 (109'-214')]; dímero (218-218":219-219":222-222":225-225")-tetraakisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGESLRI SCKGSGYSFS TWISWVRQM PGKGLEWMGK 50
IYPGDSYTNV SPSFQGGVTLI SADKSI STAY LQWSSLKASD TAMYYCARGY 100
GIFDYWQGT LVTVSSASTK GPSVFP LAPC SRSTSESTAA LGCLVKDYFP 150
EPVTVSWNSG ALTSGVHFTF AVLQSSGLYS LSSVVTVPSS NFGTQTYTCN 200
VDHKPSNTKV DKTVERKCCV ECPPCPAPPV AGPSVFLFPP KFKDTLMI SR 250
TPEVTVCVVD VSHEDPEVQF NWYVDGVEVH NAKTKPREEQ FNSTFRVVSV 300
LTVVHQDLN GKELYKCKVSN KGLPAPIEKT ISKTKGQPRE PQVYTLPPSR 350
EEMTKNQVSL TCLVKGFPYS DIAVEWESNG QPENNYKTFP PMLDSGSGFF 400
LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTKQSLSLSP GK 442
```

Light chain / Chaîne légère / Cadena ligera

```
SYELTQPPSV SVSPGQTASI TCSGDNIGDQ YAHWYQQKFG QSPVLVIYQD 50
KNRPSGIPER FSGSNSGNTA TLTISGTQAM DEADYGCATY TGFGLAVFG 100
GGTKLTVLGG PKAAPSVTLF PPSSEELQAN KATLVCLISD FYPGAVTVAW 150
KADSPVKGK VETTTFSKQS NNKYAASSYL SLTPEQWKSH RSYSCQVTHE 200
GSTVEKTVAP TECS 214
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 143-199 256-316 362-420
22"-96" 143"-199" 256"-316" 362"-420"
Intra-L (C23-C104) 22-87 136-195"
22"-87" 136"-195"

Inter-H-L (CH1 10-CL 126) 130-213' 130"-213"

Inter-H-H (h 4, h 5, h 8, h 11) 218-218" 219-219" 222-222" 225-225"

*In addition to the isoform A, isoform A/B characterized by an inter-H-H (h 4 - CH1 10) 218-130' and an inter-H-L (h 4-CL 126) 218'-213", instead of the inter-H-H (h 4 - h 4) 218-218' and of one of the two inter-H-L (CH1 10-CL 126) 130'-213", isoform B characterized by an inter-H-H (h 5 - CH1 10) 219-130 and an inter-H-L (h 5-CL 126) 219'-213', instead of the inter-H-H (h 5 - h 5) 219-219' and of the inter-H-L (CH1 10-CL 126) 130-213'.

*En plus de l'isoforme A, isoforme A/B caractérisée par un inter-H-H (h 4 - CH1 10) 218-130' et un inter-H-L (h 4-CL 126) 218'-213", au lieu de l'inter-H-H (h 4 - h 4) 218-218' et de l'un des deux inter-H-L (CH1 10-CL 126) 130'-213", isoforme B caractérisée par un inter-H-H (h 5 - CH1 10) 219-130 et un inter-H-L (h 5-CL 126) 219'-213", au lieu de l'inter-H-H (h 5 - h 5) 219-219' et de l'inter-H-L (CH1 10-CL 126) 130-213'.

*Además de la isoforma A, isoforma A/B caracterizado por un inter-H-H (h 4 - CH1 10) 218-130' y un inter-H-L (h 4-CL 126) 218'-213", en lugar del inter-H-H (h 4 - h 4) 218-218' y uno de los dos inter-H-L (CH1 10-CL 126) 130'-213", isoforma B caracterizado por un inter-H-H (h 5 - CH1 10) 219-130 y un inter-H-L (h 5-CL 126) 219'-213", en lugar del inter-H-H (h 5 - h 5) 219-219' y del inter-H-L (CH1 10-CL 126) 130-213'.

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H VH N66:

59, 59" (partially occupied, with up to two sialicacids)

H CH2 N84.4:

292, 292" (fully occupied)

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires complexes fucosylés / glicanos de tipo CHO biantenarios complejos fucosilados.

Other post-translational modifications / Autres modifications post-traduccionnelles /

Otras modificaciones post-traduccionales

H CHS K2 C-terminal lysine clipping:

442, 442"

valnivudinum

valnivudine


{{(2*R*,3*S*,5*R*)-3-hydroxy-5-[2-oxo-6-(4-pentylphenyl)furo[2,3-*d*]pyrimidin-3(2*H*)-yl]oxolan-2-yl)methyl L-valinate

valnivudine

L-valinate de {{(2*R*,3*S*,5*R*)-3-hydroxy-5-[2-oxo-6-(4-pentylphényl)furo[2,3-*d*]pyrimidin-3(2*H*)-yl]oxolan-2-yl)methyl

valnivudina

L-valinato de {{(2*R*,3*S*,5*R*)-3-hidroxi-5-[2-oxo-6-(4-pentilfenil)furo[2,3-*d*]pirimidin-3(2*H*)-il]oxolan-2-il}metilo

 $C_{27}H_{35}N_3O_6$
**vamorolonum**

vamorolone


17,21-dihydroxy-16 α -methylpregna-1,4,9(11)-triene-3,20-dione

vamorolone

17,21-dihydroxy-16 α -méthylprègna-1,4,9(11)-triène-3,20-dione

vamorolona

17,21-dihidroxi-16 α -metilpregna-1,4,9(11)-trieno-3,20-diona

 $C_{22}H_{28}O_4$
**vandefitemcelum**


vandefitemcel

human differentiation-restricted descendents (DRCs) of bone-marrow-derived adherent stromal cells (MASCs) isolated from adult donor. To obtain DRCs, MASCs were transiently transfected with a DNA plasmid encoding human Notch-1 intracellular domain (NICD) and expanded in growth media. The transfection does not result in permanent incorporation of the gene into the cells, but does result in changes in a number of proteins and in the methylation pattern of the DNA (there is complete loss of recombinant NICD protein and of the plasmid in the final cell population). The transfection changes the nature of the cells such that they no longer readily differentiate into bone, cartilage or adipose cells, and also results in cells altered in their ability to secrete trophic and chemotactic factors, and extracellular matrix proteins to support damaged neural cells.

| | |
|------------------------|---|
| | Cells are positive for mesenchymal stem cell (MSC) markers (CD29, CD90, CD105) and negative for hematopoietic markers (CD31, CD34, CD45). |
| vandéfitemcel | <p>descendants à différenciation restreinte (DRCs) humains de cellules stromales adhérentes dérivées de la moelle osseuse (MASCs) isolées d'un donneur adulte. Pour obtenir les DRCs, les MASCs ont été transitoirement transfectées avec un plasmide dont l'ADN code pour le domaine intracellulaire de Notch-1 humain (NICD) et ont été expansées par des moyens de croissance. La transfection ne résulte pas d'une incorporation permanente du gène dans les cellules, mais de changements dans un nombre de protéines et dans les méthylations de l'ADN (il y a une perte complète de la protéine recombinante NICD et du plasmide dans la population finale). La transfection change la nature des cellules de telle sorte qu'elles ne se différencient plus en cellules osseuses, cartilagineuses ou adipeuses et il en résulte aussi des cellules modifiées dans leur capacité à sécréter des facteurs trophiques et chimiotactiques, et des protéines de la matrice extracellulaire qui supportent les cellules neuronales endommagées.</p> <p>Les cellules sont positives pour les marqueurs des cellules souches mésenchymateuses (CD29, CD90, CD105) et négatives pour les marqueurs hématopoïétiques (CD31, CD34, CD45).</p> |
| vandéfitemcel | <p>descendientes humanas de la diferenciación restrictiva (DRCs) de células estromales adherentes derivadas de la médula ósea (MASCs) aisladas de un donante adulto. Para obtener los DRCs, las MASCs se transfectan transitoriamente con un plásmido de ADN que codifica para el dominio intracelular Notch-1 humano (NICD) y se expanden en un medio de crecimiento. La transfección no resulta en una incorporación permanente del gen dentro de las células, pero sí en cambios en el número de proteínas y en el patrón de metilación del DNA (hay una pérdida completa de proteína recombinante NICD y del plásmido en la población final celular).</p> <p>La transfección cambia la naturaleza de las células de tal modo que no se diferencian con más facilidad en células óseas, cartilaginosas o adiposas y también resulta en células modificadas bajo la capacidad de secretar factores tróficos y quimiotácticos, y las proteínas de la matriz extracelular que soportan las células neuronales dañadas. Las células son positivas para los marcadores de las células madres mesenquimales (CD29, CD90, CD105) y negativas para los marcadores hematopoyéticos (CD31, CD34, CD45).</p> |
| velagliflozinum | |
| velagliflozin | 2-[(4-cyclopropylphenyl)methyl]-4-β-D-glucopyranosylbenzonitrile |
| vélagliflozine | 2-[(4-cyclopropylphényl)méthyl]-4-β-D-glucopyranosylbenzonitrile |

velagliflozina

2-[(4-ciclopropilfenil)metil]-4-β-D-glucopiranosilbenzonitrilo

C₂₃H₂₅NO₅

vestronidasum alfa #

vestronidase alfa

human β-glucuronidase, natural Leu⁶²⁷>Pro variant, homotetramer, produced in Chinese hamster ovary cells (CHO), glycoform alfa

vestronidase alfa

β-glucuronidase humaine, variante naturel Leu⁶²⁷>Pro, homotétramère, produit dans des cellules ovariennes de hamsters chinois (CHO), glycoforme alfa

vestronidasa alfa

β-glucuronidasa humana, variante natural Leu⁶²⁷>Pro, homotétramero, producido en células de ovario de hamster chino (CHO), glicoforma alfa

Monomer / Monomère / Monómero

LQGGMLYPQE SPSRECKELD GLWSFRADFS DNRRRGFEEQ WYRRPLWESG 50
 PTVDMPVPSS FNDISQDWRL RHFVGVWVWE REVILPERWT QDLRTRVVLR 100
 IGSASHYAIV WNVGVDLLEH EGGYLPFEAD ISNLVQVGPL PSRLRITIAI 150
 NNTLTPTTLP PGTIQYLTDI SKYPKGYFVQ NTYPDFFNVA GLQRSVLLYT 200
 TPTTYIDDI VTTSVEQDSG LVNYQISVKG SNLFKLEVRL LDAENKVVAN 250
 GTGTGGQLKV PGVSLWVWYL MHERPAYLYS LEVQLTAQTS LGPVSDFYTL 300
 PVGIRTVAVT KQQLFLNGKP FYFHGVNKHE DADIRGKGFDP WPLLVKDFNL 350
 LRWLGANAER TSHYPYAEV MCMCDRYGIV VIDECPGVGL ALPQFFNVVS 400
 LHHMQVMEE VVRRDKNHPA VVMWSVANEP ASHLESAGY LKMVIAHTKS 450
 LDPSRPVTFV SNSNYAADKG APYVDVICLN SYYSWYHDYG HLELIQLQLA 500
 TQFENWYKKY QKPIIQSEYG AETIAGFHQD PPLMFTTEYQ KSLEEQYHLG 550
 LDQKRRKYVV GELIWNFADF MTEQSPTRVL GNKKGIFTRQ RQPKSAAFFL 600
 RERYWKIANE TRYPHSVAKS QCLENSPFT 629

Glycosylation sites (N) / Sites de glycosylation (N) / Posiciones de glicosilación (N)
Asn-151 Asn-250 Asn-398 Asn-609

Disulfide bridges (C)

inter-chain 622-622' 622"-622'''
intra-chain not determined

voretigenum neparovecum #

voretigene neparovec

recombinant adeno-associated serotype 2 (rAAV-2) virus vector that carries the RPE65 gene, encoding a retinal pigment (RPE)-specific human retinoid isomerohydrolase, containing a modified Kozak sequence at the translation start site and under the control of the cytomegalovirus (CMV) immediate early enhancer and the chicken beta-actin (CBA) promoter.

voretigène néparovec

vecteur viral adéno-associé de type 2 (rAAV-2) recombinant, contenant le gène RPE65 codant pour l'isomérohydrolase des rétinoïdes, humaine, spécifique de l'épithélium pigmentaire de la rétine, contenant une séquence de Kozak au site de démarrage de la traduction et sous le contrôle de l'activateur immédiat-précoce du cytomegalovirus et du promoteur de l'actine bêta du poulet (ABP, CBA).



voretigén neparvovec vector viral adeno-asociado de tipo 2 (rAAV-2) recombinante, que contiene el gen RPE65 que codifica para la retinoide isomerohidrolasa, humana, específica del epitelium pigmentario de la retina, que contiene una secuencia de Kozak al sitio del comienzo de la traducción y bajo el control del activador inmediato precoz del citomegalovirus (CMV) y del promotor de la actina beta del pollo (CBA).

vorolanibum

vorolanib *N*-[(3*S*)-1-(dimethylcarbamoyl)pyrrolidin-3-yl]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidene)methyl]-2,4-dimethyl-1*H*-pyrrole-3-carboxamide

vorolanib *N*-[(3*S*)-1-(diméthylcarbamoyl)pyrrolidin-3-yl]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihydro-3*H*-indol-3-ylidène)méthyl]-2,4-diméthyl-1*H*-pyrrole-3-carboxamide

vorolanib *N*-[(3*S*)-1-(dimetilcarbamoi)pirrolidin-3-il]-5-[(*Z*)-(5-fluoro-2-oxo-1,2-dihidro-3*H*-indol-3-ilideno)metil]-2,4-dimetil-1*H*-pirrolo-3-carboxamida

**vunakizumabum #**

vunakizumab immunoglobulin G1-kappa, anti-[*Homo sapiens* IL17A (interleukin 17A, IL-17A)], humanized monoclonal antibody;
 gamma1 heavy chain (1-453) [humanized VH (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (124-221), hinge (222-236), CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfide with kappa light chain (1'-213') [humanized V-KAPPA (*Homo sapiens* IGKV6-21*01 (80.00%) -IGKJ1*01) [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213')]; dimer (232-232":235-235")-bisdisulfide

vunakizumab immunoglobuline G1-kappa, anti-[*Homo sapiens* IL17A (interleukine 17A, IL-17A)], anticorps monoclonal humanisé;
 chaîne lourde gamma1 (1-453) [VH humanisé (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (124-221), charnière (222-236), CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfure avec la chaîne légère

vunakizumab

kappa (1'-213') [V-KAPPA humanisé (*Homo sapiens* IGKV6-21*01 (80.00%) -IGKJ1*01 [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213'))]; dimère (232-232":235-235")-bisdisulfure

inmunoglobulina G1-kappa, anti-[*Homo sapiens* IL17A (interleukina 17A, IL-17A)], anticuerpo monoclonal humanizado;
 cadena pesada gamma1 (1-453) [VH humanizado (*Homo sapiens* IGHV1-2*02 (82.70%) -(IGHD)-IGHJ4*01) [8.8.16] (1-123) -*Homo sapiens* IGHG1*01, G1m17, nG1m1 (CH1 (124-221), bisagra (222-236), CH2 (237-346), CH3 D12>E (362), L14>M (364) (347-451), CHS (452-453)) (124-453)], (226-213')-disulfuro con la cadena ligera kappa (1'-213') [V-KAPPA humanizado (*Homo sapiens* IGKV6-21*01 (80.00%) -IGKJ1*01 [5.3.9] (1'-106') -*Homo sapiens* IGKC*01, Km3 (107'-213'))]; dímero (232-232":235-235")-bisdisulfuro

Heavy chain / Chaîne lourde / Cadena pesada

```
EVQLVQSGAE VKKPGASVKV SKASGYTFT DYEYVHWVQR FGOGLWMMGV 50
IDPFGTGGVAY NQKFEGRVTM TADTSTSTAY MELRSLRSDD TAVYYCTRY 100
LFYGSFPYAM DYWGQGLTVT VSSASTKGPS VFPLAPSSKS TSGGTAALGC 150
LVKDYFPEPV TVSWNSGALT SGVHTFPFVAV QSSGLYSLSS VVTVPSSSLG 200
TQTYICNVNH KFSNTRKVDKK VEPKSCDKTH TCPPCPAPEL LGGPSVFLFP 250
PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE 300
QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR 350
EPQVYTLPPS REEMTKNQVS LTCLVKGFPY SDIAVEWESN GPENNYKTT 400
PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSMVHEALHN HYTKSKLSLS 450
PGK 453
```

Light chain / Chaîne légère / Cadena ligera

```
EIVLTQSPDF QSVTPKEKVT ITCSASSSVN YMHWFQKQPD QSPKLWIYRT 50
SNLASGVPSR FSGSGSSTDY TLTINSLEAE DAATYYCQR SSYPWTFGQC 100
TKLEIKRTVA APSVFIFFPS DEQLKSGTAS VVCLLNNFYP REAKVQWKVD 150
NALQSGNSQE SVTEQDSKDS TYLSSTLTL SKADYEKHKV YACEVTHQGL 200
SSPVTKSFNR GEC 213
```

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 150-206 267-327 373-431
 22"-96" 150"-206" 267"-327" 373"-431"
 Intra-L (C23-C104) 23"-87" 133"-193"
 23"-87" 133"-193"
 Inter-H-L (h 5-CL 126) 226-213' 226"-213"
 Inter-H-H (h 11, h 14) 232-232" 235-235"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:
 303, 303"
 Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantennarios complejos fucosilados

Other post-translational modifications / Autres modifications post-traduccionnelles /

Otras modificaciones post-traduccionales
 H CHS K2 C-terminal lysine clipping:
 453, 453"

- # Electronic structure available on Mednet: <http://mednet.who.int/>
- # Structure électronique disponible sur Mednet: <http://mednet.who.int/>
- # Estructura electrónica disponible en Mednet: <http://mednet.who.int/>
- * <http://www.who.int/medicines/services/inn/publication/en/>

**AMENDMENTS TO PREVIOUS LISTS
MODIFICATIONS APPORTÉES AUX LISTES ANTÉRIEURES
MODIFICACIONES A LAS LISTAS ANTERIORES**

Recommended International Nonproprietary Names (Rec. INN): List 32
Dénominations communes internationales recommandées (DCI Rec.): Liste 32
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 32
(WHO Drug Information, Vol. 6, No. 3, 1992)

| | | |
|------|--------------------------------|--------------------------------|
| p. 9 | <i>suprimáse</i> tacrolimus | <i>insertese</i> tacrólimus |
|------|--------------------------------|--------------------------------|

Recommended International Nonproprietary Names (Rec. INN): List 34
Dénominations communes internationales recommandées (DCI Rec.): Liste 34
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 34
(WHO Drug Information, Vol. 8, No. 3, 1994)

| | | |
|-------|-------------------------------|-------------------------------|
| p. 19 | <i>suprimáse</i> sirolimus | <i>insertese</i> sirólimus |
|-------|-------------------------------|-------------------------------|

Recommended International Nonproprietary Names (Rec. INN): List 43
Dénominations communes internationales recommandées (DCI Rec.): Liste 43
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 43
(WHO Drug Information, Vol. 14, No. 1, 2000)

| | | |
|-------|----------------------------------|----------------------------------|
| p. 64 | <i>suprimáse</i> pimecrolímús | <i>insertese</i> pimecrólimus |
|-------|----------------------------------|----------------------------------|

Recommended International Nonproprietary Names (Rec. INN): List 44
Dénominations communes internationales recommandées (DCI Rec.): Liste 44
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 44
(WHO Drug Information, Vol. 14, No. 3, 2000)

| | | |
|--------|--------------------------------|--------------------------------|
| p. 194 | <i>suprimáse</i> everolimus | <i>insertese</i> everólimus |
|--------|--------------------------------|--------------------------------|

Recommended International Nonproprietary Names (Rec. INN): List 54
Dénominations communes internationales recommandées (DCI Rec.): Liste 54
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 54
(WHO Drug Information, Vol. 19, No. 3, 2005)

| | | |
|--------|----------------------------------|----------------------------------|
| p. 266 | <i>suprimáse</i> temsirólimus | <i>insertese</i> temsirólimus |
|--------|----------------------------------|----------------------------------|

Recommended International Nonproprietary Names (Rec. INN): List 56
Dénominations communes internationales recommandées (DCI Rec.): Liste 56
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 56
(WHO Drug Information, Vol. 20, No. 3, 2006)

| | | |
|--------|---------------------------------|---------------------------------|
| p. 233 | <i>suprimáse</i> zotarólimus | <i>insertese</i> zotarólimus |
|--------|---------------------------------|---------------------------------|

Recommended International Nonproprietary Names (Rec. INN): List 76
Dénominations communes internationales recommandées (DCI Rec.): Liste 76
Denominaciones Comunes Internacionales Recomendadas (DCI Rec.): Lista 76
(WHO Drug Information, Vol. 30, No. 3, 2016)

p. 496 **enoblituzumabum #**

enoblituzumab
 enoblituzumab
 enoblituzumab

replace the structure by the following one
remplacer la structure par la suivante
sustitúyase la estructura por la siguiente

Heavy chain / Chaîne lourde / Cadena pesada

EVQLVESGGG LVQPGGSLRL SCAASGFTFS SFGMHWVROA PGKGLEWVAY 50
 ISSDSSAIYY ADTVKGRFTI SRDPAKNSLY LQMNSLRDED TAVYYCGRGR 100
 ENIYYGSRLD YWQGGTTTVV SSASTKGPSV FPLAPSSKST SGGTAALGCL 150
 VKDYFPEPVT VSWNSGALTS GVHTFPAVLQ SSGLYSLSSV VTPVSSSLGT 200
 QTYICNVNHK PSNTKVDKRV EPKSCDKTHT CPPCPAPELV GGPSVFLPP 250
 KPKDTLMISR TPEVTCVVVD VSHEDPEVKF NWYVDGVEVH NAKTKPPEEQ 300
 YNSTLRVVSV LTVLHQDWLN GKEYKCKVSN KALPAIEKT ISKAKGQPRE 350
 PQVYTLPPSR EEMTKNQVSL TCLVKGFYPS DIAVEWESNG QPENNYKTP 400
 LVLDSGDGFF LYSKLTVDKS RWQQGNVFSC SVMHEALHNN YTQKSLSLSP 450
 GK 452

Light chain / Chaîne légère / Cadena ligera

DIQLTQSPSF LSASVGDRTV ITCKASQNVN TNVAWYQQKPK GKAPKALIYS 50
 ASYRYSGVPS RFGSGSGTD FTLTISSLQP EDFATYYCQQ YNNYFPTFGQ 100
 GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNFY PREAKVQWKV 150
 DNALQSGNSQ ESVTEQDSK STYLSLSTLT LSKADYEKHK VYACEVTHQG 200
 LSSPVTKSFN RGEK 214

Disulfide bridges location / Position des ponts disulfure / Posiciones de los puentes disulfuro

Intra-H (C23-C104) 22-96 149-205 266-326 372-430
 22"-96" 149"-205" 266"-326" 372"-430"
 Intra-L (C23-C104) 23'-88' 134'-194'
 23"'-88"' 134"'-194"
 Inter-H-L (h 5-CL 126) 225-214' 225"-214"
 Inter-H-H (h 11, h 14) 231-231" 234-234"

N-glycosylation sites / Sites de N-glycosylation / Posiciones de N-glicosilación

H CH2 N84.4:

302, 302"

Fucosylated complex bi-antennary CHO-type glycans / glycanes de type CHO bi-antennaires
 complexes fucosylés / glicanos de tipo CHO biantenaricos complejos fucosilados

p. 511 **leniolisibum**

leniolisib
 léniolisib
 leniolisib

replace the chemical name by the following one
remplacer le nom chimique par le suivant
sustitúyase el nombre químico por el siguiente

1-[(3S)-3-({6-[6-methoxy-5-(trifluoromethyl)pyridin-3-yl]-5,6,7,8-tetrahydropyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

1-[(3S)-3-({6-[6-méthoxy-5-(trifluorométhy)pyridin-3-yl]-5,6,7,8-tétrahydropyrido[4,3-d]pyrimidin-4-yl}amino)pyrrolidin-1-yl]propan-1-one

1-[(3S)-3-({6-[6-metoxi-5-(trifluorometil)piridin-3-il]-5,6,7,8-tetrahidropirido[4,3-d]pirimidin-4-il}amino)pirrolidin-1-il]propan-1-ona

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the *Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances* and *General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances* will be reproduced in proposed INN lists only.

Les textes de la *Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques* et des *Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques* seront publiés seulement dans les listes des DCI proposées.

El texto de los *Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas* y de los *Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas* aparece solamente en las listas de DCI propuestas.